var title_f37_22_38240="Azelastine: Patient drug information";
var content_f37_22_38240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azelastine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/54/12132?source=see_link\">",
"       Azelastine (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/17/38164?source=see_link\">",
"       Azelastine (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11107 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38240=[""].join("\n");
var outline_f37_22_38240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/54/12132?source=related_link\">",
"      Azelastine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/17/38164?source=related_link\">",
"      Azelastine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_22_38241="DRI trace elements";
var content_f37_22_38241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary Reference Index (DRIs) of trace elements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"36%\">",
"     </colgroup>",
"     <colgroup span=\"16\" width=\"4%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Life stage group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Zinc",
"        <br/>",
"        (mg/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Selenium",
"        <br/>",
"        (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Iodine",
"        <br/>",
"        (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Copper",
"        <br/>",
"        (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Chromium",
"        <br/>",
"        (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Manganese",
"        <br/>",
"        (mg/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Fluoride",
"        <br/>",
"        (mg/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Molybdenum",
"        <br/>",
"        (&micro;g/d)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA*",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"         <sup>",
"          &bull;",
"         </sup>",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"17\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-6 mo",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2",
"        </span>",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         15",
"        </span>",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         110",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         200",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.003",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.01",
"        </span>",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7-12 mo",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         20",
"        </span>",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         130",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         220",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5.5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.5",
"        </span>",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"17\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         20",
"        </span>",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         90",
"        </span>",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         340",
"        </span>",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         11",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.2",
"        </span>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.7",
"        </span>",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         17",
"        </span>",
"       </td>",
"       <td>",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         90",
"        </span>",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         440",
"        </span>",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         15",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.5",
"        </span>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1",
"        </span>",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         22",
"        </span>",
"       </td>",
"       <td>",
"        600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"17\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-13 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         8",
"        </span>",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         40",
"        </span>",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         120",
"        </span>",
"       </td>",
"       <td>",
"        600",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         700",
"        </span>",
"       </td>",
"       <td>",
"        5000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         25",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.9",
"        </span>",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         34",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         11",
"        </span>",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        900",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         890",
"        </span>",
"       </td>",
"       <td>",
"        8000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         35",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.2",
"        </span>",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         43",
"        </span>",
"       </td>",
"       <td>",
"        1700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         11",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         900",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         35",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.3",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         4",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         11",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         900",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         35",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.3",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         4",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        51-70 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         11",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         900",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.3",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         4",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;70 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         11",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         900",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.3",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         4",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"17\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-13 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         8",
"        </span>",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         40",
"        </span>",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         120",
"        </span>",
"       </td>",
"       <td>",
"        600",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         700",
"        </span>",
"       </td>",
"       <td>",
"        5000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         21",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.6",
"        </span>",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         34",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         9",
"        </span>",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        900",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         890",
"        </span>",
"       </td>",
"       <td>",
"        8000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         24",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.6",
"        </span>",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         43",
"        </span>",
"       </td>",
"       <td>",
"        1700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         8",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         900",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         25",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.8",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         8",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         900",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         25",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.8",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        51-70 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         8",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         900",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         20",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.8",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;70 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         8",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         55",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         150",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         900",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         20",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.8",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"17\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         12",
"        </span>",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         60",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         220",
"        </span>",
"       </td>",
"       <td>",
"        900",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1000",
"        </span>",
"       </td>",
"       <td>",
"        8000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         29",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.0",
"        </span>",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         50",
"        </span>",
"       </td>",
"       <td>",
"        1700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         11",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         60",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         220",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1000",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.0",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         50",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         11",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         60",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         220",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1000",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.0",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         50",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"17\">",
"        Lactation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         13",
"        </span>",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         70",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         290",
"        </span>",
"       </td>",
"       <td>",
"        900",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1300",
"        </span>",
"       </td>",
"       <td>",
"        8000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         44",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.6",
"        </span>",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         50",
"        </span>",
"       </td>",
"       <td>",
"        1700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         12",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         70",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         290",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1300",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.6",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         50",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         12",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         70",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         290",
"        </span>",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1300",
"        </span>",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2.6",
"        </span>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         50",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <span style=\"color: #ff0000;\">",
"      RDA: recommended dietary allowance;",
"     </span>",
"     <span style=\"color: #008000;\">",
"      AI: adequate intake;",
"     </span>",
"     UL: upper tolerable level.",
"     <br/>",
"     * The RDA is the level of dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The AI represents an approximation of the average nutrient intake that sustains a defined nutritional state, based on observed or experimentally determined values in a defined population.",
"     <br/>",
"     &Delta; The UL is the maximum level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals in the specified life-stage or gender group.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Otten JJ, Hellwig JP, Meyers LD (Eds), The National Academies Press, Washington, DC 2006. pp.530-541. Copyright &copy; 2006, National Academy of Sciences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38241=[""].join("\n");
var outline_f37_22_38241=null;
var title_f37_22_38242="Right arch compression CXR";
var content_f37_22_38242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Type II right aortic arch with aberrant left subclavian artery compressing the trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 450px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHCATQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5v0PQptSKPjETZ2nOM84/xrq4/AiNLGACyMDuJyMHjHfp1ruPh1pSXHw+0W88j5o/NDsByymZwP1rvNO06IuPkznv/ntQB5bb/DSwkjBNuwZunzt/jW1b/CXScjfaMy9yZXH9a9fg09d0Rztb1x1q7JZAAEAH5gDnqaAPFk+EOmXE8UEVntkfIBEshx7n5q67Tfgd4WkASXT5GC8NK08o3H2AYV7ToHh1vJXcoTcAXfHb0FdZbWlvZR5VRkfxEc0AeP6R+z34Ech73w+fL/ute3AJ/KStZv2f/heuM+GsZ/6f7r/45XpRllYF/wDVoP73Fc/4p8TaTomk3V9qN8CkS4/dnnPtQB5rrPwe+FdruSLw7tdeG/065yD6f6yvO/FPgj4Z2XyW+mvE7d1upn2/m9a3iL4v+DrRniOmahczMdzMHBwPWuEv/iT4H1CPy20nUoASeflJB9Qc0AQR+BNDllLabYQXynpFJcSxMfod3NTzeF/DGlxRNq3hG4j3EKWa4nK5+qvxWpp154WvI4I9H1u1jkIBVbiTY+T2wcc16TobX9lp67omucAgEHchX60Acronw/8AhtqhBt9FSXI6C9uPlPofn64ya6O3+E3w2+7L4aBb3v7kfykrXs73Tb24eC8tVjuZmH71Dg+gHpxzxW5e+Fru3tPMsb9ZFPQkcr7GgDHsvgx8LJyEk8MlHPTN9df/ABytWH4A/C9xx4az/wBv91/8crF/t/VNAvY4b3bLEOmf4h6g16l4Y12HVE2qgVuxHQ0AcPcfs/fDJYiV8NYbt/p9z/8AHKpH4A/Dfygx8PlD731x/wDHK9b1IlbWQgnp2rLuJHisYidrbuSTQB5v/wAKG+GqDL+HAR2/0655/wDIlXrf4AfDGSIP/wAIz1/6f7r/AOOV1scksj5cM3piug0sOLfD9c5oA80k+AHwviRnfw2AgGSTf3X/AMcrFm+C3wwcv9n8NEAdM31zz/5Er1TxVcmK08sfx81zlrYyXUOdxjRuhOenrQB5pqnwl+GVnBK7aKqiNcu3224O3/yJXmmp+DvCE9y0WieHpZySQojuJmz6HJevpNvDmmzhop4Gkiwc7m6/WuduJrbQriWz0S0it07vt3MfagDxqw+CD39qbl9IgsIcZBmuZCT+G6tDSPg74Ut3Y65IrgD7scki8/8AfVd7qd7rNzpkr6nLBaQMpCyzMI1wP89q8z13x/4O06JY2vLnVLkct9jQbc/7zYGPpQB0Vv8ADz4aO4ii0Npmwfma9nG7H0eun8OfCL4Z300kNx4Yy2MoxvrkZ9ekleKy/HOa1j2aH4ftY9v3ZbpzIce6gAfrW34Z+PPiw65pEBtNIZLhhvEVsQVU54B3cetAHvC/AD4Xtx/wjPP/AF/3X/xyo5/2fvhkyHy/DpUj+7fXJ/nJWjp/xKU4F9bxn1MZwT7gHNami+ONC1K8McF00Fyxx5U2MMfY0Aed6t+z14LwTp+k7WH8LXU5z+O+uS1L4K+GYCWTSHTZkOhuJfzHzV9PhN+1029O3Q1Xv7CG/TEiBZQMZx+lAHzNb/CLwcwQHSAxPJ/0qbp/33Q3wf8ACQkwNGznt9qm4/8AH69g1DSjpl7sYfITlOOCKelp8hdhjPr2oA8P1H4WeEreNimj5I6f6VN/8XXeeDfgz8NtU0Wznu/DgaZl2SML65Hzjrx5neukl07e2W6DtWn4RRbWea1kb922CB6E9P1oA4vU/gH4DhuZI49DKIfuMLuc4/OSvJ/G/wAFrPSJJ0trdkjbPlSCRm/DkmvsWa2S4iUSffXvVC80q3vbWS2ukEiEdxQB+ZmoWzWV/c2rnLwStET7qSP6UVt/Ee3Sz+Ifii2jzsh1S6jX6CVgP5UUAfSXwKtUufhVpKOpKss4PGcfv5ORXaWWnKnSPcyn/P4VzP7PI2/CzR2JGCJ//R716PBCqgkgDPvQAyO3wAQccAn2roNF0MXDJc3S4jByqetSaDYifFxOFEKnj3P+FdKjbuBgAdvagBwX5dowq9ABWdrWpQaZb753CrjhR1JqxfXRto8Rxl5COB0H415xr1tJf3jNqGpKhzwsYzt9qAOf8U+LdSv5pI7djHD91VB7+9eM/GrWLm38IWVuk20Tz4IU5yAM/wA69em07SYZ0+a4u5ScAs2369K84+NMGnnVdLjGkQzxC1YhnLfKc89+vSgD52N5IbR7dgrKzBixBLfn6VXA7nOK9GtrHS5ruS2bSEyrbgFLdO+TmsDXbOydoksbRrSFDjlyzSE9TgmgDm3CABo2J56Ec11uj+LNZ0oaYNO1S4tY1LEnzCQxJ7jOKqyaFppEai+mglYAjzY8g59CMVrW3w/1R7e3kT7PcQM7bXhl56Z+6cd8UAe1eAviPFq08Vv4ks4VcruF7AoDDHXI/wDrV9A2QtTpIltbgT27jKujZIr4xsIrzS7ZRqttcWsgBGTCSqgeprv/AAB8SD4UWJWBnt5n+eM5xt/vL70AeyeJtIjuLQi6JBA3Iy9QP89qqeA4r7TNQt1nUmEsTuHKsPUGums57HWrGK706RprZ1yR3XPYiksLZ9NuIY7dt1qzY2sOmaAO2VlmiJBBUiq1zHEyopGV28ADPSn2iwrIxgbIPDL6UkqrESx7Z/KgCnD5IAZBn0OKuafJ5m/rxis+NDvPBx1Fa1qFWHIGB3oAp6vYR3bRtJuypwFHes++VoVbYcADaoArecZcZzg9KwPGWpWWk2S3F/JtQZ+Ucs30FAGaZoLO2eW8lMUI+ZnJrx74p/E2KDS7v/hEbSNrqPKSXdyuePVV6fiap+OvGF1qyOTGy2IIxFG3zKO2f/rV5Jr001xpjTo7PGzNEc5DdOgHcUAcX4h8R6rrYRtW1O7vNgJUyEkbs9MHjH4fhXPHrmtiHw/rVzE7JYXPlJyS42r+tK+gz2txFDqTrbPJjZGP3jt+A/rQBjVreGrl4tctH3vncEGBk+mPanw6agYKYLiZ1bkDAB9sDn9a734f6bYtei5bSU2ghW35JRsdtx96ANW412eGJoxKQI+d7deT0H+FYNzrlz9uEyzbJIydrhiAGPYeld/DFpxuTHdabatAuVEZBGMcise78L6FfzSNJYSxAtu2wyEhfoP8aAPVfgz8VLuR007WJluIl48xjlxX0JG8dzCksLhkYZVlNfH/AIO8Fw2lwh0++cIpGUnjweh4r6N8CPe2UCQXWHhOB8rbgDQB1l/ZxahbmKZcMOVYdjXLtbSRNJDN8xU4/wAK7IoGGR9aguLdbgB9oEi9DQByslpkKAvTjmmWtqF1XccDcu3+orpFsGbrhMGljsLeOZWbLuO9AFy3O+BScbsUSRmRGB4YjFSqoUYUYHtS0Afmr8VRj4oeMB6axef+j3opfiz/AMlU8Zf9hm8/9HvRQB9S/s+wFvg3oDKmSxn/APSiSvTrGwee5SLZlTyW9BmuS/Znso5vgh4Zcvhv9JyD/wBfMtes2toIFbBBcjGfagBmxMJbxDCJjgVadliQs3CilRFQYFUtRt57pgiELEOpz1oA5jWNWe5kZIXYDOAB37Vz82h3F5NvmAgjxu3yNtzXS3yzWYaLTrWKSU9Xc1yOq+HNe1S68251BUTP+qBOAKAGTy+HNKD/AGvUQ0gG7y4ep9RmvNvHvjHQ2tvOTSWmiiILPK4B2+oH5V6BJ8Mbe4LTXF85+XZtU4HWmWfw30EW81vdJJLE0bIxZuxoA8G0rxdo2oXTSiyuYmTO2MSISzY4BI6iuen1nRdStXQsINQMjbvNGAMfp69K9o/4Vx8OrWeZItLvGlVSFYzNgn6VzQ+F/gmdX8r7XHIThY2kOQfz6UAchb6La3IRf7QSRigdlADYA6cV1Wj6XePJGhm3KflMnQKf938qS6+COjsglsdanhkUdWkHb3xkVf0X4cXWnXUbQeLZ+G3Rl28wYxzQBp3V5caG6Wt0oZJOu4bs9unasLV/BQ8RL9q8OgRXgbDQyH5T6svofavT7Cw0+YW0HiW5fUI8MPMij2AfU9q6u10XSLSwjm0F40tkbcUyCw/HuaAPP/h9NeeG4Y45naYk+XKVUjYB3IPQ16rY6jBJJbhyjo7kkr69qwI4lv7+4kChXIwMqBuHqfWr9hoVxYylSh+zv8w3deaAO2/cW0gSJcbsc9adqMbNDuXOcY4qOz+aKPeAGCciru4NEwII44zQBh2/mYO89uOa2LJsxbOTisaK5VbjymTlTxWxbM2cDG32oAku2Kxjb1yMV4l8WtRN5rDiNmbyV2Ig7epr2y8jZ1Hl/ernm8NWEF691cxrKzneS3JJ9PpQB89+F/B9zrks13qDTwacoIJc7fMJ6AZq7rNpoOg2Ris7BIZIm6kbi5/3j0+tey+IvDMmrTIliFtlA4x9wD6evvXB+JPh9fQyRXDXH26aPH7iOQAfjmgDzTxhfC/ijs3U7JI18p41zsYddx71xNj4YjufEfmCeUva/vFYktk9/wAvTpXpXiTwr451ORE07QdNt0jz5cs85dgcdQAMD9a5Sw+B3jm+kc6prcNn5w6CdjuPoQMCgDO1QWml3P75rJEcb2bcFznvyetdzoGoeBNC023kudTtZJZQC3lvu2k9TkVHpf7O+iabcwr4i1xp32/vIoiEGfY9f1rvn8O/DzSrOC30/TI7x0i25kwTtHbJoA4tPFHw/uLyZo9WigTG132/eJ+tbOlaRomtWx/sTWredmwVUAq2O1Xb2TQYTIlloOmwStGCsXkqWI6g9KTR9bnB3fZYbdQMBViAP8qANDTvCut20wMllKQnSTqH+pr0PQ9OvLchpNsfAJXqa57Rdf1uERgSI8PA2vwcdzXc2GoQ3aqbiMxTHnigDYiOUHIJ9qfUEMRj5U5U1PQAjZI4OKYsYHJNLK5VG243gcCsaa8mlQgnH0oA2ZZViXLflUCXiuRtUkVBHG00YaTJX61VuYZUYvbrlgOhPUUAfnj8Vzn4peMT66zef+j3opnxSbf8TPFzYxnV7s49P3z0UAfaX7L8e74G+GTxz9p/9KZa9aAwMV45+y20h+Dnh1Qx2AXPHb/j5lr2OgA7Vh32oTGfy0Uqg/WtC9vPJkWJY3dmGSR0A96oTXWnwsGupCrD1HFAGdLJMxIAYk8VTuY5HkCsGycENg10yXtkxBheEnGcjrSmaOSP5GDe45oA5yOO5RWiVJXCDIG3A/GqWoSGGLM0XknHzcc/SutnEqjcgO5zk9KytYs7q5XzYpiNqbdnGD70Aef3/klDJEuyFhhhx8vuK4aSyL3MgS4IkVmK7eMjtivXJdFLr5tzFFMMYIOARn6Vlav4bs4P30drJEAoICkkfTPY0AeFXlzqMd8qtcyearjK54I7nP8AStibVvKithumjkj3rgcBsng/nXeweBrTUtQaM3LQysPkLLwO/wCJrC1P4eapaajeSuBd26Kwj2HJZf8A9dAFFdcuf7LhtpJS5nyuMZI/GtjTfEv9ixx28qNPH95mOOPwrlntXsbu1huIXEkSYC85GfX0PvXR6LpKS6hF5+ZGYrmNjjmgD2PwRpcb2w1F0x5oBjTOQB1rqbmNZcCRcjFUNGzb6fGqqBGvAA9PatOTDKD0oAhihBAOfwqwRyOKFXApScCgDCubJhf552nkVqWcJQZbPPrU0q5QnHI6UsP3KAH1XvULRAgAlTnn0qxVTU5HjtWKjg8E+lAHL6xr4gjNtFPtlHU9OPY15nq9/Obm5Vp2jH31lLHLe3B610HiK08pmdXHPXJzzmvOPFhnstLa5cGeHzskL0HoPagDa0HxHdKxF/5pWUsqjccg+ua838UfEPUI9aURSEWitsWQnPzdOT6itm7tb3UE090luGZnJibsvt75q1rPgKK61jTi+m3EowGmiMZZScZ7e9AGZ4WbUtd1syXlwkYAyd8hYOv+NdLHoLWNy8rySvcNkQIMlCe5PpWlofhbXlut13pwtbdSDGeBlP6fjXVK+nW+oQ2N6bJvIUyKTLuYd8mgDjbPwtJM/wBslYJjG8vjJx/L8zXWaZ4ca4/erOsmSAEU8r+Peub1nxPHeyzFL8JblgiqEOCB6e1Jo8epX2pCOy8SPaWzr/q4LfG4j/aPOaAPRWsoNLQSaleW8EYXOHYbs0weLdItARbSG5f2HWuE1DwJPqV8duqxEsMM8obe31Jq1H4KvLGMyQmC4ZUAxCd2ccUAbN98RNThvYI41iSJm+6TyR3r07w1rEGs6es8LZYcOO4NfNerNONakhnQqY1BwVxz3Fel/Cm6NvdiPO1WQ5Uk5zQB67IMjIHIrDvgUnbHQnP51ugggEdDWPrKbXQqpwe9AF+Hi2QjpimOSOnHfOakhGIFHJ4ppXk0Afm/8VP+Sn+L+/8AxOLz/wBHPRS/Fbj4oeMP+wxef+j3ooA+zv2V0/4sp4ff/r4/9KZa9cFeUfstrj4F+Gz6m5J/8CZa9XPAoAzdXmSOPB5PoK5t7Ke8Z8KfL7Aiug1VLeHNzdO20DAjH8Rrjta8R3EkEi2X7jjACfeA9SaANiCwhgQGb5HGeW/qKja9jtSFgLZzjJ4Ga81fXLu3uUkupmbJ2MpPzHPeq17rVwN81ysjYG0Yk4HOKAPWZ9ZQFoJJwsuMjAzWDqV/MbYwi+fLkjIO01541ypcOl5NujwQc5GT61bm1JvMNvct5xkx5chHPvQBzes+J9ftGMInnDs+1w3OBk5Pp0q9p/jDVQn2WDVBJORlN0eQwPqa8++JV/q9l9q1KMAxR/uXjyeT2f6djXjsviPVpLtbhb2aOUcL5bFQB9KAPrPT/HviPT5YUvrWzvwcfcQqcZ6g/Su103x9pl9eyWl3Z3OlzSELG03MbsR1BHSvlGw1bWdE8Gxa5DfXDahHd7CJ1LqEIIIJ75OK7TwX8UtN1eD7H4pszYyztthvFz5e76npQB9F+JNAt9Ss0ebyxd7cRTgdPYjuK4HRrWe01+2iv4ZEcMQHJznHp7Vas9cvLXRUtWljAtpARKw3BgT9fSu6sI4dTjsriSKFYnH3jyOnYUAdZYbXsYyo7Y46CpyuSQTmmWaCODyY9gC9MDj8qeMgAHGfXFAE8eNox2p45qIEZ7Yp4b1PNADvakFIGzSjvjvQAtU9TXfblCcA1cpkiB1KvyD2oA4i50Rb6J4hzKDxn39fSqemeErPT3ltdRkF7a3XyuGXjOK6HxNcrp1mzRgoinLFOv1NcW/jS41CGS20e3WVk+9LKR83HagDf1ubQfCGnJPJbGVYv9XDCgLj/CvINR+MHibWvtDaLpltplszMsbyjc+31PbNaN1bzpp2oSa/ciCIL55nuJMBT0I9xXmWneNfC8WriPTze3EOCkiiEeWMdGBPQe9AG5puq+JtbghW6vZ5JJJNpVtwUk8Dj0rqf+EastPguFv3mivZ1wzMDxjsM9815XdfGxUmC6RooieIYjaR9xyD14rN1D4ta1eQzyOyz3iv8hAGxBjkgdTQB6ougAWUjwW64DhwzNz/APWzXReGNG1KK6t5FYbIkZvu/fY9D9BXzdp3xB8S32o83hWNzmQAfe7Yr1+2+INxBp0QhnNncABXaQcsfYUAenz297HgyIZD1bHU/SnxGRHUxh4cDcV6HAriNI8c6uZlaAw30WN8jPgYHc8V6FYeJdP1DTGOo27228+WsiHcCf50AULKePUGlXUoUnjcn/WJ8wH1rZ8O6DDDe/atMkOwA5hc5I+lNttKie08/THS4iblXVsjFa/h+N7eWR3bJAAwBQB1WmS+Zb4OQy8EGk1SLzLcHGSrD8qksyrAsOWPU1JIASQejcUARJ9xR6D1pJXEUZZeW7Z7VE52npwOMiopmyGHcigD86PimS3xO8XM3U6xeE/9/nopPih/yUvxb/2F7v8A9HPRQB9r/st/8kL8Nf8Abz/6Uy16pK6xxs7HAAya8s/Zc/5IV4Z/7ef/AEqlr0bV5NsQTPXk0Ac/4lla6tmfnCcgD0riLxliQtI6qvQnHOPSuzuC7OywoX3grgDIrlj4cu5pmN3iEE4IkfqPXHY0AchcwLPK8iFg20hWHUe/4VSlt11C3KRcuMq23+I/3q7O48HosO9tUXJyMIpJArOh8J6dayAy6ld+Y6EZRdv45oA4i4i+zgOlx5JiVY/nODn/AAqxaXWbWZZplNxvyrd1/Ou1u/C+lXlp9keW4diBh2xk471kP4DXajWerADbgxyJz6frQByXidze6ZbsxjKAMHzwHz1+vpXgfi/RTpssd1Bg2UxIiPdT/dPpjNfS3iL4Z61qOiwx217ButnZgoG3KkHA/OuE1LwJqt7avZX1mJRGCWWIglGA4IoA8o8NXCXGn6hYX0z7ZwrRgkn592PwzXu+hWxtfDmlDUIbGWBXVEklXJjTPQqeM+9eSaJY22g/2muv2EvlBR5Vw8R457cdR6V6GPFFvH4ee2iklawkYSRyOm4KCOSe4X2oA920KXw5eaC062aHyQWljQ7RgHuO9XLXxFY+KEWPTZfJNq3lmLb93HQivmvwD48TSotXt9Sn2WGoMqRSBvlPqfw9K1dD8Tx6B4oE1sZXtriNnkkVSVz2zjpkUAfXGkEeTkEE9GYnqav/AC56VwPw316PUo1KTrKjL83qp7ZrugwZyO9ADnUYBHFG3Kgjg+tKW2gDrQGGOlADQMZHepUGBUW8bzgVMOlABUVwwRd3foDUtZutXDw2xEW0PjOW7UAYmuX8Fnfxy35jS3nXyTvI5/CvKvGV0+h6klto7SQW0gLB4wA0hPYDsK5T4v3l3qhuViuJFitB5ks+cZHXA9680l+ID6zEWndvtMa4h+b+JRxj0GKALni/xDLdyxQXU6X/ANtmNumW+aMkgc59Diq/iTwBH4H8DahNfaqh1udkQwxtgKh529eSRXD+Hyj60+pagGKbnkK55z1zmquo6lFqgury/eeW4kuCyAvk4wAAT+VAGLGjO21Ac4NXNPhaWGbAXC4OGOOfp3q9oFrNItzcLZSSxqoHyRk856CtPRfBHiLXJZLr7BcR2yjc8sg2DHoM+tAF3w1byzXDSRbY7aFT5e4jMjgccenP4Yq7Bbi4t7P7VdEz24ClhyC3fJ7ntmtyLwVql3pttDbx2en29s2Dvm37ieo9zW/a/DvUZbqJd8EcaLhH34wB1JoAi8JwCW4yQyQLw7AZDei571u6/qC2uLG0dnJO8RxZ6k9yK04/CeoWKvLAbeW3hH7qOOUAyufUfWse48J+J5YCVs5BJI5clMZP1IoAt+Hr/U9Ikjmt7mZZCd21W+XHoQe1e8+E9bj1fTYFv41gvHGcr09q8d8N+HbjzrZbtihUbpdynIUDkY9a72NlE26IhVByqg9cUAen2yNBLtP3SMZqxMDkHtWT4evDdWaxSn96n3Se4rZcZSgCjcna5xxmqz/dK55IqzcAlwRxkVWK9evpQB+dfxRGPiZ4tHpq93/6Oeil+KX/ACU3xd/2F7v/ANHPRQB9sfsuf8kK8M/9vP8A6VS16TdwCV90hxGBjjrXmv7Ln/JCvDP/AG8/+lUtem3THcFAOcGgCi4VY2WJQozxWPqtvJMu8L8wHzZPUVvLCQCxwT1PtWRfTQpOAZNvYkHoKAOdW1kgnTOGJPOecjuKq3kWxmLxL5fbDcj6Ve1bWYbG4VFhL5B5I/WucuL2S4md7dsnHG5uME5xigCy8IMuInVmUcqzdRUX2lreFZSqKSNqbuorK0vUkg1ZluIwWdCwUttBP90VjeLfGdhPceTHbeXOg2BI/mw3rigDqF1G9uIbhbdnkKfMU3YyAeahm1iWzTFsscm777Dls1yPh3xdAmpfZ7yOeFGORMEyrfT8a0l8UeHLfWpLa7vYY2kbI81SAQe9AHTCztNT0C6XVraGaO4iIeGRASAfQevvXHaX4E0K40U2gQ2WxHiHlzFgRnOWU13vhK2s9cuLq70m+glBUIuyVTtx1Fc1qcE1hqOq208YWaZiI2z1AHrQB86eM/h1rWiazNHZQx3Vm4yDDgg+vHr9KjsNZl8O6vNa6jAAjRhERhtGMdfTj0r6G8J6XcSx5vo/MhPMas27aOhOT3rmfid4Ks7qJLi5tFzE4TKf3T6mgDoPgzqUD30UtmjxB1AcbuH4yD9a+gAd+HHHsa+V/gz4cvfD9+08V289l5vEbHgJ7e9fUemy+bDk5I6jIxQBaLcD86RWySP5USnC5qGOXA55OaAJs/MePxqaI81XXkcjmpozyDQBK7BULHjArj9WlNx5iuxyQTjNdfIu5COORjmsC501Fy0pKk8YAoA+c/ir4d1TXIWsdJSXYw/0iXB2gdt3pXiWleCdThupUlubS1IJUOx3McccD+tfaXjGVLXTPs0EYjV+X2d89CTXyTrWlX58V6omkwy3srPwJHKiInuPXn0oAunwLpOkeCri71R7iXUmLCUZKqoByCOOc1taToenSaLHF4Z0+ylupcKTKPMwSOWDHpWpo/hrWPEWmjS7vcb1nyZT8qrgYxk9a9h0S38PeELEWUtpBHPBEzSBcZJIwW+vpQB4pqWpXH2uLw5paRraWgWK6nVcBm7gY9a6vRIWeNNPjhlMLDEh5YkdBiqum+FnNx9vs5oGt5ZGmTc+HbqcEHp9K2B4ttPDfh0yR2yvf3EpiQsM+T6n8KAJLHw7EL3bezJbRhiEBPzY9Pc11mkJaRo8cMTSRIpT94fmbHavOtN1QW0f9oySm9vi4LSSZ2oMcH2qZvGcdqf3alH3fOxU/Nn09RQB2Oox3dw0P2GIFEOQQMD8asXy33mLEZvLwN+FODkjnpXPWXiiVvLSWM7HXOF6/QD+tdNoTW1/NHcSPswcrHMcEHuf/rUAdFpYEdqkdzskZhl2YY/CrT6PbzEPZEK2clO34UyOJXOyNflBJL461fWZ7WPdgFscAUAUrK5e31OC3RWUo/zcdSa7nPcdDXJ2sEd3KGI/eIM7h7101sT9mj3dQMfiKAIbnhwOtQHgHsasXY/eL7iq7dCcmgD85/il/wAlN8Xf9hi7/wDRz0UfFP8A5Kd4u/7DF3/6OeigD7X/AGXP+SFeGf8At5/9Kpa9Ou3jiiMspwF715j+y5/yQrwz/wBvP/pVLXd6zc5ZouoxjHvQBSv9SkngLRKUj6bfX61hSyRDaXJ3k8Drk/5/rUf2uVpiqkqCTnPGD6VTmKCYLsZ8NzyeKAKWpwebZhmOX3kdegryzVLq9kupRayTCS2zuiVTyM9fce9emXqPqNy7W7mAow4PC+9crqNzJJJPbW0OLo/KLhcEsvdfxoA5u51u9eCKK2EUt84yiSEY/D0rE1HW7rUbdUby7S5V8EsoySDyQe9Tz2tobrYlwqybyRGDiQEDnJrL1o+bGzkNK6NvMYYZ+tAGVLquqRTvcaijrp1r863EZ+Xp0x71DFrWmvdWc+qt5lkysRKVBdfb6E8c1o6drFneaFdw39rI1pCcnauAg9NtczregWl3oP2ixmMrI4MTgHBQ54x7cUAbWkajbw6mj+HZ4rIdXmtmP3v7rAdR716l4Z8aWlzLa2viORzqMsmy2mByJTjHOK+a9JeDTdatXivPNTcQ5jBH0HuDXbXkklwVugnnRLICkigo0ZyOBj3HWgD6fsLU6Ndy+feRo7MNqSNjHHQVU1qUXy3sMiJIrENxwD9K8503V49SjhillZ50cLPFcyfO5x/Aa2dH1yz0+WGKGScRNlWV4ywH5dqAOu8BQQLLdCSFAuQQtetWLKgRYx+7IHWvNPCdvAb9rhZVdJcjcrZU16PaNEIkEbZK0AXJxzx+tQxhQx3BalLZOf6UgyQePxoAQAZHcZqygGOnSoVPOfSplPJJNAD6zb3/AF2zcBnn61okhRkkAVi3t0ZZcw7SvQHvQBj+JdMW4tZvMYrEycev5etfGnxG8Sa5purMdPWbS7dZGRdygSOQevTivtp5VbKY8zIwT/hXkvxw+H1hrugTXcNuft4bO/049PWgDwTw1r+qatLHB/aV0qQRh1k8w5kc8nNdFJf6lqNvIk8kQ8yYK85b55VX+Ej6iuQ0+4TQ/Dd6ssO28gOxsr91ulZtp4oi0+exOlqonlIEs0gz8pPPHY0AepaF4rsdGlisXXzbmSYo5OSpbqAB61znjyTVI5P7auYZYbCSQqF28pnjAFca3iZ9J1G9vYJoL3UPMIhnKDywrdSB1zx1p1x4817WtJltLphN5Z85pBxjHTjpQBraJrWoDW4YEilh0ePm4Eg5mX3z/SvQYb7wudZM+oTXCacmDGkXzGRyMjp6V57ptpq2urp+mWBMi3EZe6viuVU56BumB0/Gr97bxW+srp/lTLDCoiJI4LYxwfU560AdZvh1nUkuba6lis45MBVyPMAPAB9cV31mWuYpsYBQDhee+MVyGhXBtNPjiggEUcDKpDDopHY+ua6bSH0+5uCiNNBcuMsy8r7fSgDqtB1C9t50jikLR55UH5R3xXW22s2d9P8AZpT5Mw4AJ+V/oa8yk1WLRg1kIXkunGXlBxtB75qz9ouZniVmRxjh17e5oA9atIjbjgAZPp2rftyGtlI5rkfDGrGVI7S6x0xGzdR6A111ohSHYaAGXOMKfQ8VVIGBk+3WrVxkKB6GqpOVB/WgD86Pilx8TfF3/YXu/wD0c9FHxT/5Kd4u/wCwxef+jnooA+1v2XePgT4aOP8An6P/AJMy112rSHO9cFu4rkP2X/8AkhHhv/t6/wDSmWu1nsmuZNxOxAevc0ActqsTF9kQG6XLjuSfSn2+mXlxEjEpAw4cscZ/CuikSNYSLeMZQ53HqaoEOSXBJ5z1560AZV74Xtp7cpPdyDHJ8v5c8dKpQ+FtNtY2kSJZGRuHLkkHsa2peCcuWBAAHrWbqMgjQAkovJ2jv9aAMG48O6J5stxaaXbm4mBWZtnzc9SKyb3wzpUREk9lBCGO08kbvfir93qADxiOUpMudoByG965fxBruo2zKblhKjkMiN19Me1ACro3hq31Sf8A0d0iIO9gSw6ccd+azodFsbWTy9Pl271YIGA4JHPFadrG+sRFZIjbSbNhYHk56c1Rm0+/tnO8Z+zY2shBJ4oA4qf4KXGrede2txHBh8sQvH1wOnNOXwX4r0+ALBcwXEcbDcYWwMD616dZ391ZeC7145mkuH2sFY7Sqk8irXhLWI23WrTR3fyBmj24Az2oA8H8R6HqN34qspRb3VldxBcsRkPj+JR2r1DwT4s0vSNEvo9Wga7lhJ3NGuWVsc8V1/iPwmbyOa+jmb7SBiFAPu/WuG8B+Ers6reJdW0iWczbWZxnOOtAHQfBjxANR1O+kgb/AEaSXzEUjG0Ht9a9stUcBwjbUzkkV5joHhqy0DU3W3ZPIDAoFHAr1RAqRAjlT0oAvRSbvk3AkDnBqwh4H1rPt8dB25/GrQb5Sec+1AFjdycbevrT4z82KqIenPHerKHPPpQBU1ibFjKwOCOBXPKTsBQZz1OeldDq8Ae0kJ+7jJz3rn7GRSAFyV69KALdojEj5G9eB1q1fWTXumTQGNvmXg45zVu1YrGp6k1cjJYAAD3FAHyh8WvhRqF3ZXV9pZERUb7hZGwGUH+deE3HhoR6jb2i3ZUsjM8rpgDAyNo6mv0O1vS4ZreVWXdFKCHH1r5f134cyP48e2uIv9ERi0Erfexj7v0HpQB4rbeDppQpkvreJeN2ckjPQD1OO1dpoHwlu54pFOq2yGZShQqQWGeMGuk0/Rls9enTWWRkh+bhcLEg749atWvjG1v71k0NJXG9tsgGVyvT6UAULXwj4t8NwJBod7pzyRjZ80uAqnvgjknNb0PhXxDf6VbXd7p8JvIZDG3kygoe+6taPNxGtxLM/wBouCAY3OCcccCux0G2vNP0+Zr5MW854iQHIH+NAHnMOl65teG6tbi3tl/eeZsyHP8AdrWl1C304NFbW5zKv7wrwR7V6VYpdvcmGOOSGPbuDMc4FQTWs10skclrbsAdoEi4bP1oA85truC65vFkG4/LtA3Y7AA11GmQmzikMe8tJ0LgcDtVmDwvpmoXh+0Qtauh3b0b07fTNTXGhXdqjSWzG7QHHXLIM+lAF7SpmDAK7MQR8xr1DSrj7TYIxPzgANXkmkl2uV4YFeoPB/KvSPDc4ZgvQMnSgDWvOI9xOBnmqjc8dvSrV3GHjOedp6GqfIPbmgD87Pin/wAlO8Xf9hi7/wDRz0UvxT/5Kd4vz/0GLz/0c9FAH2p+zBgfAjw0SOB9p/8ASqWvRLtfMPUqCARivOv2Yjj4EeGP+3n/ANKpa9FuZUiiLSHoSB7+1AFRowEJ3AqOueM1jahcfZ5lMBVEfjcegPpUOr3kk4KpII4uhyeBXP3JX7LcG7ZntRhWKtnB7HNAD77W9tyLdcyDOFwO/wBazdUl1CUPJb27TcF9px90DmuZvtTl+1rDHH5YThd3VvQ0DxBdoFhS4UT7cCPGQcgjk/nQBl6tqFzLZqtvstkLcPjO38e3pWVNeTLE0msPbyRSAKkYX50Pr69q0JtR1G3g8ua1hkDYaRSnPWsLXNHjmlGoaiZYkZSsZRuMelAGCuv3Y1iW3up5oQuCj7uCpyegFWbjxrfLLaS21k8spwsgdti47EHvWTcXekoyorSxiMFhIwyc9/8A6496z9X1GcaUjsEe33lY4IOZOvVj/SgD3Xwf468K/ZLq21uGSGedRvlUb1A7r+BrZsNK0O9vkuPDF4s25gfKB2n2yK+R57yS/SVzfSiYtgWzADbjuRWz4E8e6r4R1VGMn2i3YFdx5OD3B/pQB9pabFIQsV3EUHKlmPAFWYDBEHaBQII88nvXHeD9es/EukhraS48wt5v7w44/wD11tIZiRHCrBGbknkD8KAL9xplncXNvM0vllF+4OjE10bJG1qg2ncOAOxrgXmeYPEspjeN85b+LB6V22nK32ZJ2fcrLnigC3ACHGFOMdBVoNtGGQkd6r2pYc54qcuQp5OKAEBGe/pVqLbkDv61UV8nAqWPcGyG4HWgCee3E0RSViydx3NYogiBZF2h+xxWy0xVCD1I6ViXkiQygjBf2NABZGVJgh7HaTnjFbUCoAP3gJxXOT3UrZO4BWHar+nriFGYkAdiaANqUpHEWfG3rzXkPxauoXs/t0Mskd1Zt5y7Bg7R1H416jfAyRADkeleMfEGwnnVkZcopw+3hiM9M0AczdeINN8QeFLafyIpftX+snKcnHaqnhbQdGmmtYPD0MaOzksiH7wxzXk+rwTeFL24t3uJxArbrZGk4EbDPK+gORmq+jeNdW8Kwi7srYxQSIRE8g5YtnJHpQB9JzWFlol0ftawqYwdnOWPv9Kmh8R2jWc8896rCEgbYxyuegIrx6w8Wwataafe6qJ5Z7h8bnXhBjrj0461uBFS3ni0C5iurecgTNJy+ew/DtQB6ZB4xtbqJ7aOUiZlALEZIz3+tWLqGYlbtHldoz90HO76eteIqL7QS32sSJJKfkkC53HP8u1dnpWt3OlWsTSl5pJCMRg5EY9PzoA9H+xyvCrtEwZjn5vXv9avxFrVowit5p+9njArE07XYr23jW4maOc/Oig9Pxrdi33KRl1zkZY56e9AE8tja3zb+Ibl+NwGMjPerehu9tqSJKu0k7ce3ao7SIlzL1AUYBrSgCzvGXGJFOVOaANyYbsqe4rNI4y1aTnDjPU9qoMMDg9+lAH51fFP/kp3i7/sMXn/AKOeij4pf8lN8Xf9he7/APRz0UAfaf7MjrH8BfDTv90C5/8ASqWuk1m6ld5MHk/dX0Ncf+zfNj4E+G4x1C3Lf+TUtdDqE0iTKwbP485NAGbNcJLF9okbdjgx/wAI9jWJfP5rSxiRQxwwjU4BAz29BVh2caq9h5YMcgygB9e/9KfceHL1pDKVZQBtPmHAAoAw76xmmjE9tChwARkZ4/z/ACrEuLS1S5/f/u5QMhQ3AI7V2dr4ev51kD3hiUEHMQ4x71ZPhHSC6s6NNMf9Y8znknvQBwVtrSy6ktoTADv2lmPylT3B9vesjxJb2rXWbidJrZHPlMWIDDuFHevQZvC2j267YNKgeIHkgk4PrVG40vSrnTkzpsU3k4Izkn/61AHkhfTLi5lt9Ps1MnD4kHTHXnpmotO1S30PVSE01LgFiXZhwAOpA7H+de+6T4c0m60vK2cUU+AFG3ofXNWP+EO0iO2ELxwsIlzISASdx70AfNf9g6D4kvri6sklhdmLsTmMrkeh6iq+neHpobq6Jt45FjjJDqM7lz19jX0PPpWiRxTlLa2AjGwrtwcHvmq9rptixEdtbJGGJVirZAX1oA574UNqF19pnS1kSC3iCKWQjOc5/HNdFqN/qMRBivJN+48J9wY9TXrei21jpejR2+moBbhM89eeua4W70xWvna3Q+U7FiP6UAR6XJbX1rDczrtnIIZWONx7ketdPpc4igSAEtDj5cnpXIanD5NxDGseMHK8cD6V0Oik5fzf4cYBHSgDqoiFUD2pzN8vBqqhygI5z607dj0IoAl3/MKkhcnjsapIWYdD9atQA5BP4UAN1VnQ4ViAV6isfzi4AZulbl6hlVfVRWCbJldhtYOTk56UABjZGDHlW6e1adtMTs3gD096oJBMwKYBzyAKuRQSIBlR0AIzQBsxL5iANyexrn/FeiQ3cMmSQ23nA6iuhUSG3wMAjpWLq9xcwRH92zYPVRQB87/EvTPDekahbXGt3cbyOTCg24ypyRn8a8n8WyzanbSQWVsJrW3UuZGORHj0Ar2r9oHw2uveD59Rt7OaS9sl3YCHIXua8V0jUbY6Glzap9kjMPkyonzF5QeMj075oAwvD2rvfX7jVIt6LAYlKqQIx7j2ro/DdwukW3n2z3czCT/VBiNzYyDzWbrFnqUSxSC+XzL9x5jxx7VJ6YAx+ddB4Q0mWC2hE92vmKzYkK5A564NAHqWl6y3iawgNzBFC8eFIjXcA2OPp/jSNpl/FcCTU2xGD+7VRyx7VD4furbTnU2kjMrZYqoG045zW5c6oniC1RDcC3njbCMON340AUH8m21bZtkeQncA3QV0dvrlzavFDEQpbBKN93HcVQmgksIw1+qTvj91IQBg/X2qKztDdXwENwJGc5IcZxjrzQB6roOoR38Sh18u4K5KdQR2IPpWpF8twBjj61w1hODOAG2TJ91ga7qxm+22olUAyqMNz3oA15MHY54z+lUnXLenNW1G+DaDzis+XduYA+v0oA/O74pf8lN8Xf8AYXu//Rz0UnxR4+Jni3nP/E3u/wD0c9FAH17+zg2Pg34XUjIIuRx3/wBJlrvrrSvNLG4JAU/KF61w/wCzUAPgt4ZOCCRdfN2H+kycV6ZeIWQsGy2PzoA564tY7aMy2caiVBgk/McHvmiGOe6PzkvIBjGc1OGIk27VY4OQ35VSeR7CZnd1bHRPUUARXMfl79zN8nOAcc+/5VmXTwx3SnzWAk/n6Vo3OqboGmWOJgq5POeK5+71jEplaCNrfqcDkGgCee4FgDIrPLG/LY5C/j3punarY3kojjRlLHBX7vB71mNcx3FqbaWdIUlwVVmHB7YrgvEmtz6Gyx20T3V1IxXMSHap7fXNAHpWuNqEN7HHYeatoyhf3a559SRUNtpVzPczwTSzqsibHZjjrz1rjPAHjPxANZit9ajH2Vl2gj5SB9K1fiFpF9fX0OqaVql1GkKbmiWQ7HPY/SgCeXSruzd9nmXcB4JXnvzn2rV0KH7NqkccYVlf5m47VyWgatr1nbJfLqENzcMCDahcnjqfpXReDPFUmoxPdaxZQ2zlyiywtnJHYg0AejWrSKqwl/LiIJHqfwp8iyQkiE5buSO1V7TVbF0CswWaT7x9D2AqfVJkt7dFDkNIMZPORQBxk0k1zqM8MMhkCSDO7kg129lbJHAD5hZ9o3BR3rFhl06x8+6kiXzDhSV7810kF158MbxrGwI4OOaALUBieI7DnFSx7NoyOO1RwMdvKqD9KlViOcCgCMFCuQh+lWItvA2kYHSmZbdgAZqRHIPoaAJAylyMHOKp3MbCXIzgj86vbwGBwDxVeX5pTwMe9AFaGLDZJxj14qa6G6APH2oljV04PB6hqUBRDtJCqRjPpQBYsZ2aIbwenNLdkbDvOAahs3j8hgJQSOtWIZYZIyCy0AZUgjkGwuoyNrIeQw9K+ctQ0DSdG1/WrG1itkdZy6JIuFCsc4B719B6xEsOZlYAIN2c9a+dPjdpO26tdcgviibxFcxK+AyN0PsQe/vQBv2xsp7Vi2m28kinEZUbsDtita38E6PqmmlHj8q5mPmNGG27Rjha838GNPouqpHfzH7MSPIVTnfjnJPcV6bZ6mftcj6k7W65Ah8sZYg+v50AYi+CbnR7l0hkaMMhCiYZDD6iqyaFqkMqgWkptWY/KpDJxyDx35r2Kytk1rSDHbMJfJbH7zhqxJ4L+Fgtg42nIdSMbcelAHAPqEN3H9jvFLIjbY0/iyDyM9q6PS7R7OR7zkQuNqDso9zWrZaWt3PnULWIkEkuUAJFbh0y2nd0AZEHyt3UD0FAGJEsWN0eNxABOcjNb/h+9NtfwxEnbJ94Z/AVUfSxAcMB5XQOp4HvVPS8C+yNzfNu/Dt/KgD1IABvaqM6bZn6ZNWbZ/Os4pM8+tQ3gG9WIPSgD85fij/yUzxd/wBhe7/9HPRR8Uv+Sm+Lv+wvd/8Ao56KAPsb9mld3wS8NHqQLn/0plr0O6dY48SuAM4rzb9nS5W3+B/hgE5ZvtWB/wBvMtd3IguopHkGVbjnsaAMq+vnjneOBCrg5zjk/Ssa/BuwpeSQuhOFXnd7Vsi5DMZI4/M2fKw9/es26JlDSJiMKc7D19qAMeG8fIhVVKM+33AqxNDFcbbVY5kcnc3yfKPTn60+6ggspDeQW7SmVQHyeFPX9azF126nlNvFJtfOQMc9OlAFXWfDtlLIGv7ho2JwuPUUms/YdNsopdLRbmRYwG/vEAc9at26Pd3RMzB8ZxG/r1rHvxbWWrTNdO6zScRonOwjnJ9qAOL1DxE8+oLixEDg5Yg8gDvn1rc0TXb2+IsdQVkhAxuUZ3qegJqprFnaxOJ42VoJD5kjDse4PtVR9WtItNFx8x8vgMg+RR6mgC34psrmH7J/Y8iRRy4R1U/NyeSfausmttOgisLCzkR/3eZXAwAe/wCNQ+GbO31PQILlkV/tTbYhn5lHeu0HhOysLUspDEnO5ueTQBz2iW/2ueOaSRlghJU8dSOmPwrotfvJbOeJYsE7RsEp+UDHep7yGHT7a3dAd8zbQAPun3FcZ4vjub2O7ublyFiJUP2H0oAu6prkKWzRXsGPPXHB5B7Hiu/8JzRyeHLdkbcw+U141oTpd2Ets8heVFBVQM8Yr1vwlbG00S2TONy5x2oA6SDJUFqkHBz1x0pkX3BmpGPPpQAKTu68e9SIRnJ4NV88gZpwJ4wRz60AWJD8wwfzrPkYmRgSc7u3FWpnOzI6ist5W859xJGcigCy7HOAfzPFDxtMikAgDtVYNvPU1pWp/dRrnk9QaAKzqYTkZAxzRG6nA3DcRnHrVqcLJlGH41nSQruGxvmByDQAy9ga8idV+8eNp6Y715L4w8MSX8F9YXKFoWRlwnceleu3ltdR7Zoh8mPmFUr1I59kgQM20hxjrnvQB8n6dr6W3idLC+RYYrBAI5hyoXA2g+9ehSavcXkZ3QI0pOYHXow/u/Q9a5b4weAmi1O21DS7ZnW4nWOYjPyITyce1MXUxpiQ6dp3lvHbkI8uDnPQ/SgD1jw/rdxp1oLae4eO8uV8wRjqFGRg+lalldTwNEXcOjjPPVj6A+tefaeyC8W6nilm8wlBKhzsGOMj1rqNKz9tl3MzRkjCHoo/vYoA7+OESIkto2QeDnqKfJJtwjv0JBIrDs9We2kLKxaAf3epx2rWW9s7hiy/JuALEjpQBohkWJUx8zDHPOR3FVBpyLIbi1BBUfMn5dKkhkV8PGVZc4HpjNXITgFh97PWgDU0KXzNOYAcqxOKsyfNCCCeD3qDSdhjleMAbuTjpn1qc4MMikcdaAPzj+Kf/JTvF3/YYvP/AEc9FHxT/wCSneL/APsMXn/o56KAPqj9nycj4QeH4wMlRcY9gbiX/CvRFmGzDyMATxj/AArzP4CDy/hV4Ydl/dslypx1z9olr0HdEFbl1Kc4PJFADZWNlqRVsiGbOWHQnuazr+KUzSDBURgYzz7/AI5q9Oxv4fKtUZpgwYE8j3q9p8U8kDC62iVDhVHO4UAc+uoAWwQAKnKtuHUHqRWLd3cejg3E9sLrd/qmSPLFc+3eux1LT1jiDi13lcE55x7U2xLXEQglgEQDBojgdu30oA5tLq4khE9vpsqzs4YEJ2NZOp2X26Waea3uTdMMZRCMj0Nd8b27Mm2WBI9nXn8qQakihGZGLN225oA80sfCGoXNvctPbTC1yCi/3j7V0K/DS41GG3jMcaW3yrLG46r1x716BprlyrsCYV+bB6VoNqCRwNuYLx8oBxQBxL6NJp88MFvFBFFCuAM9vQVqCCe3t2d5VaQgeWuOAcU6Nle+82UhoQOx4qfV/L+xNdW7Bki5OTx0oAyZow4ge+OZhIG4Pf6elcJ4wn1CddQt7dhGkkgVUByG7tmrnh+7vtc1+S4llItkbhduFPPFT6jA0t6YpYxuDnBA5oA5/wAFaFPZXrzPcFydoKE8Jmvd47Nooo02bVVQBzXl+j24h1YopJtZNoyT39K9VTZGkYlYuT0B7UAWFQqoximMozyQPrTiV4IBxUTMpHANADgqdmBIpVQZ4Ipg2AZxz9aljaPd059aAHiLcT0wRWXdwETuBg1qnbx1GeetU7gK0h578UAUfJYA4YDtg1PbM+0E4O001o8E7jz61HF8kwx07j2oAvW53SlSDzzmo7rYsiuQVParEJHmKQOKL0Foxxn0oAUXKmMKT8h4Oe9VvJgimBQ5QchTzmmW5RmMbD5eufep5IlcAcr7igDjvE4juLWe1i4aRGIbZnBr52t5b61169tdU8qLzDsLNjO8dGH6V9S6zp4ERNs4+YbckV8/fEDwjqQ1KOR4Ptlo+Ud0fBXP9aAF0Wfa8lvJqSFBhy6DjPZfrmu41LVY720RZLcrMFxvi43j1NeR2unDThHpkT+SFHmFpRhm54IJ6kV2tr9pu7KDyEc3EbbcLyGHqaAOitvIt4HMssw4yBnOTWraXAQmGKUSH77MOQCe1cpDqiCIK0SS7Tsdv7r+mfatSxjhsAs4Yuki/OpOeexH4dfpQB1Nld3NtNGgGY2PIPPGa6uKSN4g0LhkAxgdQfeuN0yRn3bm8xB9zPBye1a9nd+TJ8oCgHkHvQB2Wk4CMOxHYVZI27hjIx+lQWDKYFZOhqxLxg4zjg0AfnD8U/8Akp3i/wD7DF5/6Oeij4p/8lO8X/8AYYvP/Rz0UAfUXwKgeT4O+F2RSQGuPmJwB/pEtekQWCZ86Ri+4cj+HmuM/Z8iST4GeHfM4ANween/AB8y16DDOixtGcHaMgEdKAFhdLeQCBVUe3AqrIJbebzfMAjdsqemPWnAhiWkXbnkHPFR6jc28sH2QsC4BK4OMHigCpNJLcz5huWEQyTg8cetZN7ezyTlYXAkP3SvQfWi2nggHlfMElyHYnpjoKzNQ1Kz02KQ2zpdMV+UdD9TQBsNI0tifNnaS7xjKAE4/wAakudasNMSJG2iVYwMN97P0rh9Kvrh5VunZgFfKIOgHbNYvihp7u6e4t5cyNkHZyGIHP0NAHoet+PbWysovJt5GywEmzoST0rPXxddXz/Pp4FsBuEvmdR3rh/CVrPLo73WpOY4ZJNqK3U49PSrOtSf2pYx6dpFwsM7SCJ0bqq+tAHaWfjWzuIjGunOsag5cNxj1qNvFelSWrwsLuG2YhCW5Vj6D1rjLKymdRpNlnyExHPKf4yOoFXPFloLeBZ5nRLW2GACMKTn+dAHplrHo8NrFJbylAy7gAvNZk11Dm4eCWKSWMcqeGFcJfa/DY2+mWwmjt5pEPzyE9B2q8+jRxaZbX7yKt1cuDw/UHtmgDp/DNx9uvzHMp8wHzCcccdq9FDi4RHAGeleWeHS9jriWJZslTIVznAr06wkVbRc8EnIoAtoSBhjkUhGHJzzikXkHHYcEUAnnJzmgA7jPrUgBz2HvUakAj2qRT6du9AEpb5QevYCq0m0yNuIBzipyAVGDis66UrOTg7euTQBNOsfeQAj1qqfLVixkAxUTzZyhHB6etNIV1Ix8vQEUAadhcRSISsmQOpqYyRSMAJFGOvNZdodrPGFCgcZ9aZMThioAIoA0mtxkOjY9xViIEgbgOlZCTbHRWJViO1aEFwrLtTn+lAC3ZVI9jruB6ECuX1u2j8iSEAuZupI4A9K69og5X+I1j6zbvFG7IoMjDPH86APPda8Ky3luki20MpK7UDDp+Paqdnoc2n2ky25EFwW/eFDuCir+qavc2d0sN1K0ENwPl2cncOv6Vh6ta6ksk0sV3JcWpwCQMcEcE/jQBm33hy8S/zvSW1fGQgw35etalpGRK0UuVG7C7lIOPWrGi3d7LAkEwLndwcdsV0lrbhlAuSJmAOFAztoAhgU26rEGJwfvDgdOtXllWadCvCcZPrimrZ7wDayD/rm/wDQ1VSXyJxFIjB34IPb1NAHeaDOduG+4xwpx6Vst0buPSuZsXMUcYHB6107NhlY4wwB4oA/N/4qf8lO8X/9hi8/9HPRR8Vf+SoeMP8AsMXn/o56KAPrn9nPLfBTw4uDgi4+n/HzLXbxobdnYJ5sig4APH4159+z5M4+C/htE4A+0Zx3/wBJlrsb8TKZHDBAy5BB7+lAEdxNPK4JQnJwoHYVWe28hxJetgZyiY5P+NRG6ljaNkkEj5xwcc+9F/eyuY2cRySAY9x7UAZWv+czPeWzKkYxuU9vf8q5uxgjguZJjJ52DnGMqmef8iukiVQ5lnRmi25IH3foRXKa3qUens0cAKrNKGAjTdj60AaEwt4raYsH2A7mVeCwrB0qaBJXnRZXCk7U28AcdafJJqchVTH5iOQqt0GDwc1saHol4SrRWZSLnIz94nrigC3rDRfYI1jiRr2UfJbnjex/u1wvhiwuhNMblfIu2bc7MDknJ4X04r0DSfBF9feIBdas4NuFyi7seX7fUetdXceHLKzUyzyEIg7D360Acz4baHT5YY5Cv7zLAMcsVFeb/EfxIdS1lNO0yGSdEl2sV5VSM4B7V6FcR2NprTXRzLI/AkboF9PypNT8LWs0CPZBY1bEoIXG4ep70AecDwdqet3UFzqMLrauMKjtjkeld3eWMVrols9zI+y3YfJ/Ccd6tar9s1bUYLW1lMVraheRwXb0FQeLLhV0qwguQWEmVm28sTg4FAFP4XX6az4wuIlZ3njztPYpnivcJIfLVQDwBXg37O9uF8Wa7OoAi2iOJSeVI619AzfMm7aeaAK0ZKr35pwyWwOcDtSAE/KBjFOG+NSxI9AKAHDd6cU7bxn0phbdnGSepz3qRegHb60APDYHQ1m326OflicitMcAZ61Vv03KO5HQ5oAy2+TLMQT6+9OtpVywOFHYAVLtDDDKB2zUUkK7V2HBHNAFmxG6Z+mCM064iyhKHk8YNV7JzC4DqRk465Bq3O373K8mgDLUOzbnB3occjqKni3pPuQEn371ZmAIBTGSeaUspA4xjt3oA0IJGkiLDh17e9VtUmcxoyqOeopglKsdvYetTHF1asi4ViME9xQB4Z8Y9dubOSKUWo8mCUGUlMjYeuKg8N6/EJvIe4DLN821jkbB/Sux8caT9ptXgvUWRwrAbvuuMcZrwyxstStZYxJA8UkO6MsgyioehX0FAHtGlWyNeCe0vRLZKxKxnqPatu5nK3LGFGAZidw7+1ea6RfyWqJJbb1hJAk9ccc12NhqJ+1uLhWKO3yleBj60AdPYtHIpOCobuTg471KLWO9dPNTG0/KwHOBUSyQtGoUDfIOMjoPetPTA+xi2MrwKAHKHjdVcc5/SupTmCMk8hawRGJnAxyemeorbhz9mUcce9AH5zfFX/kp/i//ALDF5/6Oeij4qf8AJT/F/wD2GLz/ANHPRQB9T/AFWf4MeHxkquZ/x/0iWu01FQ1rJnO5P4R3Fcd+z4zH4OeHs42qLjGe/wDpEnFd1OdiupUkuME+gNAGFdWU8kIMTxxuRuUjqPr71RFo15dCLzPJuJCA205A7UhtNQuzchQBGp8ssTjbzRZxvb3wMMyysg3MgGR6UAas2nOojtIRlcfO7HH40q2WkW8XlytE8j/K5RecjpzWZML67laUySBWyAR91QPb1qKGOO1QhwXcttBxksf8KAOg0yHRtNDRPCJZ8bgxGT+HtVt9WDp8rIgUHbHtxisKzDTyl51KyIB5eRgIP65rMvNQFrFdeZGXZiVODwPpQB2dlq5jiZygm3JggYwDVHW3ub3Tg0QV0JB2Z5wa83ufFMWi6JNdNIpjOS0WfyFcBrHxI12LSvMW6EVrKBHGY1B5znk0AepatYTrbh5EiFv5gYKTgEdyK6a11nTr+HFpdQlRGUxGT+PNfKWreNb6aGU3OpSSzyQhERGO2P1J9zmu08CW0mk+Bkme8Yz3YaSKMH5tvt/WgD1rVJIIbTNg4dQOArYOc+tccmpTJZySyRPsikJPmHJI/wAa8cufFupWur29pbapKbdZNsjA5GGIyPwr2DSb+caJeDVILa8tYm3K/wB1lHXdnvQB2nwKhYx3d+8Bjd5HKkjG9SeDXsM9w3lehxXEfDG58zwjbXE6eWtxl0UjBVewrrVPmqcnt1oAdC2SGNSMSfMySP8APWo0Taqrn5jz6U8qwcE8Y96AHZ4A70BuOCM1GAcEHtUgXofzoAsIOMmq9wcMhJ49KsQ+hziorzAVWJAHNAELRjIZR1qKSMA4B59fWlju0BKqee1BuoQCrpk+poAjhOWCkjirjxxtH0yc9RVJpollVWG0tVhW2zkK3G3OfWgCFEkimYb1ZfQ1DL50bHcoKZ6jtRO7JK/LcnINTQXO87XwePzoAr5zcA7jkjGD0+oq3E4R9ykDHY0g8uN9yLlucA1HcMm0YGwk5b60AUfF2nRatpreTIouU+ZSRxn0rw2RNQtL/U9IlVpMxiTeDzjk4HtXut+Zbe0e4jXc3RtvQV4143Y33iPT7mzuTbTA4btn2Pt7UAY+gTNBdLcTzkNuEZglHyt7/hXUy655M4ju4lWIHapQcAnoK5TVLOW3194LsbYpNrh2OM98ip7a6S/hmjt7osYyXj3DHI4NAHeaPqkstw7vNudAA0J9Pau802dJrcKMRzDlh7+1eX+GIpr4mec+XJCAWZf4sV1VjdzxYd3yzMQh7UAdvbPmQAg8etbMf3eO3FYOkSedB5uNpxyCOprctmJfkDkc0AfnR8VP+Sn+L/8AsMXn/o56KPip/wAlP8X/APYYvP8A0c9FAH1R8AyT8FfD+08j7QPp/pMhruxaPcgFwfJAyQSQeK4b9nVUT4RaC8udjCcYz/08SV6Ndl8sokATr/8AWoAyNY3fZlaIpFETtb3rKjNnp80k0fzSyJ8vf8q1pYYm3RyuFjbHXuawJreNLyVkcxoowqg5GKAKMOpXbTPHDuSE/eLDsT1q7d6/Z2cYQBXYJtRh13VQ1fWrWGwENskc0q5DMvWuGs5nuXubmVAbeEkuCcsGxwaAOzTWZWjklkk27gR5a8s57fSsLUb+O5tBDPG8Splz82CrnkA+v0rH0QXW6XUNR3ImThUORtxjr+FF3eXOsf6MbL5WbLyDH4E+woA5Xx9qMU2lvGg8+YAJGuMbj3b6D39K8lS+ubK3nhUbonO1hJyPXgV3njt1igitIppcM7AbByfXPtXD2emz6q4FnHI4U/Pgcsfb3xQBBoumPqt0sMRAYsB0z1PWvR/H2sNp1hZ2Vn8sqW2whOiDoTWv8OvBGvTRXIGitHB5eI5rtdhye+BzxXoHhf4LLa2E02p3Bu76bDPJJ0C9MKO3NAHzZ4S0eXVtZtogjlS4YttJBANfU2heDTKYl1GWNbHZu8tDgO3ofaum8J/D/TtDRzBAjsx5LLz+Fbs9izSxgqscUfYdaAJLFlkgjgRkEcWFVE7D0robbakR3Y9hmuX0nT9l87rkIx7GuqWHCjHIA4J60ANdyzcYpTkn39cVGykScVOn3Rvx9KAGqSByOtPU/THem4+VgKdGOKAJ48NgjPXjFQ38Z8luDnGRUiYx+HrUr8xMDzuH5UAcwv8ArSwH/wBap1ZH27izfpUE+IZWGcZOBURuQGY8HA/OgC/Innux2jevQ+lVopJFuCzEjbxz0P0qWxnDQs3BJ6ew96r3E6M6ouchsn60ALcXoW4O5wpPQGmi5VG+TGfzqvqFt5jb8HI5GP61QEM5BKYK9CScUAdE04n284boAD1PtVhyNgEi5fP+TXO20coVDHIN6kHGen41rvP59u7oMSoMlR3oAuI4UkbhtbjnpXi3xj0OKHUrG8tEkVZH+bacKfY16jNfR5IQ8AdR0riPizdMPDNpcJIoZZRlgM4XPP40Acjqz2+oaZbfbt0TogjkfOQewArBSGTTr5TArSj+DA4YH+vNbeiiCayNvcsslrMMZz93nj9a2ND0uTzXl3pJGh2w7epPc0AbGhxRRWKqjkA/NIueS56j8K2dNeXcACiqOMHr+A/rWDpltE13MtuzxXCZJV+hP07V0NihOya4XZKoO8L39xQB0+muYEQNglzucZ7ZrprYjzBg8GuL0lmlcykHpyTXUaXL8yocA8Yz0PagD8+Pit/yVHxh/wBhi8/9HvRR8Vxj4o+MR/1Gbz/0e9FAH1b+z6VHwT0Dc5DYuAABz/x8S12cknmAkSfMp2lcda4r9n0qvwa8O5Gc/aCP/AmWuqv7m2gk8115UHhT97/P9KAI9QePyyGfAHAGe3rXG6xqkbIzhzGlvyEAOZV7g+ntT9Y1db2RbSEiORxgsp7dqxtXiS20pWlDvsG4DqWPYn9KAOP1m5v9RliFhH5FvI/3mOOep+lZyXTRxXVla3kcjXDKHJOMkepHaovF13qWuXv2TS4WmuVA3KgOCSOTx/niur+H3wukEIm1NDASu0RdW+rNQBy+v6xq9jZ22l6bDPPO8isYY0LDAPDA9hW94N8HeOby+nu7mW3s4JV2/vOX+mBwK9o03QYdNtUSHAPC5xk4HStS2tjG+3ccZx6ZNAHMaX8MdHmhU60huZSoGG6HHoK6nSfCOk6Q6/YdPtoI05+VAK2tPs5EKSN16nNXWdGbByMHvQBVciUhEC7McccGlkhVE3DGQMYx1qRsFsLjGfwxRK4KcDjPHFAEdpFIQxd1JPI4rPvLYtKS2QSexzmtFiSOm0d6asfmZZvpQBnWMbxMVbGwnIrcjQtEN+fbmqrQjACkcGpjKF+XsKAGvGegb9aVYzgDv6mjfkenr9KjaQGQjPQUASRLjPHQ1KrbsAkZFQqTjBqSPn60APQEdcGpdyjqvJH51EvPFPl4TGeT0oA529j3kkqwbJKnFYF9NsJRep4IPGK6ebIiYN17Zrl9SCyNIChQtwT60ANt70RLhZABnBA9KlE6pcbopNyE5/GsG6iktowUI2enc+1ZllezyXBiGE+bpjk0Aei390qQFtwXdgH2rMMjRybw+2Fxge9ZDailx/ojLI0gG7KiorYapcTGKCxkMeR80p2ge9AHQwSwjc3m7ADnGPSq9rq0LyncSsjMfxHrU9toF7Mxa7mVT3SNfvfjVqHwxEs6yOgYAYAA7UAcZ4h1QWcrxIQZHyd2eF+lcr4w1mOXwndRTYchRLsJ5bpkfWvYpPCmn3O7fbqSD1PWuc8S/DPTNTgkh8slJF2NyemKAPDPB90Lq+ghjkWS3Rd8oZvm2k8V6ra3qWGpxGPmDAIizwB3H1rmbr4NSafbquh3skcyMdwkG7cD7/hxU0FrqmlWkserWkjpAeZkGVPpQB3mqwW+oyx3NmDC7r8pB6gdj/jT7WaW3tjb3KHzVcHd68fyrH8N3edOEpkEilsIh6jjr+tdFDFmFAiBw3Unt7igDb05h5AkGCHPAxitaxObiI7sqCOPU1jWmbfZBIQwxwQO/U1tWA/eAk9OaAPgL4rf8lR8YYJP/E4vOT/13eim/FLn4m+Lj66vd/8Ao56KAPqn4EThfgf4fAzujFw3HU/6RLwKfrGpfa3e2jhkyFOGU4yfeub+EF1NH8INAjjVtpE46/e/0iTinavql3pymNoV+0EfM3TAP8u3NADJp7bTI7i7ljDi3IK5bnPuKz7BLnxlqsZWF4oON7BzgewxVTRNP1TxXqElnZkBZRmVz91FByf5V7l4S8M2fh7TYrSzjARV5J6lvWgDM8MeD7LSXMsEKmYgBpDyTXSrZrGMgAdjWnaQYXnhc1YMSqNyjk4BoAoJa42kLhBzyKsQW6rltvU9TVgL8nzZGPXvTGcjGNuPegB2/CdSP5VVKk4weKlaZdijGT+lV2dpCACBzyKAHq/lv1wD1HU01pTuChflz1zTWQqhJOc96S3BVu5A9etAFgyYTLDJHrTkkR04yp64x1qHJ37iflNQzNjPqOeKALMq4B2nryKRcug3Abs1lyzyfwsQPbmtS0ZvKVpT1HHvQA5sjOMY7UrAEdQMfrSNgndnjuKe2MHA4xQAxRk89hxUsQ7YJ/GmAHseakjoAeh55FTSAOmSPaogQoHPTrUqZOf0oAzXhMjHIyOmDVC50hJQQVYKTnirNyHS6ZQWAzkc1JbyS5IDZHoaAMG70OCUqCpKg8nPI/Cn23h+1ilafyULDgYHNdHIquBxtx3pFhxGwXk55oAwrXSliu/MwrEnqR2raa3QqCqhTjn3qVEAxuFS9D0z3xQBEmcAAjjvUqYVT6dTxSNEeqcDvSpkDnp1NAEsQ2kEDIPbFStApBz948mmp93qakibP3z16+9AFGS0VZywHyn171FJp8DrIrRKyuRkEcYrUkXJzyRSAcY9RQBweq+ArfeZ9GY27ZJ8sfdJ9fY1Q083Wm3H2e/jPGWIbuP616Uo2Hjp0PvUWo6dDewESKN3Y46UAc2qI3zkgRtyM9auWTFAeRvJxxUCW0lgjQy/MN2VJ7ip0U+avcr14oA+BPil/wAlN8Xf9he7/wDRz0UvxTP/ABc7xf8A9hi8/wDRz0UAfRfwRkdvhNocSEA7puv/AF3kNSarpFx4n1gw2CYhH7u5kbJEfofc+1VfgBZXGo+A9Gt4gREPOLyf3f3z/rXvGjaPbabarBaxhE6t6sfUnvQBkeD/AAvpnh3QhbWK/P8AeaVuWdvUn19q6K2hJSPeOv8AOpVgG7BwOasghUCjr0zQAxYtuRimkBQxABJxT+V4z+dRuRzg/jQA12PzH7x9KpsSWPPTtV1V7kn6etQ+VwcckdhQBWKjoevWlVAWBJ79KnKYC4GSadHGMEnrQBX8osxPP0qYKvlZxt561IevAHPFI/C4yAc0AVsHp0HpVO8fPCnjpVyZwhIXP41SkUuMNw2cg0AVYl8yQYzgHnitYnlVAwAKqohiTkEd+e9XraIFCxPPpmgBqkl844xTtwzxyQORinOhA6jBpzDoBjp2oAYBz0wB0p45G7pSEEjAwT7U9QRjp9KAGD73J61ai74J/GoNpJPQe9SRkgn3oApaou2RH/D61Wt3Ic5UqeuK0b+PeEG3ODnpVTaFB5wM85oAuggp65qMKyhhyarx3B34B4HT6VYMhYHHHHFAEmMgYHHpQzLtyep6D2qMyMFXkHnnimlmAyQdo5xigC1Hk8etPCDOG4Haq0U+eR0+lWlcsgDDigBwUg8DgU4DGBn8qOcHHX3p7D5OOo60AAzswaZ0zj+dIG6Ej8qeTwOM8daAHIPm6VJjAGO1MjILE5qTsRigCC8tEuo/mGR1z6Vi28RWco+Sy9ff3rfLbOD0JxVK8tllmiccgZJAPDccA0AfnZ8U8f8ACzvF2MY/ti8xj/rs9FHxS/5Kb4u7f8Te7/8ARz0UAfWn7MqiP4RaKyqoZ2nbgcn9/IP6CvXVPyKCMkCvJv2bCsfwc8Ouf+njPv8A6RLXqsJG0tuwo568CgCYgHnnNOQ56gYpCeODUUsnloFB+agBS46DsMUwc9BzUf393P1ycULgIRQBOSOwJ56Ug4BPAzUKv1AzjrxT/N+XPAP1oAdwvrgUuflzx1qBpwTnvTXlyrDv0oAkZwpOfmOeBULuSD/DyPxphJYg5z6Uh3nPA5NAELAlue3Sp4Ycks2cdqmigw+SB7mrDKBwDQBSljLgqR05+lWoQERR1P8AOkYADgYJ70sa5C56igB3cYGDUbnAyWFSr1ORUTjk59egoAZv5xn6E1NGc9O1RenQ9qlQben5UASr0wOT3ojGCCM4ppU9+DUoyAOmKAIbkblB9Kqzw+Yo29jkirzjKkd/QVBtxk4zQBlmFlbJzirOSVwBzV0x7/Q4pgTB6Djg0AU5C/l/KDn2pyMXj56Crq4A4UA570YDAnH5UAV0X94DgDHpV6OTA59KrNlTlTz/ADpimQgHr+PNAF4Nxgde2KVGz3PHrVQSsCFI46fh7VKJgAAc+2aALOOPamgMCADz24piTI2AOvvS7kccsPagCePgAEDJqTqOcfSoFZeAXA70/wA6PqzqPoaAFk5BBHFRwLuRo26gggntUU17bqDhi2T0ANZeoa60DA29uDyOWPagD8//AIq5/wCFoeMM9f7YvP8A0e9FN+KD+b8S/Fsn97V7tvzmeigD6q/Z0uo/+FT+H4CcN/pGc/8AXxJXrtpOhiCk57fhXjP7PcAHwm0OZsAj7QAfbz5M16haByQ/QZwfegDdEiAFyeB05qCWXzFyeMGqU0pJ2rkBT2/nT4ycYzz1oAnaVRz1yaGlG3HX8OlQgHOTml2ZGBjAoAcJTu4A/GmuzNkY4HpT0QAn0FPCZyBQBCF2kHNShNwJ7nn61KseW6VKIx34ANAEKRE8dKmWLOewHeplRSB1Ht607aAvP/66AGEEfTFMJGeBn+lOc56ikI44A/OgCGRm424HrxUloMhs03YPWpIhtXHc0AOdQOOcUgUZ9qcT07mlUZ5I7UARkD0pu0Fec+9SOpxj1pAvT3FACgA9vpmlHXH9KQ8Ajv64oAIPBOTQBI+MAkkHvTCvXuDStggg8CjOMfzNABtKkAflTeOmBkc81Lx6CkKgsDigBhTuOlJtOTkflUuQOpp+AR0oAqmPHAPGO9JsbPerJXqMd6btPJ546mgCuY+SQaa65GevHWrJXOCMehoKHHHTPf0oArqvp17cU7y+2PwpTGVJYHr1AqdFBAz0FAEDRbgc8kDr0qCSLaCc4b+daGzrnHXIHpTZoww/x9aAMcwZl6ZIHGPr0qpqEBaInk9ORW2EwTwMk1R1UBYGKnBCnp60Afnx8R8f8LC8UY6f2pdY/wC/rUUnxE/5KB4m/wCwpdf+jWooA+tP2doxJ8HtB3dP9I7f9PElelIvlQkZwP4a86/ZwAb4QeHxkbv9IOO+PtElelzLuCgEdeRigCGBCBwcnHBq3DGSmPX07VGqDGcNx2q9EMJxgexoAheM7BtyeeooCEemTV1RmPI+9ijyhtBGaAKuzGPzOKeEA78n2qx5XA7inLHjGewzxQBFtx05/CpQvHPJ/nUip0IHFOIwD70ARAfKBUZJIPFSNyDgUzbwefxoAYvfFLt4yBT1HT+lLtBx1oAiK5xjtTwnOQCTS/eGR0/Snxfdz6nigBhXGMYzSYOME1MR3FM+XBJIyKAGEZ7/AJUY461JlSQB09aRRuJ/T3oAjK+vftQFOM9vrUwXn2odcH/CgBpBxyKRhwD3qRx8oH5+1IVyM0AN574oGeuOacUGemRSgAHJBFADSM4z1PWlX0U9DinBSQMHnPWnbc9c0AIvv296AODgcilVccYpyYHqaAIwmAQfT1o7Yx3x0qfsadjOeP8A69AFUKGOBxmnFVTknH+f0qcLyKHAGQaAIE6f0oK7ic5yfel+brjipFUcHrQBBKgXnHbmsjVfmQIoyWGa3JBlQBj3zWcLffcszDIHC0AfnX8RlKfELxQrLtI1S6BHp+9biip/ioNvxP8AGA9NYvB/5GeigD62/ZxhA+DnhyTH3hcDPr/pMvFempznqCa8+/ZzXPwK8Mtxx9p6j/p5lr0WJDjIxgigBAgHXPt9KkXOWxjGaleL5QcDg45oC9gOtADkfJAJx7YqdeQMY9aiRMdQADUqrzx27UAScbemfakwDyKFIyMjvRxhsZ/D0oADjGQBTDknHrT8M3GB7cU4Ljpx9KAGBRjJFN29eKkYZHGetJjGemPyoAZt/OjBp5Hf+tI2cHFACEAAEnP0oOB0xRjj0JpAvPPSgBScj61GRgehzVhkGOAKaIySAQMfWgCILz6UqLjGKmMXpikCFefwoAQ8rxSqo3Z7U9R1x0+lBxjGO9AELAs/0p209+CakwTmkUFR60AMKnNLzjp+PtT8BhyBigKc5oAQnPT8qUFc9eR6UoH/ANalIBGD0IoAXHOTTVHHOcU9VwMAcUYyD69qAEU9RTgBjIGM/rShSORnNHOOOKAEzgYzzTHOTTjnHTn1oI/yaAGbR9M96EPQHqelOC+3Wggk8dulADH5H14p4QBcgdP5U1PnfntU6D5ee9AH5s/Fb/kqPjH/ALDN5/6Peil+K4/4ul4x/wCwzef+j3ooA+yf2ao93wK8MnHa5/8ASqWvQbc4yvQg9zXCfswqG+BXhoHt9p/9Kpa76dSspIH0NAFrYMD1pqxkEntToJOzficVaVcg9RQBVYbcY46U4JyeMipyq8Dj1pnH8PegBqpwd1LtB9KVRzyeaeFHc/rQAw54IpPmPU0/GTxzQBigBuMD6UY4Jp+PelPIoAjAzjvSEYxjt1zTwPrijHGOooAiI+br+QowQeMc1KRzSHOcAUAGeMNxmlA+b296coPpTth2+hNAEfUcZxSbcEHJPfk1IF4Oc8GlA6YoAj56npSKDySakK5PegDnpQA0Z4IpSATTx7dqQ+/egBvX6UAevNKBngindM5OBQAzoO2fWgj1GKXb3p2PzoAaBhcClA/MU4fWgDnrQAKcU4D8KaOuD1604dKAGleDjFNIxz1NTDpRQA1BxyKZKMcipe1RPzn1oAgiJ8w4HHQ1bx0yBxUECg59+anWgD81/iz/AMlU8Zf9hm8/9HvRR8Wf+SqeMv8AsM3n/o96KAPtD9mAZ+Bnhg46fah/5NS16JeoFbgd8159+y7z8CvDX/bz/wClMtem3ERcgjBXuKAKcK/MPU1aXqc1Gi4OM8jtUy45oAb7UuMgelLt4NSKgwD0oAaF6ntSdT1qQc9uPSgDigBm3ml280/FAHHegCPb8uOlAGfyqQDjpzSY5PrQAzHOe9KB+dPoA45OKAGbeRxSqvPIFSAcUtADAAP8aUKAMdfrTqKAGkewoI6cChi2cL6dTSjOOetACEDGTRgHmnUUAIAAPakHPI6eopcZGDz9aDwD7elADSOe1AGKUYzkDk0uKAGEE9DgU4DA4HNLilNADWHcn8KMfhTsUUAJjnpQRwcdaWkxznHNAATgjPfiloooARulRSEY4xUvPGaifGR6Z59qAHRLheMU8ZpRSA80Afmv8Wf+SqeMv+wzef8Ao96KPiz/AMlU8Zf9hm8/9HvRQB9pfsvD/ixnhnBx/wAfP/pVLXqZbgZFfNnwH+MXgfwt8KND0bXdc+yaja+f5sP2SeTbunkYcqhB4YHg9670ftA/DPnPiUfX7Bdf/GqAPUpCpPNCAdBXlT/H74Ztn/ipfp/oFz/8bpyfH/4Zgc+Jv/JC5/8AjdAHqoxg/wBKdn16V5T/AML/APhlj/kZv/JC5/8AjdCftA/DTJ3eJsDoB9gus/8AougD1Yehp3515UP2gfhl/wBDN/5IXX/xul/4aB+GOf8AkZv/ACQuv/jdAHqnTH86XtXlR/aB+GJznxN1/wCnC6/+N0v/AA0F8Mf+hm/8kLr/AON0Aep96O9eWf8ADQXwx4/4qb/yQuv/AI3QP2gvhj/0Mw/8ALr/AON0Aeqe2aa2QMg9O3rXlv8Aw0F8Mf8AoZv/ACQuv/jdA/aC+GP/AEM3/khdf/G6APVAcgEd6WvKv+Ggvhj/ANDN/wCSF1/8apP+Ggvhl/0M/wD5IXX/AMboA9WHvSc15X/w0F8Mf+hm/wDJC6/+N0f8NBfDH/oZv/JC6/8AjdAHqgUL0AGeaCOnJryv/hoL4Y/9DN/5IXX/AMbo/wCGgvhjn/kZv/JC6/8AjdAHqtFeV/8ADQXwx/6Gb/yQuv8A43R/w0F8Mf8AoZv/ACQuv/jdAHqlFeV/8NBfDH/oZv8AyQuv/jdH/DQXwx/6Gb/yQuv/AI3QB6pQDnpXlf8Aw0F8Mf8AoZv/ACQuv/jdNH7QPwxBP/FTdf8Apwuv/jdAHq2aK8q/4aC+GP8A0M//AJIXX/xugftBfDHH/Izf+SF1/wDG6APVaK8q/wCGgvhj/wBDN/5IXX/xukX9oP4ZFQW8S4PcfYLo4/8AIdAHq1FeV/8ADQXwx/6Gb/yQuv8A43Sf8NBfDH/oZ/8AyQuv/jdAHqtFeVH9oL4Y/wDQzf8Akhdf/G6QftB/DIk/8VIRzj/jwufz/wBXQB6tSV5T/wANA/DLn/ip856f6Bc8f+QqF/aA+GI6+Jhn/rwuv/jdAHqxGRzQAO1eV/8ADQXwx5/4qYf+AF1/8apB+0D8MQP+RmH/AIAXX/xugD4s+LPHxT8Zf9hm8/8AR70VV+IWoW2r+PvEupafL51leanc3EEm0rvjeVmU4IBGQRwRmigD9BD8OfBGJP8AijvDfAP/ADC4P/iaP+Fc+CMR/wDFHeG+cf8AMLg/+JoooAl/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImiigA/4Vx4H/6E3w3/AOCuD/4mo/8AhXPgjb/yJ3hv/wAFcH/xNFFACn4c+CNn/IneG+3/ADC4P/iaf/wrjwP/ANCb4b/8FcH/AMTRRQAz/hXPgjH/ACJ3hvv/AMwuD/4mn/8ACuPA/wD0Jvhv/wAFcH/xNFFAER+HXgj5f+KO8N/dP/MLg/8AiaU/DnwRj/kTvDfUf8wuD/4miigCT/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4I/wChN8N/+CuD/wCJqFfh14Jy/wDxR3hv7o/5hcHv/s0UUAP/AOFc+CNp/wCKO8N9/wDmFwf/ABNP/wCFceB/+hN8N/8Agrg/+JoooAP+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaKKAD/hXHgf8A6E3w3/4K4P8A4moh8OvBHzf8Ud4b+6P+YXB/8TRRQBL/AMK48D/9Cb4b/wDBXB/8TR/wrjwP/wBCb4b/APBXB/8AE0UUARD4c+CPNcf8Id4bxj/oFwf/ABNB+HPgjen/ABR3hv7x/wCYXB6f7tFFAB/wrnwR5mP+EO8N434/5BcH93/dqX/hXHgf/oTfDf8A4K4P/iaKKAD/AIVx4H/6E3w3/wCCuD/4moofhz4IKDPg7w2f+4XB6/7tFFAEv/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTRRQAf8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNFFAEX/AArnwR5rD/hDvDeMf9AuD/4mj/hXPgjzVH/CHeG8Y/6BcH/xNFFAEv8AwrjwP/0Jvhv/AMFcH/xNH/CuPBH/AEJvhv8A8FcH/wATRRQAf8K48D/9Cb4b/wDBXB/8TRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph from a woman treated for asthma for many years prior to diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38242=[""].join("\n");
var outline_f37_22_38242=null;
var title_f37_22_38243="Perflutren protein type A: Patient drug information";
var content_f37_22_38243=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Perflutren protein type A: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/23/35187?source=see_link\">",
"     see \"Perflutren protein type A: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3033664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Optison&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some patients have very bad side effects during the infusion. Tell your doctor if you have any bad effects during the infusion.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before a heart imaging test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to perflutren protein type A, albumin, blood products, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart shunt.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12042 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38243=[""].join("\n");
var outline_f37_22_38243=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033664\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015964\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015966\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015965\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015970\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015971\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015973\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015968\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015969\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015974\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015975\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/23/35187?source=related_link\">",
"      Perflutren protein type A: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_22_38244="Cisapride (United States - available via limited-access protocol only): Patient drug information";
var content_f37_22_38244=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cisapride (United States - available via limited-access protocol only): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/46/29414?source=see_link\">",
"     see \"Cisapride (United States - available via limited-access protocol only): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/51/32565?source=see_link\">",
"     see \"Cisapride (United States - available via limited-access protocol only): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Propulsid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       An unsafe fast heartbeat may happen. Tell your doctor if you have a history of fast heartbeats, kidney failure, low potassium or magnesium levels, or lung failure. Check all drugs with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691310",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used in patients getting tube feedings who have high residuals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692020",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat poor stomach clearing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cisapride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703553",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Fast or slow heartbeat, heart disease, hole in the GI (gastrointestinal) tract, bowel block, kidney disease, low magnesium levels, low potassium levels, lung failure, very bad GI bleeding, or a very weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks; quit smoking; raise head of the bed; avoid large meals before bed; lose weight; and avoid fatty foods, chocolate, caffeine, or citrus.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695822",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 to 30 minutes before meals and at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been more than 1 hour, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect tablets from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12210 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-965172F715-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38244=[""].join("\n");
var outline_f37_22_38244=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152071\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017657\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017659\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017658\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017663\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017664\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017666\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017661\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017662\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017667\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017668\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/46/29414?source=related_link\">",
"      Cisapride (United States - available via limited-access protocol only): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/51/32565?source=related_link\">",
"      Cisapride (United States - available via limited-access protocol only): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_22_38245="Laparoscopic mobilization of the transverse colon";
var content_f37_22_38245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Laparoscopic mobilization of the transverse colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows laparoscopic mobilization of the transverse colon by dividing the greater omentum. The specimen is distal to the gastroepiploic arcade.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38245=[""].join("\n");
var outline_f37_22_38245=null;
var title_f37_22_38246="Bupivacaine and epinephrine: Drug information";
var content_f37_22_38246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bupivacaine and epinephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/10/3236?source=see_link\">",
"    see \"Bupivacaine and epinephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Marcaine&reg; with Epinephrine;",
"     </li>",
"     <li>",
"      Sensorcaine&reg; with Epinephrine;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;-MPF with Epinephrine;",
"     </li>",
"     <li>",
"      Vivacaine&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sensorcaine&reg; with Epinephrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Do not use solutions containing preservatives for caudal or epidural block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Caudal block (preservative free):",
"     </b>",
"     15-30 mL of 0.25% or 0.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Epidural block (other than caudal block, preservative free):",
"     </b>",
"     10-20 mL of 0.25% or 0.5%. Administer in 3-5 mL increments, allowing sufficient time to detect toxic manifestations of inadvertent I.V. or I.T. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Surgical procedures requiring a high degree of muscle relaxation and prolonged effects only:",
"     </i>",
"     10-20 mL of 0.75% (",
"     <b>",
"      Note:",
"     </b>",
"     Not to be used in obstetrical cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Local anesthesia:",
"     </b>",
"     Infiltration: 0.25% infiltrated locally (maximum: 175 mg of bupivacaine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peripheral nerve block:",
"     </b>",
"     5 mL of 0.25% or 0.5% (maximum: 400 mg/day of bupivacaine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Retrobulbar anesthesia:",
"     </b>",
"     2-4 mL of 0.75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sympathetic nerve block:",
"     </b>",
"     20-50 mL of 0.25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infiltration and nerve block in maxillary and mandibular area:",
"     </b>",
"     9 mg (1.8 mL) of bupivacaine as a 0.5% solution with epinephrine 1:200,000 per injection site. A second dose may be administered if necessary to produce adequate anesthesia after allowing up to 10 minutes for onset. Up to a maximum of 90 mg of bupivacaine hydrochloride per dental appointment. The effective anesthetic dose varies with procedure, intensity of anesthesia needed, duration of anesthesia required, and physical condition of the patient; always use the lowest effective dose along with careful aspiration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following numbers of dental carpules (1.8 mL) provide the indicated amounts of bupivacaine hydrochloride 0.5% and vasoconstrictor (epinephrine 1:200,000). See table.",
"    </p>",
"    <table border=\"1\" frame=\"void\" rules=\"all\">",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         # of Cartridges",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (1.8 mL)",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Mg Bupivacaine",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (0.5%)",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Mg Vasoconstrictor",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Epinephrine 1:200,000)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.009",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         18",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.018",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         27",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.027",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         36",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.036",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.045",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         54",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.054",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         63",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.063",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         72",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.072",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         81",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.081",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.090",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adult and children doses of bupivacaine hydrochloride with epinephrine cited from USP Dispensing Information (USP DI), 17th ed, The United States Pharmacopeial Convention, Inc, Rockville, MD, 1997, 134.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F143003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]: Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (10 mL, 30 mL); bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Marcaine&reg; with Epinephrine: Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (10 mL, 30 mL) [contains edetate calcium disodium and sodium metabisulfite]; bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (3 mL [DSC]; 10 mL, 30 mL) [contains edetate calcium disodium and sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sensorcaine&reg; MPF with Epinephrine: Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (10 mL, 30 mL) [contains sodium metabisulfite]; bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (10 mL, 30 mL) [contains sodium metabisulfite]; bupivacaine hydrochloride 0.75% and epinephrine 1:200,000 (30 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution: Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (50 mL); bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Marcaine&reg; with Epinephrine: Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (50 mL) [contains methylparaben, edetate calcium disodium, and sodium metabisulfite]; bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (50 mL) [contains methylparaben, edetate calcium disodium, and sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sensorcaine&reg; with Epinephrine: Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (50 mL) [contains methylparaben and sodium metabisulfite]; bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (50 mL) [contains methylparaben and sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Marcaine&reg; with Epinephrine: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (1.8 mL) [contains edetate calcium disodium, sodium metabisulfate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vivacaine&trade;: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (1.8 mL) [contains edetate calcium disodium, sodium metabisulfate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2234382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetic (injectable) for peripheral nerve block, infiltration, sympathetic block, caudal or epidural block, retrobulbar block",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bupivacaine, epinephrine, amide-type local anesthetics, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Bupivacaine-containing products have been associated with rare occurrences of arrhythmias, cardiac arrest, and death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-articular infusion-related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is",
"     <b>",
"      not",
"     </b>",
"     an approved use; chondrolysis (primarily shoulder joint) has occurred following infusion, with some requiring arthroplasty or shoulder replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest, especially when administered near the head or neck.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection or administration near the head or neck.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or compromised blood supply.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not recommended for use in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstetrical anesthesia:",
"     <b>",
"      [U.S. Boxed Warning]: The 0.75% is not recommended for obstetrical anesthesia.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Preservative-containing solutions: Do not use solutions containing preservatives for caudal or epidural block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: Some commercially available formulations contain sodium metabisulfite, which may cause allergic-type reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Test dose: A test dose is recommended prior to epidural administration (prior to initial dose) and all reinforcing doses with continuous catheter technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Dental practitioners and/or clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: EPINEPHrine (Systemic, Oral Inhalation) may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2234383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2234384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Marcaine/Epinephrine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-1:200000% (50 mL): $10.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-1:200000% (50 mL): $13.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Marcaine/Epinephrine PF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-1:200000% (10 mL): $3.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-1:200000% (10 mL): $4.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sensorcaine-MPF/Epinephrine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-1:200000% (10 mL): $5.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-1:200000% (30 mL): $9.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75-1:200000% (30 mL): $11.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sensorcaine/Epinephrine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-1:200000% (50 mL): $14.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-1:200000% (50 mL): $15.85",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2234496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, state of consciousness; signs of CNS toxicity; fetal heart rate during paracervical anesthesia",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F142992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Barcaine (KP);",
"     </li>",
"     <li>",
"      Carbostesin mit Adrenalin (DE);",
"     </li>",
"     <li>",
"      Carbostesin mit Epinephrin (AT);",
"     </li>",
"     <li>",
"      Duracaine (PY);",
"     </li>",
"     <li>",
"      Kamacaine adrenaline (IL);",
"     </li>",
"     <li>",
"      Marcain + Adrenalin (HN);",
"     </li>",
"     <li>",
"      Marcain Adrenalin (FI, IT, SE);",
"     </li>",
"     <li>",
"      Marcain with Adrenaline (AU, NZ);",
"     </li>",
"     <li>",
"      Marcain with Adrenaline Dental (AU);",
"     </li>",
"     <li>",
"      Marcain-Adrenalin (DK);",
"     </li>",
"     <li>",
"      Marcaine Adrenaline (HK, TW);",
"     </li>",
"     <li>",
"      Marcaine met Adrenaline (BE);",
"     </li>",
"     <li>",
"      Marcaine with Adrenaline (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Marcaine+Adrenaline (NL);",
"     </li>",
"     <li>",
"      Marcaine-Adrenaline (CZ, EE, GR, IL, PL);",
"     </li>",
"     <li>",
"      Neocaina (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Epinephrine prolongs the duration of the anesthetic actions of bupivacaine by causing vasoconstriction (alpha-adrenergic receptor agonist) of the vasculature surrounding the nerve axons. This prevents the diffusion of bupivacaine away from the nerves resulting in a longer retention in the axon",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Bupivacaine; epinephrine reduces the rate of absorption and peak plasma concentration of bupivacaine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ayoub ST and Coleman AE, &ldquo;A Review of Local Anesthetics,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1992, 40(4):285-7, 289-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/1397990/pubmed\" id=\"1397990\" target=\"_blank\">",
"        1397990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(4):872-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/21263316/pubmed\" id=\"21263316\" target=\"_blank\">",
"        21263316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaffen AS and Haas DA, \"Retrospective Review of Voluntary Reports of Nonsurgical Paresthesia in Dentistry,\"",
"      <i>",
"       J Can Dent Assoc",
"      </i>",
"      , 2009, 75(8):579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/19840499/pubmed\" id=\"19840499\" target=\"_blank\">",
"        19840499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garisto GA, Gaffen AS, Lawrence HP, et al, \"Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2010, 141(7):836-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/20592403/pubmed\" id=\"20592403\" target=\"_blank\">",
"        20592403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacKenzie TA and Young ER, &ldquo;Local Anesthetic Update,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1993, 40(2):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/8185087/pubmed\" id=\"8185087\" target=\"_blank\">",
"        8185087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2012, 37(1):16-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/22189574/pubmed\" id=\"22189574\" target=\"_blank\">",
"        22189574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1994, 42(1):16, 18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/7911769/pubmed\" id=\"7911769\" target=\"_blank\">",
"        7911769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yagiela JA, &ldquo;Local Anesthetics,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1991, 38(4-5):128-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/22/38246/abstract-text/1819966/pubmed\" id=\"1819966\" target=\"_blank\">",
"        1819966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8821 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38246=[""].join("\n");
var outline_f37_22_38246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708635\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143008\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142999\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143003\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143000\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682360\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682361\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142987\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142976\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2234382\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143006\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142990\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142980\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143004\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142984\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142985\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2234383\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2234384\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323028\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2234496\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142992\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142979\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142989\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/10/3236?source=related_link\">",
"      Bupivacaine and epinephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_22_38247="Pathogen inactivation of blood products";
var content_f37_22_38247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogen inactivation of blood products",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38247/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38247/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38247/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38247/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/22/38247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major public health concern regarding blood products in general and plasma derivatives in particular is the possibility that plasma used for further manufacture and eventual transfusion or administration may be contaminated with one or more viral agents (eg, HIV, HCV, parvovirus) or with other pathogens.",
"   </p>",
"   <p>",
"    While some have argued that the pathogen inactivation procedures discussed below eliminate concerns about the presence of infectious agents in donor plasma, most authorities agree that adherence to strict standards of donor recruitment and donor screening are still necessary for ensuring the safety of these products. Blood donor screening and testing of blood for pathogens are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11498?source=see_link\">",
"       \"Blood donor medical history\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link\">",
"       \"Laboratory testing of donated blood\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26106?source=see_link&amp;anchor=H3#H3\">",
"       \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Specific donor screening procedures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safest way to prevent pathogen transmission is to avoid unnecessary transfusion. Guidelines for transfusion thresholds are discussed in the following topics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"       \"Indications for red cell transfusion in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18808?source=see_link\">",
"       \"Indications for red blood cell transfusion in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link\">",
"       \"Use of blood products in the critically ill\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/53/9048?source=see_link\">",
"       \"Red blood cell transfusions in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link\">",
"       \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link\">",
"       \"Clinical use of plasma components\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma pools in industry currently range from 500 to 10,000 liters. Each liter of plasma represents about four units of plasma from four whole blood donations, or about 1.7 donations of source plasma (600 mL donation size) from plasmapheresis donors. Thus, several thousand individual units of plasma, containing the personal infectious disease history of each donor in the form of antibodies (and sometimes infectious particles), are pooled into one vat for fractionation. It is clear that healthy, honest, well-motivated donors are key to the safety of such products. Such was not always the case. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26106?source=see_link&amp;anchor=H4#H4\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Pre-donation screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;If inactivation techniques reduce a target virus by five logs (ie, to 0.001 percent of the starting concentration) it is still mathematically possible that the inadvertent inclusion of one or more high-titered infectious units of plasma could render the product infectious. However, in current experience more than two million units of",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    FFP have been given worldwide without reports of transmission of the major viral pathogens (HIV, HCV, and HBV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Continuing health concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical use of human-derived coagulation factors is considered far less risky than in the past, members of the hemophilia community (patients, families, and care providers) are acutely aware of the tragedy of HIV infection that has occurred following their use.",
"   </p>",
"   <p>",
"    Even with requirements for nucleic acid testing now in place for plasma products, there remains a level of scientific concern about what the next unknown intruder into the plasma fractionation system might be [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/1\">",
"     1",
"    </a>",
"    ], and how we would recognize it in time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of this continuing concern, the use of recombinant DNA techniques, the production in transgenic animals of coagulation factors in (and isolation from) maternal milk, and the use of cloning techniques to produce biologically active proteins for human medicine have become increasingly important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=see_link&amp;anchor=H20#H20\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Recombinant coagulation factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGEN INACTIVATION OF FRESH FROZEN PLASMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods of pathogen inactivation of blood products focused first on FFP, since it contains no cellular elements that might be disrupted or functionally disturbed by such processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the mid-1980s, methods have been available to inactivate infectious viruses that have lipid envelopes in the derivatives fractionated from human plasma. This was first accomplished when pasteurization of serum albumin (10 hours at 60&deg;C) was shown to kill what was then called the serum hepatitis virus (hepatitis B virus). The fractionation process itself removes or kills some infectious particles, but in the 1980s various viral inactivation techniques were brought on line, including \"wet\" pasteurization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/4\">",
"     4",
"    </a>",
"    ], chromatography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/5\">",
"     5",
"    </a>",
"    ], and solvent-detergent treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For transfusable plasma components (as opposed to plasma derivatives), there are four methods of inactivation available in Europe, one using a solvent-detergent",
"    <span class=\"nowrap\">",
"     (S/D)",
"    </span>",
"    step, the second using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    and visible light, the third using amotosalen and long wavelength ultraviolet light, and the fourth using riboflavin and ultraviolet light. The",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    method is used in pools of plasma, whereas the other methods are used to treat individual plasma units. The",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    method is approved for use in the United States, whereas the others are not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/1\">",
"     1",
"    </a>",
"    ]. All four methods are effective in inactivating several logs of viruses with lipid envelopes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Limited ability to inactivate hepatitis A virus and parvovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-enveloped viruses, such as parvovirus B19 and hepatitis A virus (HAV), are not efficiently inactivated by",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However,",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    treated plasma contains antibodies to HAV and parvovirus B19; the presence of these antibodies may be protective.",
"   </p>",
"   <p>",
"    Prior to the current use of parvovirus nucleic acid screening tests for plasma units undergoing",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    treatment and for plasma units destined for the manufacture of plasma derivatives, parvovirus B19 transmission following the use of",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma had been documented. However, no such transmissions have been reported since screening tests have been implemented. A linked donor-recipient study involving parvovirus B19 DNA positive individual blood components (mostly red blood cells) transfused into 24 susceptible patients (ie, anti-B19 antibody negative individuals) found no viral transmission when the components contained less than 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    of viral DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HAV transmission has been documented more rarely than parvovirus B19 transmission. HAV transmission is less likely to be detected since viremia in hepatitis A is low grade and transient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inability to inactivate prions",
"    </span>",
"    &nbsp;&mdash;&nbsp;No known sterilization procedure usable with human plasma has any effects on prions such as are associated with Creutzfeldt-Jakob disease (CJD) or variant CJD (vCJD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40728?source=see_link&amp;anchor=H5#H5\">",
"     \"Variant Creutzfeldt-Jakob disease\", section on 'Transfusion-related vCJD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the experience with AIDS and clotting factors in the early 1980s, governmental regulators have adopted a conservative position with regard to vCJD transmission. Accordingly, current and proposed FDA regulations bar from donation anyone who might have contracted the disease while living in areas in which such infections have been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11498?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood donor medical history\", section on 'Creutzfeldt-Jakob disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Solvent-detergent method",
"    </span>",
"    &nbsp;&mdash;&nbsp;A method involving solvents and detergents to disrupt the membranes of enveloped viruses (such as HIV, hepatitis B, and hepatitis C) was licensed in Europe in 1991 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/1\">",
"     1",
"    </a>",
"    ] and in the United States in May 1998. In addition to its use in treating FFP, this",
"    <span class=\"nowrap\">",
"     \"S/D\"",
"    </span>",
"    method has also been widely used in the United States and Europe to treat plasma fractionation products, such as immune serum globulin and coagulation factors. It was first described in 1984 and was used initially to inactivate HIV and HBV in coagulation factors prepared from pooled plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This treatment, which includes tri-n-butylphosphate as the solvent and triton X-100 as the detergent, does not affect the structure or function of most, but not all, plasma proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. It disrupts the membranes of the following lipid-enveloped viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatitis B and C viruses (HBV and HCV, respectively)",
"     </li>",
"     <li>",
"      Human immunodeficiency virus (HIV)",
"     </li>",
"     <li>",
"      Human T-lymphotropic virus (HTLV)",
"     </li>",
"     <li>",
"      Epstein-Barr virus (EBV)",
"     </li>",
"     <li>",
"      Cytomegalovirus (CMV)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With current methods of pathogen inactivation,",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma, intravenous immunoglobulin, and plasma-derived clotting factors are considered safe with respect to the risk of transmitting hepatitis C, hepatitis B, HIV, or other enveloped viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    FFP is available in several European countries.",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma was unavailable in the United States during the early 2000s, but an",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    FFP product was approved by the United States FDA in 2013.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Special properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following properties of",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma are of importance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      plasma has the same indications as standard FFP, although previously marketed form of",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      plasma (PLAS+SD) was deemed contraindicated in liver transplantation, another product (Octaplas) does not share this contraindication. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'S/D plasma use in liver transplantation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      treatment removes larger von Willebrand factor multimers, and theoretically might therefore be valuable in the treatment of thrombotic thrombocytopenic purpura (TTP-HUS). In the absence of clinical trials reporting on the risks and benefits, we do not advocate for one plasma product over another in TTP-HUS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Viral inactivation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      treatment results in the loss of about 80 percent of selected clotting factors in FFP, including protein S, alpha-2 antiplasmin, and alpha-1 antitrypsin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/17-21\">",
"       17-21",
"      </a>",
"      ]. Whether this represents a risk factor for treatment of certain conditions, such as TTP-HUS, is not clear at the present time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/17\">",
"       17",
"      </a>",
"      ]. Studies in which patients were randomly assigned to treatment with either FFP or",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      FFP have failed to show any difference in efficacy in patients with a prolonged prothrombin time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/12\">",
"       12",
"      </a>",
"      ], or in the complex coagulopathies associated with open heart surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/22\">",
"       22",
"      </a>",
"      ], liver disease, or liver transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/20,23\">",
"       20,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      treated plasma appears to have a lower risk of transfusion-related acute lung injury (TRALI). This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28282?source=see_link&amp;anchor=H11655932#H11655932\">",
"       \"Transfusion-related acute lung injury (TRALI)\", section on 'Use of solvent detergent treated plasma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     S/D plasma use in liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the occurrence of serious thrombotic events or excessive bleeding in six patients undergoing orthotopic liver transplantation for end stage liver disease, a \"black box\" warning was added to the labeling for PLAS+SD, a solvent detergent treated pooled human plasma that was available in the US in the 1990s. The warning contraindicated the use of this product in patients undergoing liver transplant or those with severe liver disease and known coagulopathies. In contrast, the",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma product Octaplas, licensed in the United States in 2013, does not have this restriction and, in fact, is specifically licensed for use in liver",
"    <span class=\"nowrap\">",
"     transplantation.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;S/D",
"    plasma is more expensive to prepare than FFP. It has been estimated that",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma costs over $200,000 for one quality adjusted life-year saved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/13\">",
"     13",
"    </a>",
"    ], and may be significantly more costly than this now that nucleic acid testing of donor blood has reduced the number of virus-infected blood products. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link&amp;anchor=H8#H8\">",
"     \"Laboratory testing of donated blood\", section on 'Infectious disease screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    treated plasma could be considered even less cost effective in those patients who also receive other blood components (eg, red cells) for which there are as yet no licensed pathogen inactivation procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Removal of anti-A and anti-B isoagglutinins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A product is in development (Uniplas",
"    <span class=\"nowrap\">",
"     S/D),",
"    </span>",
"    in which anti-A and anti-B isoagglutinin antibodies have been removed using resins coated with synthetic A and B antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/13\">",
"     13",
"    </a>",
"    ]. This product, if and when approved, might eliminate reactions to plasma transfusion due to ABO incompatibility, reduce the need for large plasma inventories, and enhance the blood supply in emergency situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Methylene blue method",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    (MB), coupled with visible (white or red) light treatment, has been used in Europe to inactivate viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/24\">",
"     24",
"    </a>",
"    ]. MB combines with cellular membranes and, when activated by light, disrupts them.",
"   </p>",
"   <p>",
"    In the past, units so treated were faintly tinged by the dye and, in large doses could lead to slight, temporary discoloration of the skin and mucous membranes in recipients. However, the technology has now been modified to include filters that remove the MB prior to transfusion. Such products have reduced concentrations of some coagulation factors (eg, fibrinogen, factor V, factor VIII) and thus may be less effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. This product is widely used in many European countries, but is not yet licensed in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other inactivation methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viruses (including parvovirus B19 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/29\">",
"     29",
"    </a>",
"    ]), bacteria, and other pathogens have been inactivated in blood products following addition of the psoralen compound S-59 (amotosalen) and exposure to long wavelength ultraviolet light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Activity of plasma proteins and coagulation factors is not adversely affected by this treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This product has been successfully transfused in Europe without adverse side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This technique is currently not licensed by the United States FDA; phase III trials are in progress for the use of FFP prepared by this method for the treatment of patients with acquired coagulopathies and TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/13,38\">",
"     13,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The process of lyophilization (ie, freeze-drying) contributes to the safety of plasma derivatives, in particular with the inactivation of hepatitis A virus, although it is less effective for other viruses (eg, parvovirus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     VIRAL INACTIVATION OF FIBRINOGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, the United States approved a virally-inactivated human",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/20/14659?source=see_link\">",
"     fibrinogen concentrate",
"    </a>",
"    (RiaSTAP) prepared from human pooled plasma, for use in the treatment of acute bleeding episodes in patients with congenital afibrinogenemia and hypofibrinogenemia. Use of this product is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H11520867#H11520867\">",
"     \"Disorders of fibrinogen\", section on 'Fibrinogen concentrate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PATHOGEN INACTIVATION OF PLATELETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of photochemical treatment, using a psoralen compound (amotosalen) and exposure to long wavelength ultraviolet light, to inactivate viruses, bacteria, protozoa, and leukocytes for use in the transfusion of platelets has been under active investigation since the early 2000s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This type of pathogen-inactivated platelet product has been approved for use in several European countries and tens of thousands of these units have been transfused without any documented adverse effects and without an adverse effect on blood component use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelets treated with a different inactivation method (Mirasol pathogen reduction methodology with riboflavin and ultraviolet light) have also begun to be used in a few European countries. In one study the platelet count increments at one hour following platelet transfusion were significantly lower with Mirasol-treated platelets than with control platelets (16,939 versus 11,725) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38247/abstract/45\">",
"     45",
"    </a>",
"    ]. The clinical importance of this observation is not clear at this time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37945?source=see_link&amp;anchor=H16695488#H16695488\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Measuring response to platelet transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25087815\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pathogen inactivation of blood products is considered to be important because of concerns that these products have in the past, and might in the future, transmit viruses (eg, HCV, HIV) or other pathogens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Solvent detergent-treatment of fresh frozen plasma",
"      <span class=\"nowrap\">",
"       (S/D",
"      </span>",
"      plasma) is effective for inactivating enveloped viruses such as HBV, HCV, and HIV. Solvent detergent treatment does not effectively inactivate non-enveloped viruses, such as HAV and parvovirus B19, and has no effect on prions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogen inactivation of fresh frozen plasma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      treated plasma appears to have a lower risk of transfusion-related acute lung injury (TRALI). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28282?source=see_link&amp;anchor=H11655932#H11655932\">",
"       \"Transfusion-related acute lung injury (TRALI)\", section on 'Use of solvent detergent treated plasma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"       Methylene blue",
"      </a>",
"      treatment of plasma inactivates viruses but also depletes some clotting factors (eg, fibrinogen, factor V, factor VIII) and may be less effective for some indications. This product is available in Europe but not the United States. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Methylene blue method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A virally-inactivated human",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/20/14659?source=see_link\">",
"       fibrinogen concentrate",
"      </a>",
"      , prepared from human pooled plasma, is commercially available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H11520867#H11520867\">",
"       \"Disorders of fibrinogen\", section on 'Fibrinogen concentrate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Photochemical techniques have been used to inactivate pathogens in platelets. Such products are in widespread use in European countries. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pathogen inactivation of platelets'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/1\">",
"      Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998; 38:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/2\">",
"      Ludlam CA, Powderly WG, Bozzette S, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006; 367:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/3\">",
"      Pamphilon D. Viral inactivation of fresh frozen plasma. Br J Haematol 2000; 109:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/4\">",
"      Schimpf K, Mannucci PM, Kreutz W, et al. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. N Engl J Med 1987; 316:918.",
"     </a>",
"    </li>",
"    <li>",
"     Lawrence JE. Affinity chromatography to remove viruses during preparation of plasma derivatives. In: Virological Safety of Plasma Derivatives, Brown F (Ed), Karger, Basel 1993. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/6\">",
"      Horowitz MS, Rooks C, Horowitz B, Hilgartner MW. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate. Lancet 1988; 2:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/7\">",
"      Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/8\">",
"      Schneider B, Becker M, Brackmann HH, Eis-H&uuml;binger AM. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Thromb Haemost 2004; 92:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/9\">",
"      Kleinman SH, Glynn SA, Lee TH, et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009; 114:3677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/10\">",
"      Prince AM, Horowitz B, Brotman B, et al. Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang 1984; 46:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/11\">",
"      Pehta JC. Clinical studies with solvent detergent-treated products. Transfus Med Rev 1996; 10:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/12\">",
"      Lerner RG, Nelson J, Sorcia E, et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000; 79:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/13\">",
"      Snyder EL, Dodd RY. Reducing the risk of blood transfusion. Hematology Am Soc Hematol Educ Program 2001; :433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/14\">",
"      Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/15\">",
"      Horowitz B, Busch M. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. Transfusion 2008; 48:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/16\">",
"      Dichtelm&uuml;ller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009; 49:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/17\">",
"      Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000; 15:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/18\">",
"      Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 1999; 94:3922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/19\">",
"      Nifong TP, Light J, Wenk RE. Coagulant stability and sterility of thawed S/D-treated plasma. Transfusion 2002; 42:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/20\">",
"      Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/21\">",
"      Zeiler T, Wittmann G, Zimmermann R, et al. The effect of virus inactivation on coagulation factors in therapeutic plasma. Br J Haematol 2000; 111:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/22\">",
"      Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002; 82:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/23\">",
"      Freeman JW, Williamson LM, Llewelyn C, et al. A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during Orthotopic Liver Transplantation. Vox Sang 1998; 74 Suppl 1:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/24\">",
"      Lambrecht B, Mohr H, Kn&uuml;ver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/25\">",
"      Zeiler T, Riess H, Wittmann G, et al. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994; 34:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/26\">",
"      Atance R, Pereira A, Ram&iacute;rez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001; 41:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/27\">",
"      Suontaka AM, Blomb&auml;ck M, Chapman J. Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion 2003; 43:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/28\">",
"      Moog R, Reichenberg S, Hoburg A, M&uuml;ller N. Quality of methylene-blue-treated fresh-frozen plasma stored up to 27 months. Transfusion 2010; 50:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/29\">",
"      Sawyer L, Hanson D, Castro G, et al. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007; 47:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/30\">",
"      Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/31\">",
"      Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001; 38:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/32\">",
"      Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004; 125:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/33\">",
"      Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/34\">",
"      Schlenke P, Hervig T, Isola H, et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008; 48:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/35\">",
"      Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/36\">",
"      Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective. Semin Hematol 2001; 38:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/37\">",
"      de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/38\">",
"      Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107:3753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/39\">",
"      Unger U, Poelsler G, Modrof J, Kreil TR. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products. Transfusion 2009; 49:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/40\">",
"      Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/41\">",
"      Wagner SJ, Skripchenko A, Myrup A, et al. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light. Transfusion 2009; 49:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/42\">",
"      Kerkhoffs JL, van Putten WL, Novotny VM, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/43\">",
"      Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/44\">",
"      Osselaer JC, Doyen C, Defoin L, et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38247/abstract/45\">",
"      Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50:2362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7929 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38247=[""].join("\n");
var outline_f37_22_38247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25087815\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Continuing health concerns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGEN INACTIVATION OF FRESH FROZEN PLASMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Limited ability to inactivate hepatitis A virus and parvovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inability to inactivate prions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Solvent-detergent method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Special properties",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - S/D plasma use in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Removal of anti-A and anti-B isoagglutinins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Methylene blue method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other inactivation methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      VIRAL INACTIVATION OF FIBRINOGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PATHOGEN INACTIVATION OF PLATELETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25087815\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40728?source=related_link\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_22_38248="Bipolar disorder in pregnant women: Treatment of major depression";
var content_f37_22_38248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in pregnant women: Treatment of major depression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38248/contributors\">",
"     Victoria Hendrick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38248/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38248/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/22/38248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H226768143\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are commonly used to treat pregnant patients, including those with bipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/1\">",
"     1",
"    </a>",
"    ]. At least one prescription drug is taken by more than 60 percent of pregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/2\">",
"     2",
"    </a>",
"    ], and psychotropic drugs are taken by 21 to 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic discusses treatment of bipolar major depression in pregnant patients. Treatment of manic, hypomanic, and mixed episodes during pregnancy, prenatal maintenance pharmacotherapy for bipolar disorder, the teratogenic and postnatal risks of pharmacotherapy for bipolar disorder, and the general treatment of bipolar major depression are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4362?source=see_link\">",
"       \"Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=see_link\">",
"       \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link\">",
"       \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H226768150\">",
"    <span class=\"h1\">",
"     DEFINITION OF BIPOLAR DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/5\">",
"     5",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6762982\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy is indicated for pregnant patients with bipolar major depression that is characterized by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suicidal or homicidal ideation or behavior",
"     </li>",
"     <li>",
"      Aggressive behavior",
"     </li>",
"     <li>",
"      Psychotic features (delusions or hallucinations)",
"     </li>",
"     <li>",
"      Poor judgement that places the patient or others at imminent risk of being harmed",
"     </li>",
"     <li>",
"      Moderate to severe impairment of social or occupational functioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102296868\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar mood episodes during pregnancy are usually treated by perinatal or general psychiatrists in collaboration with obstetricians and primary care clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/4,7-10\">",
"     4,7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For pregnant patients with bipolar major depression, treatment is based upon randomized trials that excluded pregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/11-14\">",
"     11-14",
"    </a>",
"    ], as well as observational studies, birth registries, and clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional information about the general principles and management of treating bipolar mood episodes during pregnancy are discussed separately, as is the general treatment of bipolar major depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4362?source=see_link&amp;anchor=H86321418#H86321418\">",
"     \"Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255235\">",
"    <span class=\"h2\">",
"     Duration of individual drug trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest treating pregnant patients with bipolar major depression for six to eight weeks before determining whether a specific drug is beneficial, based upon the duration of most randomized trials (which excluded pregnant patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/11-13,16\">",
"     11-13,16",
"    </a>",
"    ]. Response is defined as stabilizing the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H226769424\">",
"    <span class=\"h1\">",
"     SELECTING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar major depression during pregnancy is typically treated with pharmacotherapy because it is easier to administer, more widely available, and more acceptable to patients than electroconvulsive therapy (ECT). However, refractory patients may benefit from ECT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140365932\">",
"    <span class=\"h2\">",
"     First line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant patients with bipolar major depression, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    as first line treatment, based upon efficacy in a meta-analysis of randomized trials that excluded pregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/14\">",
"     14",
"    </a>",
"    ]. Up to 40 to 50 percent of patients may respond (defined as stabilizing the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of symptoms). In addition, the reproductive safety profile of lamotrigine is generally regarded as favorable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/4,17,18\">",
"     4,17,18",
"    </a>",
"    ]. The efficacy of lamotrigine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    appear to be comparable, but there is more experience using lamotrigine during pregnancy than quetiapine. In addition, there is more evidence supporting the efficacy of lamotrigine compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    or lamotrigine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and prenatal treatment with monotherapy is preferable to treatment with drug combinations due to concerns about teratogenic effects.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , and lamotrigine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ; reproductive safety profile of these drugs; and the dose schedule, side effects (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"     table 5",
"    </a>",
"    ) (including life-threatening skin rash), and pharmacology of lamotrigine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H6#H6\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Lamotrigine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H5#H5\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Lamotrigine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140365939\">",
"    <span class=\"h2\">",
"     Treatment resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant patients with bipolar major depression who do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    or cannot tolerate it, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/19\">",
"     19",
"    </a>",
"    ], based upon randomized trials that excluded pregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Up to 50 to 60 percent of patients may respond (defined as stabilizing the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of symptoms). In addition, other studies suggest that quetiapine is not associated with teratogenic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/24\">",
"     24",
"    </a>",
"    ], and use of quetiapine for bipolar major depression during pregnancy is consistent with practice guidelines from the United Kingdom National Institute for Health and Clinical Excellence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. There is more evidence supporting the efficacy of lamotrigine compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    or lamotrigine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and prenatal treatment with monotherapy is preferable to treatment with drug combinations due to concerns about teratogenic effects.",
"   </p>",
"   <p>",
"    We generally taper and discontinue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    at the same time that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    is started and titrated up. Lamotrigine is usually tapered by the same amount for each dose decrease over a one to two week period. As an example, lamotrigine 200 mg per day is decreased by 50 mg per day every three to four days.",
"   </p>",
"   <p>",
"    Second-generation antipsychotics may cause metabolic complications (eg, hyperglycemia and obesity) that are associated with risks to the mother and fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. These risks are discussed separately, as are monitoring of metabolic parameters in pregnant patients taking second-generation antipsychotics and the efficacy, dose, reproductive safety, pharmacology, and side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=see_link&amp;anchor=H22544288#H22544288\">",
"     \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\", section on 'Metabolic complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link&amp;anchor=H317515#H317515\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\", section on 'Quetiapine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link&amp;anchor=H1561513#H1561513\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Second-generation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link&amp;anchor=H76524693#H76524693\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Quetiapine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140365946\">",
"    <span class=\"h2\">",
"     Refractory patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant patients with bipolar major depression often do not respond to sequential trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    . For these refractory patients, we suggest tapering and discontinuing quetiapine over one to two weeks at the same time that another medication regimen is started and titrated up. (Response is defined as stabilizing the safety of the patient and others, as well as substantial improvement in the number, intensity, and frequency of symptoms.) Quetiapine is generally tapered by the same amount for each dose decrease. As an example, quetiapine 600 mg per day is decreased by 50 to 100 mg per day, every one to two days.",
"   </p>",
"   <p>",
"    We suggest using the following treatments in sequence for pregnant patients with refractory bipolar major depression, based upon their efficacy in randomized trials (which excluded pregnant patients), reproductive safety profiles, and adverse effects. Although the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    appear to be comparable, neither fluoxetine nor olanzapine appear to be associated with teratogenic effects. By contrast, lithium is generally regarded as teratogenic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The proportion of patients who respond to any of the following treatment regimens may be as high as approximately 50 percent, based upon trials in nonpregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      &ndash; Fluoxetine plus olanzapine is efficacious for bipolar major depression in nonpregnant patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/12,32\">",
"       12,32",
"      </a>",
"      ]. However, second-generation antipsychotics, especially olanzapine, may cause metabolic complications (eg, hyperglycemia and obesity) that are associated with risks to the mother and fetus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. These risks are discussed separately, as are monitoring of metabolic parameters in pregnant patients taking second-generation antipsychotics and the efficacy, dose, reproductive safety, pharmacology, and side effects of fluoxetine and olanzapine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=see_link&amp;anchor=H22544288#H22544288\">",
"       \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\", section on 'Metabolic complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link&amp;anchor=H317524#H317524\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\", section on 'Olanzapine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link\">",
"       \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Specific medication interactions that can occur may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the online search page or through the individual drug information topics in the section on Drug Interactions. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; For pregnant patients with bipolar major depression who do not respond to or tolerate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      , we suggest lamotrigine plus lithium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/11\">",
"       11",
"      </a>",
"      ]. Fluoxetine plus olanzapine are usually tapered and discontinued concurrently over a period of one week, and subsequently lamotrigine and lithium are started and titrated up. Fluoxetine is generally tapered by the same amount for each dose decrease, as is olanzapine. As an example, fluoxetine 40 mg per day is decreased by 10 mg per day every two days, and olanzapine 15 mg per day is decreased by 5 mg per day every three days.",
"      <br/>",
"      <br/>",
"      Although lithium is generally regarded as teratogenic due to increased risks of cardiac defects (eg, Ebstein&rsquo;s anomaly) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/29-31\">",
"       29-31",
"      </a>",
"      ], many authorities consider the absolute risk small [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/1,4,18,33,34\">",
"       1,4,18,33,34",
"      </a>",
"      ]. The reproductive safety profile of lamotrigine is generally regraded as favorable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/4,17,18\">",
"       4,17,18",
"      </a>",
"      ], based primarily upon studies of patients with epilepsy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link&amp;anchor=H1561534#H1561534\">",
"       \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Lithium'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=see_link&amp;anchor=H10#H10\">",
"       \"Risks associated with epilepsy and pregnancy\", section on 'Lamotrigine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The dose schedule, side effects (",
"      <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"       table 5",
"      </a>",
"      ) (including life-threatening skin rash), and pharmacology of lamotrigine are discussed separately; as are the use of lithium during pregnancy, dose, use of serum concentrations to establish the proper dose, side effects, and pharmacology of lithium. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H6#H6\">",
"       \"Bipolar disorder in adults: Maintenance treatment\", section on 'Lamotrigine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H5#H5\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Lamotrigine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=see_link&amp;anchor=H328730#H328730\">",
"       \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\", section on 'Refractory patients'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Specific medication interactions that can occur may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the online search page or through the individual drug information topics in the section on Drug Interactions.",
"     </li>",
"     <li>",
"      <strong>",
"       Electroconvulsive therapy (ECT)",
"      </strong>",
"      &ndash; For refractory pregnant patients with bipolar major depression that does not respond to sequential trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      , and lamotrigine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , we suggest electroconvulsive therapy (ECT). Lamotrigine and lithium are tapered and discontinued over a period of one to two weeks prior to starting ECT. Lamotrigine is generally tapered by the same amount for each dose decrease, as is lithium. As an example, lamotrigine 200 mg per day is decreased by 50 mg per day every three to four days, and lithium 1200 mg per day is tapered by 300 mg per day every three to four days.",
"      <br/>",
"      <br/>",
"      Reviews have found that ECT is efficacious and safe for patients with bipolar major depression who are not pregnant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/35,36\">",
"       35,36",
"      </a>",
"      ], as well as patients who are pregnant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]; ECT is thus recommended by several practice guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/7,39-42\">",
"       7,39-42",
"      </a>",
"      ]. The efficacy, adverse maternal and fetal effects, and reproductive safety of ECT are discussed separately, as is the technique for performing ECT during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/1/5146?source=see_link&amp;anchor=H2570440#H2570440\">",
"       \"Bipolar disorder in postpartum women: Treatment\", section on 'Electroconvulsive therapy (ECT)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4362?source=see_link&amp;anchor=H4605992#H4605992\">",
"       \"Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes\", section on 'Electroconvulsive therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link&amp;anchor=H1561541#H1561541\">",
"       \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Electroconvulsive therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=see_link&amp;anchor=H13734882#H13734882\">",
"       \"Technique for performing electroconvulsive therapy (ECT) in adults\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256399\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181132977\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant patients with bipolar major depression who are treated with pharmacotherapy, we suggest adjunctive psychotherapy based upon randomized trials in nonpregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/2,6,43\">",
"     2,6,43",
"    </a>",
"    ]. As an example, a one-year randomized trial compared intensive psychotherapy plus pharmacotherapy with brief psychoeducation plus pharmacotherapy in 293 nonpregnant patients with bipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/44\">",
"     44",
"    </a>",
"    ]. Intensive psychotherapy consisted of family therapy, cognitive-behavioral therapy, or interpersonal and social rhythm therapy, with up to 30 sessions (50 minutes each) administered over nine months; brief psychoeducation included three 50-minute sessions instructing patients about the clinical features and treatment of bipolar disorder. Recovery occurred in more patients who received adjunctive intensive psychotherapy compared with brief psychoeducation (64 versus 52 percent), and outcome did not differ significantly among the three intensive therapies. Using psychotherapy is also supported by randomized trials in pregnant patients with unipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/45\">",
"     45",
"    </a>",
"    ], and is consistent with treatment guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256442\">",
"    <span class=\"h2\">",
"     Omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant patients with bipolar major depression, dietary supplementation with omega-3 fatty acids (eg, eicosapentaenoic acid 1 to 2 grams per day) as adjunctive treatment is reasonable, based upon limited evidence in meta-analyses of randomized trials (which excluded pregnant patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38248/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] and the apparent lack of serious side effects. In addition, prenatal intake of omega-3 fatty acid supplements may have modest beneficial effects on fetal neurodevelopment, and do not have known harmful effects. The efficacy of omega-3 fatty acids and the risks and benefits during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link&amp;anchor=H3148203941#H3148203941\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\", section on 'Omega 3 fatty acids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=see_link\">",
"     \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17026212\">",
"    <span class=\"h1\">",
"     RESIDUAL INSOMNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar major depression in pregnant patients often includes insomnia, which may persist despite resolution of the depressive syndrome. For patients with residual insomnia, we suggest behavioral therapy, including education about sleep hygiene (",
"    <a class=\"graphic graphic_table graphicRef71116 \" href=\"mobipreview.htm?6/3/6203\">",
"     table 6",
"    </a>",
"    ) and stimulus control (",
"    <a class=\"graphic graphic_table graphicRef77189 \" href=\"mobipreview.htm?3/54/3947\">",
"     table 7",
"    </a>",
"    ). Patients unresponsive to behavior therapy typically receive additional treatment with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    . Treatment of insomnia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H21#H21\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Psychoeducation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256488\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      ), hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      ), and major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      ), as well as mixed episodes (major depression concurrent with mania or hypomania). (See",
"      <a class=\"local\" href=\"#H226768150\">",
"       'Definition of bipolar disorder'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacotherapy is indicated for pregnant patients with bipolar major depression that is characterized by (See",
"      <a class=\"local\" href=\"#H6762982\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Suicidal or homicidal ideation or behavior",
"     </li>",
"     <li>",
"      Aggressive behavior",
"     </li>",
"     <li>",
"      Psychotic features (delusions or hallucinations)",
"     </li>",
"     <li>",
"      Poor judgement that places the patient or others at imminent risk of being harmed",
"     </li>",
"     <li>",
"      Moderate to severe impairment of social or occupational functioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An individual drug trial for pregnant patients with bipolar major depression typically lasts six to eight weeks before determining whether treatment is beneficial. (See",
"      <a class=\"local\" href=\"#H102296868\">",
"       'General principles and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant patients with bipolar major depression, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      as first line treatment rather than other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H140365932\">",
"       'First line treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant patients with bipolar major depression who do not respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      or cannot tolerate it, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      rather than other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H140365939\">",
"       'Treatment resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant patients with refractory bipolar major depression that does not respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      are often treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      , lamotrigine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or electroconvulsive therapy. (See",
"      <a class=\"local\" href=\"#H140365946\">",
"       'Refractory patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant patients with bipolar major depression who are treated with pharmacotherapy, we suggest adjunctive psychotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H181132977\">",
"       'Psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/1\">",
"      Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.",
"     </a>",
"    </li>",
"    <li>",
"     Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB.  (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1373.",
"    </li>",
"    <li>",
"     Owen JA. Psychopharmacology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Inc., Washington, DC 2011. p.957.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/4\">",
"      ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/6\">",
"      Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011; 117:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/7\">",
"      Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/8\">",
"      Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005; 186:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/9\">",
"      Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/10\">",
"      Shah N. Mood disorder in the perinatal period. BMJ 2012; 344:e1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/11\">",
"      van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/12\">",
"      Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/13\">",
"      Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/14\">",
"      Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194:4.",
"     </a>",
"    </li>",
"    <li>",
"     Frey BN, Macritchie KA, Soares CN, Steiner M. Bipolar disorder in women. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M.  (Eds), Wiley-Blackwell, West Sussex 2010. p.463.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/16\">",
"      Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/17\">",
"      Marangell LB. Current issues: women and bipolar disorder. Dialogues Clin Neurosci 2008; 10:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/18\">",
"      Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/19\">",
"      Sharma V. Management of bipolar II disorder during pregnancy and the postpartum period--Motherisk Update 2008. Can J Clin Pharmacol 2009; 16:e33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/20\">",
"      Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/21\">",
"      McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/22\">",
"      Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/23\">",
"      Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/24\">",
"      Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38 file://www.nice.org.uk/ (Accessed on December 30, 2011).",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. NICE clinical guideline 45. Antenatal and postnatal mental health: Clinical management and service guidance. April 2007 file://www.nice.org.uk/CG045 (Accessed on January 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/27\">",
"      De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/28\">",
"      Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012; 46:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/29\">",
"      Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/30\">",
"      Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep 2010; 12:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/31\">",
"      Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010; 44:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/32\">",
"      Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/33\">",
"      Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/34\">",
"      Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/35\">",
"      Goodman WK. Electroconvulsive therapy in the spotlight. N Engl J Med 2011; 364:1785.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Executive Summary: Prepared for the January 27-28, 2011 meeting of the Neurological Devices Panel. Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM240933.pdf (Accessed on May 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/37\">",
"      Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002; 47:426.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Use of electroconvulsive therapy in special populations. In: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition, American Psychiatric Association, Washington, DC 2001. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/39\">",
"      Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition file://psychiatryonline.org/guidelines.aspx (Accessed on December 19, 2011).",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients With Bipolar Disorder Second Edition file://psychiatryonline.org/guidelines.aspx (Accessed on December 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/43\">",
"      Swartz HA, Frank E, Cheng Y. A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Bipolar Disord 2012; 14:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/44\">",
"      Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007; 64:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/45\">",
"      Spinelli MG, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 2003; 160:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/46\">",
"      Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev 2008; :CD005169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38248/abstract/47\">",
"      Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012; 73:81.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 82788 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38248=[""].join("\n");
var outline_f37_22_38248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H256488\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H226768143\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H226768150\">",
"      DEFINITION OF BIPOLAR DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6762982\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102296868\">",
"      GENERAL PRINCIPLES AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255235\">",
"      Duration of individual drug trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H226769424\">",
"      SELECTING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140365932\">",
"      First line treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140365939\">",
"      Treatment resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140365946\">",
"      Refractory patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H256399\">",
"      ADJUNCTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181132977\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256442\">",
"      Omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17026212\">",
"      RESIDUAL INSOMNIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H256488\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/82788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/82788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/28/3533\" title=\"table 4\">",
"      Common side effects of AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/34/30252\" title=\"table 5\">",
"      Rare serious side effects AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/3/6203\" title=\"table 6\">",
"      Rules for good sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/54/3947\" title=\"table 7\">",
"      Bootzins stimulus control",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/1/5146?source=related_link\">",
"      Bipolar disorder in postpartum women: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4362?source=related_link\">",
"      Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=related_link\">",
"      Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=related_link\">",
"      Risks and benefits of fish consumption and fish oil supplements during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_22_38249="Pathological findings in B mandrillaris amebic infection";
var content_f37_22_38249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Pathological findings in Balamuthia mandrillaris amebic infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) At scanning magnification, a pattern of ill-defined granulomas occupying the reticular dermis (H/E 40x).",
"    <br>",
"     (Panel B) The granulomatous pattern is usually accompanied by the presence of multiple giant cells (H/E 400x).",
"     <br>",
"      (Panel C) A trophozoite with ample cytoplasm, round nucleus and nucleolus (H/E 1000x).",
"      <br>",
"       (Panel D) A round trophozoite, with bubbly cytoplasm and eccentric located nucleus (H/E 1000x).",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38249=[""].join("\n");
var outline_f37_22_38249=null;
var title_f37_22_38250="Oral toxicity associated with chemotherapy";
var content_f37_22_38250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral toxicity associated with chemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38250/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38250/contributors\">",
"     Jean-Francois Bedard, DMD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38250/contributors\">",
"     Joseph A Toljanic, DDS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38250/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/22/38250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/22/38250/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/22/38250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral complications resulting from cancer and its therapy can cause both acute (mucositis, saliva changes, taste alterations, infection, bleeding) and late toxicities (mucosal atrophy, xerostomia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/1\">",
"     1",
"    </a>",
"    ]. Disruptions in the function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    integrity of the mucosal lining of the gastrointestinal (GI) tract are a particularly important problem in patients receiving chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy. Mucositis, which reflects a short-term, self-limited adverse effect of treatment, can affect the entire alimentary tract. The range of symptoms include oral ulcerations, dysphagia and odynophagia, gastritis, diarrhea and malabsorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20137?source=see_link\">",
"     \"Gastrointestinal toxicity of radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mucositis is the principal manifestation of acute oral toxicity related to chemotherapy, while much less commonly, xerostomia (dry mouth) results. Among the other potential oral consequences of chemotherapy are infection of oral soft tissues, gingival bleeding, and alterations in taste; all of these complications may can cause pain and impair nutrition.",
"   </p>",
"   <p>",
"    Chemotherapy-associated acute oral toxicity will be reviewed here. Oral mucositis in the setting of high-dose chemotherapy and hematopoietic cell transplantation (HCT) is discussed in detail elsewhere, as is radiation-induced oral mucositis, osteonecrosis of the jaw related to use of osteoclast inhibitors in patients with advanced cancer, and late oral toxicities in cancer survivors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H10#H10\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Mucositis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14185?source=see_link\">",
"     \"Oral health in cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MUCOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral mucositis affects on average 35 to 40 percent of patients receiving cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The frequency is higher in those undergoing HCT, particularly allogeneic HCT, and in those who are prepared with radiation-containing regimens. An exception is in the setting of reduced-intensity or non-myeloablative allogeneic HCT, where mucositis is rare. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathobiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathobiology underlying damage to the oral mucosal barrier is complex, and a series of stages has been described, summarized as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation: chemotherapy and radiotherapy damage both DNA and non-DNA targets, both as a direct effect, and mediated through reactive oxygen species.",
"     </li>",
"     <li>",
"      Upregulation and generation of messenger signals: the initial injury activates the transcription factor nuclear factor-kappa B, leading to the production of a variety of biologically active proteins, including proinflammatory cytokines.",
"     </li>",
"     <li>",
"      Signaling and amplification: as proinflammatory cytokines accumulate, they damage surrounding tissues directly, and the effect is amplified via feedback loops. This phase precedes the development of overt clinical mucositis.",
"     </li>",
"     <li>",
"      Ulceration and inflammation: loss of mucosal integrity results in clinically painful lesions, and allows secondary bacterial colonization.",
"     </li>",
"     <li>",
"      Healing: mucositis generally is self limited, and healing begins once the tissue insult is withdrawn.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Etiology and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors influence the extent and severity of mucositis, including the specific drug, dose, route and frequency of administration, and individual patient tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/5\">",
"     5",
"    </a>",
"    ]. Chemotherapeutic agents that are DNA cycle-specific (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) are more stomatotoxic than those that are cell phase non-specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6\">",
"     6",
"    </a>",
"    ]. Certain drugs (eg, methotrexate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) may be secreted into the saliva, further increasing the potential for stomatotoxicity.",
"   </p>",
"   <p>",
"    The conventional cytotoxic drugs that are most commonly associated with mucositis are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       Bleomycin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       Cytarabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      (high-dose)",
"     </li>",
"     <li>",
"      5-FU (bolus administration schedules)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (particularly low-dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, oral mucositis is reported in 30 to 40 percent of patients receiving therapy with the molecularly targeted agents",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    (which are orally active receptor tyrosine kinase inhibitors that target, among others, vascular endothelial growth factor receptors) and in 10 to 20 percent of patients treated with agents that target the epidermal growth factor receptor such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651229272#H1651229272\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Stomatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, severe oral mucosal lesions (oral mucosal ulceration associated plus discrete aphthous-like ulcerations) have been seen in up to 40 percent of patients treated with the mTOR inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. In general, the oral mucositis seen with molecularly targeted agents tends to be of a lesser severity than with conventional cytotoxic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more comprehensive list of drugs with the potential to cause mucositis is provided in the following table (",
"    <a class=\"graphic graphic_table graphicRef68013 \" href=\"mobipreview.htm?40/47/41724\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pretreatment oral disease is thought to increase the risk of chemotherapy-induced mucositis. Within the general population, up to 75 percent has chronic periodontal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of dental conditions have been causally linked with an increased risk for stomatotoxicity based upon empiric evidence and published data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor oral hygiene",
"     </li>",
"     <li>",
"      Caries and associated periapical pathology",
"     </li>",
"     <li>",
"      Periodontal disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local radiation of structures around the head or neck can exacerbate chemotherapy-induced stomatitis both by directly altering oral mucosal integrity and by altering supportive structures such as salivary glands and bone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H10#H10\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Mucositis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Younger patients have a relatively greater risk of chemotherapy-induced stomatitis, perhaps related to a higher epithelial mitotic rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/18\">",
"     18",
"    </a>",
"    ]. Other factors that may modulate the severity of stomatitis include nutritional status, the type of malignancy, the quality of oral care during treatment, pretreatment neutrophil counts, and the use of hematopoietic growth factor support during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Preventive treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A role for genetic susceptibility (eg, inherited polymorphisms in drug metabolizing enzymes and proinflammatory cytokines) has been suggested, but not yet proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct stomatotoxic effects begin shortly after therapy is begun and usually peak at about day 7. The severity ranges from mild mouth soreness with a paucity of clinical findings to severe erosive mucositis that is accompanied by severe pain and an inability to eat or drink.",
"   </p>",
"   <p>",
"    The initial clinical manifestation is soft tissue erythema of the buccal mucosa or soft palate with a burning sensation in the mouth. This stage may be followed by the development of solitary elevated white desquamative patches that are slightly painful. With further progression, epithelial sloughing results in multiple shallow ulcerations with a pseudomembranous appearance, which coalesce to form large painful ulcerations and cause dysphagia and reduced oral intake. Severe pseudomembranous or erosive mucositis can lead to secondary infection or sepsis (particularly in the presence of concomitant neutropenia, see below), and necessitate the use of parenteral nutrition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    opiates. In addition, oral or gingival bleeding can occur if the patient becomes thrombocytopenic.",
"   </p>",
"   <p>",
"    Mucositis is a self-limited phenomenon. The mucosal lesions spontaneously begin to resolve within several days, and are usually completely healed within 10 to 14 days after chemotherapy administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe (grade 3 or 4, see below) symptoms may necessitate dose reduction during subsequent chemotherapy cycles. However, only rarely is cessation of therapy required because of severe mucosal toxicity (eg, in a patient with dihydropyrimidine dehydrogenase [DPD] deficiency who is receiving 5-FU). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link&amp;anchor=H5#H5\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on '5-Fluorouracil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Grading systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of grading systems incorporating both subjective and objective criteria have been utilized to define the severity of mucositis. The most commonly used, the National Cancer Institute Common Terminology Criteria, grades the severity of mucositis on a scale from 1 to 5, based upon the clinical findings and symptomatology; the most recent version (v4.03) is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef60597 \" href=\"mobipreview.htm?15/30/15851\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another scale, the University of Nebraska Oral Assessment Score, has been used to evaluate the clinical course of mucositis in recipients of high-dose therapy and HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/24\">",
"     24",
"    </a>",
"    ]. It assigns a numeric grade to eight different aspects of the oral assessment (possible range of scores, 8 to 24). Patients with higher peak mucositis scores (&ge;18 versus &lt;18) had a significantly greater incidence of positive blood cultures (60 versus 30 percent) and a higher transplant-related mortality rate (24 versus 4 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infectious complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intact oral mucous membrane creates a physical barrier to pathogens and provides clearance of adhering microorganisms through the regular sloughing of surface epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/3\">",
"     3",
"    </a>",
"    ]. Breakdown of the mucosal barrier predisposes to bacterial, fungal and viral superinfection, which may remain localized or become disseminated, particularly as the hematologic nadir is reached after chemotherapy. The incidence and severity of infection rise when the absolute neutrophil count (ANC) falls below",
"    <span class=\"nowrap\">",
"     1000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    majority of oral infections in patients with mucositis are due to Candida albicans (70 percent in one series of patients with solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/25\">",
"     25",
"    </a>",
"    ]). Herpes simplex virus (HSV) accounts for most of the remaining cases, and is especially common in transplanted patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An altered mucosal barrier can also serve as the portal of entry for other pathogens, including other viruses, fungi, and bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/2,26,27\">",
"     2,26,27",
"    </a>",
"    ]. The relationship between mucositis and systemic bacteremia was shown in a study of 69 patients undergoing autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients who developed alpha hemolytic streptococcal bacteremia (n = 24) were significantly more likely to have ulcerative mucositis (62 versus 36 percent), and in turn, the presence of ulcerative mucositis increased the likelihood of developing bacteremia threefold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Oral candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the most common superinfecting organism in patients with chemotherapy-induced mucositis is Candida albicans. Many of these patients are already at risk for superficial oral candidiasis because they are immunocompromised as a result of their advanced cancer.",
"   </p>",
"   <p>",
"    Mucositis also increases the risk that a superficial infection will disseminate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6,28\">",
"     6,28",
"    </a>",
"    ]. As an example, in one series of patients undergoing high-dose chemotherapy for acute leukemia, systemic fungemia occurred almost exclusively in those with prior oropharyngeal candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29972?source=see_link\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Superficial oropharyngeal candidiasis can be treated topically with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    troches or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    suspension. Systemic therapy with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is generally not needed unless the patient cannot tolerate topical therapy. Refractory infection may require oral or parenteral fluconazole or parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Prophylactic oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    has been recommended to decrease the incidence of candidiasis in patients at high risk, but its efficacy continues to be evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/29\">",
"     29",
"    </a>",
"    ]. On the other hand, the prophylactic administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    suspension is not effective and is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines from the Infectious Disease Society of America (IDSA) for treatment of oral candidiasis, as well as other IDSA guidelines, can be accessed through their website [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     HSV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral cavity can also be secondarily infected by viral pathogens. The most common is reactivation of HSV type 1 infection, which occurs in 65 to 90 percent of seropositive patients receiving high-dose chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/32\">",
"     32",
"    </a>",
"    ]. HSV-associated mucositis tends to be more severe and of longer duration than non HSV-associated mucositis. The typical vesicular lesions may not be evident in the presence of chemotherapy-induced mucositis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=see_link\">",
"     \"Epidemiology of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection with HSV should be considered in the differential diagnosis of patients who present with mucosal vesicles or unusually painful oral ulcerations after chemotherapy, particularly if candidiasis is not clinically evident. A swab of one of the lesions can be sent for viral culture; HSV is usually isolated within 72 hours.",
"   </p>",
"   <p>",
"    Particularly among patients who are HSV-1 seropositive with moderate to severe mucositis, empiric antiviral therapy (ie, parenteral or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ) can be initiated while awaiting culture results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/32\">",
"     32",
"    </a>",
"    ]. In studies involving immunocompromised hosts with mucocutaneous HSV infection (but not limited to those undergoing chemotherapy), the administration of acyclovir (250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV every 8 hours) for seven days produced significantly shorter periods of viral shedding, more rapid lesion healing, and decreased pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of high reactivation rates, HSV-seropositive patients who are undergoing either induction chemotherapy for acute leukemia or receiving high-dose \"conditioning\" regimens followed by HCT should receive antiviral prophylaxis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    (200 to 400 mg orally two to five times daily, or 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 hours IV) should be started on the day the conditioning or induction regimen is started, and continued until the ANC is greater than",
"    <span class=\"nowrap\">",
"     500/microL.",
"    </span>",
"    This reduces the incidence of symptomatic HSV infection from 70 down to 5 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prophylactic oral care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive oral examination before the initiation of cancer therapy is desirable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/16\">",
"     16",
"    </a>",
"    ]. A program of aggressive preventive oral care appears to diminish the incidence of all oral complications of chemotherapy, although the available data are limited. In a retrospective review of 495 patients treated for non-head and neck malignancies between 1979 and 1986, the frequency of treatment-related oral complications declined from 39 percent in 1978 to 13 percent in 1986 after the institution of aggressive oral prophylaxis protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prechemotherapy oral hygiene protocols should include root planing and scaling, caries treatment, and endodontic therapy, if needed. In cases of severe odontogenic pathology, tooth extraction should be considered (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pulpoperiapical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periapical radiolucencies may represent pulpoperiapical dental infection, especially in the presence of caries. However, these radiographic changes can also be associated with other noninfectious conditions, such as postendodontic healing with scarring, or leukemic infiltrates at dental root apices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, the incidental finding of an asymptomatic periapical radiolucency requires no specific prechemotherapy intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Dental or endodontic therapy should be pursued only in patients with signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms that are consistent with acute periapical infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Periodontal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretherapy dental treatment is often recommended to eliminate potential sources of odontogenic infection. However, few outcome-oriented trials have been conducted which support prechemotherapy treatment of chronic periodontal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 166 patients were randomly assigned to limited or intensive oral hygiene care to prevent mucositis during high-dose therapy and HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/39\">",
"       39",
"      </a>",
"      ]. Patients receiving intensive oral care had statistically significant (though clinically unimpressive) benefits in the incidence (85 versus 93 percent) and duration (17 versus 19 days) of moderate or severe mucositis.",
"     </li>",
"     <li>",
"      The effectiveness of a preventive oral protocol was evaluated in a prospective, controlled study of 96 children (age 1 to 16 years) with acute lymphoblastic leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/40\">",
"       40",
"      </a>",
"      ]. Compared to the control children who only received treatment for dental complications rather than prophylaxis, the children in the prophylactic group had improved oral hygiene and a decreased incidence of mucositis and oral candidiasis.",
"     </li>",
"     <li>",
"      On the other hand, in a retrospective review of 58 patients undergoing allogeneic or autologous HCT for a variety of malignancies, there was no significant difference in the incidence of infection, mucositis or post-transplant survival in the group who underwent intensive dental evaluation and treatment pretransplant (n = 36), compared to those who did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective pilot trial was conducted at the University of Chicago, in which 48 consecutive adults with hematologic or solid malignant neoplasms were assessed for periodontal health prior to chemotherapy, and no pretherapy dental treatment was given to patients with chronic dental disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/42\">",
"       42",
"      </a>",
"      ]. Of the 21 who had severe chronic periodontal disease, only two developed acute periodontal infection following chemotherapy, both of whom were managed with antibiotic therapy. In neither case was there interference with chemotherapy or an adverse effect on oncologic outcomes.",
"      <br/>",
"      <br/>",
"      The authors concluded that patients with chronic dental pathology can safely proceed with chemotherapy without dental intervention, as conversion of chronic dental disease to an acute state during chemotherapy occurs infrequently. If intertherapy dental infections do arise, they can be managed effectively without interrupting therapy or adversely affecting oncologic treatment outcomes. An exception is patients undergoing allogeneic HCT where the additional use of immunosuppressive medications adds additional risks. All efforts should be made to correct any ongoing dental issues prior to proceeding with transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because chronic periodontal disease is associated with a substantial microbial burden within the periodontal pocket, it should be suspected as a focus of infection in febrile neutropenic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6\">",
"     6",
"    </a>",
"    ]. Invasive manipulation of the soft tissues prior to chemotherapy appears to have no adverse effect on the subsequent development of fever or bacteremia, although instrumentation should be avoided during periods of granulocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Tooth extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tooth extraction is commonly recommended prior to therapy for patients with severe periodontal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6\">",
"     6",
"    </a>",
"    ]. Pretherapy tooth extractions can be safely performed without significant risk of postextraction complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, recommended guidelines include performing extractions at least ten days prior to chemotherapy, minimizing tissue trauma during the procedure, and obtaining primary closure of the wound without the use of hemostatic packing agents. Platelet transfusion should be considered one-half hour prior to the procedure if the platelet count is less than",
"    <span class=\"nowrap\">",
"     40,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    If",
"    tooth extraction is emergently needed in the setting of severe neutropenia (ANC less than 500 to",
"    <span class=\"nowrap\">",
"     1000/microL),",
"    </span>",
"    antibiotic prophylaxis that provides appropriate coverage for Gram-positive and anaerobic organisms (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    600 mg prior to the procedure) is adequate unless there is evidence of active infection. Severely immunocompromised patients or those with extensive prior antibiotic exposure may benefit from broader spectrum antibiotic coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Preventive treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of strategies have been employed to prevent or minimize chemotherapy-induced mucositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the quality of evidence derived from randomized trials is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/46\">",
"     46",
"    </a>",
"    ], clinical practice guidelines developed by the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology in 2007 identified oral cryotherapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    , and low-level laser treatment as potentially beneficial in select clinical settings, as discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the National Comprehensive Cancer Network (NCCN) advocate only the use of oral cryotherapy in patients receiving bolus-dosed 5-FU or high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    before hematopoietic cell transplant (HCT), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    in patients receiving a total body irradiation conditioning regimen before autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/47\">",
"     47",
"    </a>",
"    ]. Guidelines on the use of chemotherapy protectants from the American Society of Clinical Oncology also suggest that the use of palifermin be limited to patients undergoing high dose chemotherapy with autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cryotherapy and 5-FU/high-dose melphalan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomatitis is a major dose-limiting toxicity of 5-FU when it is administered as a short-term bolus, particularly using a monthly rather than weekly schedule of administration (the so-called Mayo regimen). Mucositis is less of a problem in patients who receive infusional 5-FU. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H11#H11\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Optimizing the schedule and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because 5-FU has a short plasma half-life, it was postulated that oral cryotherapy (ie, intraoral administration of ice chips) around the time of drug administration might induce local vasoconstriction, thereby reducing exposure of the oral mucosa to 5-FU and decreasing the incidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of mucositis.",
"   </p>",
"   <p>",
"    At least three controlled trials provide evidence for the benefit of oral cryotherapy in patients receiving bolus 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In the largest and most recent of these trials, 225 patients who were receiving their first course of bolus 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    were randomly assigned to cryotherapy (ice chips swished in the mouth beginning 10 minutes prior to treatment and continuing for 35 minutes after treatment),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    mouthwash, or a placebo mouthwash (normal saline with the same taste as the chlorhexidine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/51\">",
"     51",
"    </a>",
"    ]. Using a self-administered questionnaire, the incidence of grade 3 or 4 mucositis was significantly lower with both cryotherapy and chlorhexidine, compared to placebo (11 and 13 versus 33 percent, respectively).",
"   </p>",
"   <p>",
"    The optimal duration of cryotherapy was addressed in another randomized trial of 178 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/52\">",
"     52",
"    </a>",
"    ]. No additional benefit was seen with 60 as compared to 30 minutes of cryotherapy.",
"   </p>",
"   <p>",
"    Clinical practice guidelines recommend the use of oral cryotherapy (ice chips swished around the mouth for 30 minutes) in patients receiving bolus 5-FU-containing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/4,47,53\">",
"     4,47,53",
"    </a>",
"    ]. However, bolus 5-FU regimens are not commonly used in the clinic because of their less favorable toxicity profile as compared to infusional regimens. The benefit of cryotherapy in patients receiving infusional 5-FU is unknown. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H11#H11\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Optimizing the schedule and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data are limited, cryotherapy also appears to be effective in preventing oral mucositis in patients receiving high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], and this is included in guideline recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/4,47\">",
"     4,47",
"    </a>",
"    ]. High-dose melphalan is used almost exclusively in the setting of hematopoietic cell transplantation (HCT). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Palifermin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"     Palifermin",
"    </a>",
"    is a recombinant keratinocyte growth factor that stimulates proliferation and differentiation of epithelial cells, including those of the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of prophylactic intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    was initially shown in a double-blind, placebo-controlled multicenter trial, in which 212 patients undergoing HCT for hematologic malignancies (with a preparative regimen [fractionated total body irradiation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ] known to be associated with a high incidence of mucositis) were randomly assigned to receive either palifermin (60",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per day) or placebo for three days before and three days following stem cell infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Significantly fewer patients receiving palifermin had grade 3 or 4 mucositis (63 versus 98 percent with placebo) and the duration of mucositis was shorter (median 6 versus 9 days). These benefits were associated with significantly less use of opioid analgesics and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    support.",
"   </p>",
"   <p>",
"    Largely as a result of these data, clinical practice guidelines recommend the use of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    in patients with hematologic malignancies who are undergoing high dose chemotherapy with autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/4,48,53\">",
"     4,48,53",
"    </a>",
"    ]. A randomized trial in the setting of allogeneic HCT is in progress. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are less data on the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    among patients receiving less intense chemotherapy regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A benefit for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"       palifermin",
"      </a>",
"      in patients receiving multiple cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      plus high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over three days by continuous infusion) was shown in a double-blind, placebo controlled randomized phase II trial in which 48 patients with advanced sarcoma received palifermin (180",
"      <span class=\"nowrap\">",
"       microg/kg",
"      </span>",
"      IV, n=32) or a placebo injection (n = 16) as a single dose three days before day 1 of each chemotherapy cycle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/59\">",
"       59",
"      </a>",
"      ]. Patients who developed severe mucositis received open-label palifermin in subsequent cycles.",
"      <br/>",
"      <br/>",
"      A median of six blinded chemotherapy cycles were completed by the palifermin group, compared to two in the placebo group. Palifermin reduced the cumulative incidence of grade 2 or higher (",
"      <a class=\"graphic graphic_table graphicRef60597 \" href=\"mobipreview.htm?15/30/15851\">",
"       table 2",
"      </a>",
"      ) mucositis (44 versus 88 percent), and severe (grade 3 or 4) mucositis (13 versus 51 percent). Seven of the eight patients who developed severe mucositis in the placebo group began open-label palifermin, and none had severe mucositis in subsequent cycles. The authors did not report whether patients who received palifermin required fewer dose reductions or treatment delays than those who received placebo.",
"      <br/>",
"      <br/>",
"      High doses of doxorubicin such as used in patients enrolled on this study are not in widespread use.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"       Palifermin",
"      </a>",
"      has also been shown to decrease the incidence of oral mucositis in patients receiving bolus 5-FU-based chemotherapy for colorectal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. In a randomized phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial, 64 patients receiving bolus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated 5-FU (the Mayo regimen) for metastatic disease were randomly assigned to palifermin (40",
"      <span class=\"nowrap\">",
"       microg/kg",
"      </span>",
"      per day) or placebo, administered on days -2, -1, and 0, followed by 5-FU plus leucovorin on days 1 to 5 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The incidence of grade 2 or higher mucositis (",
"      <a class=\"graphic graphic_table graphicRef68013 \" href=\"mobipreview.htm?40/47/41724\">",
"       table 1",
"      </a>",
"      ) was significantly lower in the palifermin group (29 versus 61 percent with placebo in cycle 1; 11 versus 47 percent in cycle 2). Furthermore, the frequency of chemotherapy dose reductions in cycle 2 was lower in patients treated with palifermin (14 versus 31 percent). Treatment with palifermin was well tolerated, and there was no evidence of any effect on survival. A major flaw in this trial is the lack of a comparator group treated with cryotherapy alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results need to be confirmed in larger more diverse patient populations before prophylactic use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    can be justified in settings other than HCT, particularly in view of the high cost of this agent and the absence of data demonstrating a favorable cost benefit ratio. If prophylactic treatment with palifermin is shown to reduce suffering and improve the likelihood of completing a course of chemotherapy without substantially increasing the cost of care compared to other active preventive strategies, the overall benefit to patients would support its wider use. Updated 2009 guidelines on use of chemotherapy and radiotherapy protectants from the American Society of Clinical Oncology (ASCO) concluded that the data were insufficient to recommend the use of palifermin in the non-stem cell transplant setting, or for solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three controlled trials suggest that pretreatment with a helium-neon laser (He-Ne laser), a form of low-level laser irradiation, reduces the severity of mucositis in patients undergoing conditioning therapy for HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 30 patients undergoing HCT were randomly assigned to observation or He-Ne laser treatment to the entire oral mucosa prior to myeloablative chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/62\">",
"       62",
"      </a>",
"      ]. Those who received laser treatment had significantly lower cumulative mucositis scores and required significantly less",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      for oral pain; however, there was no difference in the need for parenteral nutritional support.",
"     </li>",
"     <li>",
"      In a second trial of 20 patients undergoing HCT, one side of each patient's oral cavity was exposed to the He-Ne laser prior to high dose chemotherapy, while the contralateral side was sham-treated and served as the control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/63\">",
"       63",
"      </a>",
"      ]. The severity of oral mucositis and pain scores were significantly lower for the treated versus the untreated side of the mouth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least some data suggests a similar degree of benefit from application of a low-power diode laser, which is less expensive and easier to use than the He-Ne laser [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 38 patients undergoing autologous or allogeneic HCT were randomly assigned to low power laser therapy (LPLT) or control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/64\">",
"       64",
"      </a>",
"      ]. A significantly higher number of patients undergoing LPLT prior to treatment had oral mucositis that was no worse than grade 2 (95 versus 32 percent in the control group), and fewer developed large (9.1 to 18 cm",
"      <sup>",
"       2",
"      </sup>",
"      ) areas of oral ulceration (5 versus 74 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another placebo-controlled trial comparing two different low-level lasers (650 nm visible red and 780 nm infrared), the 650 nm wavelength (but not the 780 wavelength) significantly reduced the severity of oral mucositis and pain scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/66\">",
"     66",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Low-level laser therapy has been recommended in consensus guidelines to reduce the incidence of oral mucositis in patients receiving high-dose chemotherapy or chemoradiotherapy before HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/4,53\">",
"     4,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other clinical settings (eg, patients undergoing therapy for head and neck cancer), there is consistent evidence from small high-quality studies that red and infrared LPLT can partly prevent development of cancer therapy-induced oral mucositis, and that it relieves pain, severity, and duration of symptoms in patients with cancer therapy-induced oral mucositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. However, the data are limited, and there are potential interactions with radiation therapy that have not yet been clarified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H722454747#H722454747\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Laser therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because this therapy requires expensive equipment and specialized operator training, it is limited to centers capable of supporting the necessary technology and training. The relative benefits of laser therapy versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    in patients undergoing high dose therapy and HCT have not been addressed in any trial. Because of these limitations and uncertainty as to optimal wavelength for beneficial effects, laser therapy is rarely used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Glutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutamine is a precursor for nucleotide synthesis and an important fuel source for rapidly dividing cells, such as the lining epithelia of the gastrointestinal tract. It is postulated to facilitate healing of the gastrointestinal mucosa following damage by either radiotherapy or chemotherapy.",
"   </p>",
"   <p>",
"    Supplementation with parenteral glutamine has been studied in the setting of HCT. There was no evidence of benefit in terms of prevention or mitigation of mucositis severity. These trials are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=see_link&amp;anchor=H11#H11\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'Glutamine supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting data regarding the benefit of oral glutamine supplements. Oral glutamine failed to prevent 5-FU-related mucositis in at least two trials of patients receiving standard dose 5-FU-based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. However, a trial in children suggested a possible benefit from oral glutamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/72\">",
"     72",
"    </a>",
"    ]. One potential explanation for the conflicting results may be that the poor solubility of glutamine may limit bioavailability to the mucosal surface. At least some data support the view that local uptake by the mucosa (provided by swishing of the product in the mouth) may be essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new oral suspension formulation of L-glutamine (Saforis&reg;, MGI Pharma) may provide greater bioavailability to the oral mucosa. In a phase III trial, 326 women with breast cancer scheduled to receive an anthracycline-based regimen (CAF, FAC, or AC) were randomly assigned to receive Saforis (2.5 g three times a day for 14 days) or placebo for the first cycle, crossing over to the alternate for cycle 2 of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/74\">",
"     74",
"    </a>",
"    ]. The incidence of mucositis grade &ge;2 was significantly reduced in the Saforis group during the first cycle (39 versus 50 percent with placebo), as was the incidence of severe mucositis (grade &ge;3, 1 versus 7 percent, (",
"    <a class=\"graphic graphic_table graphicRef60597 \" href=\"mobipreview.htm?15/30/15851\">",
"     table 2",
"    </a>",
"    )). Patients receiving Saforis in treatment cycle 1 had a lower-than-expected rate of oral mucositis when crossed over to placebo for treatment cycle 2, indicating a significant carryover effect.",
"   </p>",
"   <p>",
"    Independent confirmation of benefit is needed before routine use of prophylactic Saforis can be recommended in any setting. Updated 2007 guidelines from the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology specifically recommend against the use of systemic glutamine, but they considered the evidence on Saforis to be insufficient to prompt a recommendation.",
"   </p>",
"   <p>",
"    We agree with this recommendation. However, use of Saforis could be considered in subsequent cycles for a patient who developed severe mucositis following chemotherapy with an anthracycline-based regimen and for whom dose reduction is felt to be an undesirable strategy (eg, in the adjuvant or neoadjuvant, potentially curative setting).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Calcium phosphate rinse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit for neutral supersaturated calcium phosphate rinse (Caphosol&reg;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"     artificial saliva",
"    </a>",
"    ) was suggested in a double-blind, placebo-controlled trial in which 95 patients undergoing HCT were randomly assigned to calcium phosphate rinse plus a topical fluoride versus topical fluoride alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/75\">",
"     75",
"    </a>",
"    ]. Patients using the calcium phosphate rinse had a significantly shorter duration of mucositis (3.7 versus 7 days), and less pain and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    use. If these results are confirmed, this approach may offer a useful means of decreasing oral mucositis during highly toxic regimens such as allogeneic HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other prophylactic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other pharmacologic approaches have either failed to show efficacy in controlled studies, or insufficient data are available to assess their benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"      mouthwash &mdash; Allopurinol mouthwashes have been used in an attempt to inhibit the activation of 5-FU to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      monophosphate in mucosal cells. Early reports of benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/76,77\">",
"       76,77",
"      </a>",
"      ] were not confirmed in a randomized trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/78\">",
"       78",
"      </a>",
"      ]. Allopurinol mouthwash as a therapeutic maneuver in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      is discussed below (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Analgesia'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/4/14404?source=see_link\">",
"       Propantheline",
"      </a>",
"      &mdash; An anticholinergic agent, propantheline, has been used to decrease salivary flow and thereby reduce oral mucosal delivery of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , a drug that is secreted into saliva. In a small, randomized, placebo-controlled trial (n = 12), propantheline was associated with a lower incidence and severity of mucositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/79\">",
"       79",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A protective effect of propantheline-induced xerostomia was also suggested in a larger but uncontrolled study of 31 patients receiving high-dose etoposide (3000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      as a component of ICE regimen (high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , and etoposide) prior to HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/79\">",
"       79",
"      </a>",
"      ]. Although mucositis developed in 29 (90 percent), it was severe in only three (10 percent). The authors inferred benefit based upon a comparison with a published series of 46 patients treated with the same ICE regimen followed by autologous HCT but without propantheline, in which mucositis developed in all patients and was severe in 78 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/80\">",
"       80",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although suggestive, the data are insufficient to recommend the routine prophylactic use of propantheline in any clinical setting.",
"     </li>",
"     <li>",
"      Hematopoietic colony-stimulating factors &mdash; The possibility that hematopoietic colony-stimulating factors (CSFs) may protect against the development of chemotherapy-induced mucositis was initially raised in a randomized trial that examined the use of prechemotherapy",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) to maintain dose intensity in patients undergoing chemotherapy for advanced bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/81\">",
"       81",
"      </a>",
"      ]. Unexpectedly, G-CSF not only reduced the incidence of neutropenia, but compared to the control group, it was also associated with a significantly lower incidence (11 versus 44 percent) and severity of mucositis.",
"      <br/>",
"      <br/>",
"      Subsequently, benefit has been confirmed in at least four controlled trials using either G-CSF or granulocyte-macrophage CSF (GM-CSF) in a variety of clinical settings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/82-85\">",
"       82-85",
"      </a>",
"      ]. Despite these data, hematopoietic CSFs have not achieved widespread use for preventing mucositis, possibly because of their high cost.",
"      <br/>",
"      <br/>",
"      Topical application of CSFs in a mouthwash formulation has been explored in at least two randomized trials, one of which showed benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/86\">",
"       86",
"      </a>",
"      ] and the other no benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/87\">",
"       87",
"      </a>",
"      ]. The use of topical CSFs to prevent radiation-induced mucositis is addressed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H10#H10\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Mucositis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The clinical practice guidelines discussed above specifically recommend against the use of CSFs (parenteral or topical) to prevent oral mucositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       Chlorhexidine",
"      </a>",
"      &mdash; Three randomized trials assessing the effectiveness of chlorhexidine for mucositis prevention in patients receiving chemotherapy have yielded conflicting results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/51,88,89\">",
"       51,88,89",
"      </a>",
"      ]. Two trials, one in patients undergoing HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/88\">",
"       88",
"      </a>",
"      ] and the other in those receiving standard-dose bolus 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/51\">",
"       51",
"      </a>",
"      ], demonstrated a significant decrease in the incidence of mucositis with chlorhexidine mouthwash relative to placebo. The third trial, conducted in patients receiving a variety of mucositis-inducing regimens, did not demonstrate a benefit compared to sterile water mouthwashes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/89\">",
"       89",
"      </a>",
"      ]. Thus, the benefit of chlorhexidine mouth rinses remains uncertain.",
"     </li>",
"     <li>",
"      Other &mdash; Randomized, placebo-controlled trials have failed to confirm a consistent benefit for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/90-92\">",
"       90-92",
"      </a>",
"      ], prostaglandins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/93,94\">",
"       93,94",
"      </a>",
"      ], chamomile mouthwash [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/95\">",
"       95",
"      </a>",
"      ], and antimicrobial lozenges [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/96\">",
"       96",
"      </a>",
"      ]. None of these agents can be considered useful for the prevention of chemotherapy-associated mucositis.",
"      <br/>",
"      <br/>",
"      In animal models, several cytokines (eg, transforming growth factor beta and interleukin 11) modulate mucosal cell growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/97,98\">",
"       97,98",
"      </a>",
"      ]. Some of these molecules have received at least preliminary evaluation for their ability to prevent or ameliorate chemotherapy-associated mucositis, but none has a defined role for the prevention of mucositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/99-102\">",
"       99-102",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The trefoil factor family of proteins comprises a group of gastrointestinal peptides that are involved in the protection of the mucous epithelium. Benefit from an oral spray containing recombinant intestinal trefoil factor was suggested in a randomized, double-blind placebo-controlled phase II trial conducted in patients who developed moderate to severe oral mucositis during the first cycle of 5-FU-based chemotherapy for advanced colorectal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/103\">",
"       103",
"      </a>",
"      ]. Patients who received one of two doses of the recombinant protein had a significantly lower incidence of moderate to severe mucositis during the second chemotherapy cycle (9 to 12 versus 48 percent). Independent confirmation of these results is needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment of established mucositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of mucositis is supportive and aimed at symptom control. It consists of a combination of oral care, topical mucosal protectants, and either topical or systemic analgesia. The evidence supporting benefit for any of these interventions is weak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Routine oral care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine mouth care including removal of dentures, atraumatic cleansing, and oral rinses with a weak solution of salt and baking soda (one-half teaspoonful of salt and one teaspoonful of baking soda in a quart of water) should be performed every four hours. The oral cavity should be rinsed and wiped after meals, and dentures cleaned and brushed often to remove plaque. A soft toothbrush or foam swab (Toothette&reg;) cleans teeth effectively but may be too harsh for patients with moderate to severe stomatitis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     Hydrogen peroxide",
"    </a>",
"    (diluted 1:1 with saline or water) may be used for gentle debridement. Duration of use of hydrogen peroxide should be limited, as chronic therapy may delay healing.",
"   </p>",
"   <p>",
"    The diet should be limited to foods that do not require significant chewing; acidic, salty, or dry foods should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Mucosal coating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of mucosal coating agents have been used to protect the mucosal surfaces of the oral cavity, including Gelclair, Orabase, Episil (a patented mixture of soy phospholipid [lecithin] and glycerol dioleate that forms a bioadhesive barrier), topical",
"    <span class=\"nowrap\">",
"     kaolin/pectin,",
"    </span>",
"    and oral antacids. There is little, if any, evidence from randomized trials to support benefit from any of these preparations.",
"   </p>",
"   <p>",
"    One of the most popular products is Gelclair, a bioadherent oral gel containing (according to the US FDA label)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38865?source=see_link\">",
"     maltodextrin",
"    </a>",
"    , polyvinylpyrollidone, and sodium hyaluronate (but no alcohol or anesthetic agent). It provides a physical adherent barrier over mucosal surfaces, thereby shielding oral lesions from the effect of food, liquids, and saliva [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reduction in oral discomfort within five to seven hours of initial treatment was observed in an uncontrolled open-label study of 30 hospice patients (only three of whom had chemotherapy-related mucositis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/107\">",
"     107",
"    </a>",
"    ]. Benefit continued for more than three hours after each dose in most patients. The manufacturer recommends that the contents of each packet be mixed in one tablespoonful of water, rinsed in the mouth for one minute and expectorated, three times daily at least one hour before eating or drinking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two pilot studies suggest more rapid resolution of mucositis with topical vitamin E treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/104,108,109\">",
"     104,108,109",
"    </a>",
"    ]. In one randomized, double-blind, placebo-controlled trial, six of nine patients treated with vitamin E had complete resolution of lesions, compared to only one of nine receiving placebo. Larger confirmatory studies are needed before the topical application of vitamin E can be considered a standard approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both topical and systemic approaches have been used to manage pain associated with mucositis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      solutions provide pain relief but require frequent administration. In one trial, topical viscous lidocaine (2 percent) was more effective than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      and saline, a kaolin and pectin suspension, or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/110\">",
"       110",
"      </a>",
"      ]. Topical lidocaine is frequently combined with cleansing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coating agents, a mixture that is often referred to as \"miracle mouthwash\". One example consists of viscous lidocaine (50 mL of a 2 percent solution),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (100 mL of a 1",
"      <span class=\"nowrap\">",
"       mEq/mL",
"      </span>",
"      solution), and diphenhydramine (50 mL of a 12.5",
"      <span class=\"nowrap\">",
"       mg/5",
"      </span>",
"      mL solution) in 500 mL normal saline (resultant fluid volume 700 mL) with instructions to swish and expectorate 10 to 15 mL four to six times per day. Another type of \"miracle mouthwash\" consists of a mixture of equal parts of viscous lidocaine, diphenhydramine, and magnesium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      (Maalox).",
"      <br/>",
"      <br/>",
"      A commercially available preparation that includes both lidocaine and diphenhydramine is First&reg; Mouthwash BLM (swish and expectorate 10 to 15 mL four to six times daily).",
"     </li>",
"     <li>",
"      Topical application of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine sulfate",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in water, 15 mL swish for two minutes and expectorate) may shorten the duration and intensity of mouth pain even in the absence of significant systemic absorption. One study of 26 patients, which compared a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      mouthwash versus a mixture of equal parts of viscous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , and magnesium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      , demonstrated statistically significantly shorter duration and lower pain intensity with the morphine mouthwash [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/111\">",
"       111",
"      </a>",
"      ]. However, most commercially available oral preparations of morphine sulfate contain",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/32/14852?source=see_link\">",
"       glycerin",
"      </a>",
"      , ethanol, or both. These are not suitable for topical application, because alcohol can directly injure the mucosa while glycerin can damage tissues because it is hygroscopic.",
"     </li>",
"     <li>",
"      Pain may be severe enough to require systemic oral or parenteral opiates.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      is recommended as the opioid of first choice for patient-controlled analgesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/112\">",
"       112",
"      </a>",
"      ]. The oral route is preferred if the patient can swallow. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other narcotics such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      are frequently utilized. Often, patient-controlled analgesia with appropriate lock-outs is utilized so that pain medications can be delivered in a timely manner in hospitalized patients, especially those undergoing HCT. Typically, both a basal rate and intermittent bolus administrations of narcotics are required to achieve adequate analgesia.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      (in a candy vehicle) also produced substantial pain relief in an uncontrolled series of eleven patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/113\">",
"       113",
"      </a>",
"      ]. However, the benefit was incomplete for most patients and transient. A commercially available preparation (and a sugar-free variety) is available from Candy Kraft, or a recipe for making the candy at home can be obtained on the web [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to limit mucositis progression by blocking the mechanism of chemotherapy-induced toxicity are ongoing, but so far, they have a relatively limited role. However, mucositis due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    mouthwash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/104,115\">",
"     104,115",
"    </a>",
"    ] or to the systemic administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    or folinic acid (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     XEROSTOMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more commonly attributed to radiation therapy exposure, changes in salivary gland function can also be caused by chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6,116,117\">",
"     6,116,117",
"    </a>",
"    ]. Reduced salivary flow can also result from anticholinergic medications given for therapy-induced nausea or diarrhea (eg, for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -related early diarrhea). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link&amp;anchor=H10#H10\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on 'Irinotecan'",
"    </a>",
"    .) Clinical presentation is variable, with some patients presenting with dry mucous membranes of varying severity, while others complain of excessive saliva with drooling as a result of dysphagia or odynophagia.",
"   </p>",
"   <p>",
"    The major symptoms associated with xerostomia are dry, uncomfortable mucosal tissues and thick ropy saliva, which may impair speech and swallowing. Affected patients may also complain of dysgeusia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy-related xerostomia is typically reversible, with spontaneous resolution after completion of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6\">",
"     6",
"    </a>",
"    ]. Although it can compound other complications such as mucositis, this self-limiting form of xerostomia has no significant long-term effects on oral health. Therapy is symptomatic (eg, rinsing with saline or the use of commercially available saliva substitutes). Dry, cracked lips can be treated with petroleum lubricants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     GINGIVAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy-induced thrombocytopenia can result in spontaneous gingival bleeding, especially if the platelet count falls below",
"    <span class=\"nowrap\">",
"     15,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/118\">",
"     118",
"    </a>",
"    ]. Poor oral hygiene or minor oral trauma (eg, from poor fitting dentures, over vigorous brushing of teeth) may worsen this condition due to local inflammation. If brushing creates unacceptable tissue trauma or is painful, plaque control can be achieved with regular use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    oral rinses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gingival bleeding is reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody targeting the vascular endothelial growth factor, but is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gingival hemorrhage is usually not a serious or life-threatening complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/6\">",
"     6",
"    </a>",
"    ]. If significant spontaneous bleeding occurs, gauze soaked in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    can be locally applied to obtain hemostasis. Alternatively, custom-fitted mouth guards can be fabricated to serve as a stent with or without the application of hemostatic agents. Biting down on a popsicle or fudgsicle may aid in resolving persistent oozing. Platelet transfusions are rarely required, and resolution occurs quickly as the platelet count begins to rise toward normal levels spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20051867\">",
"    <span class=\"h1\">",
"     ALTERATIONS IN TASTE AND SMELL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient alterations in taste and smell are common in patients receiving chemotherapy, and may lead to reduced appetite, low energy intake, and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/121-124\">",
"     121-124",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two series with prospective assessment of cancer patients undergoing chemotherapy for a variety of cancer types, taste alterations were reported by 70 and 67 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/121,122\">",
"       121,122",
"      </a>",
"      ]. In one of the reports, 49 percent reported olfactory changes during chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another cohort of 87 patients receiving chemotherapy for breast cancer or a gynecologic malignancy, the significant decrease in olfactory and gustatory function during chemotherapy was restored almost completely to normal by three months postchemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/124\">",
"       124",
"      </a>",
"      ]. Olfactory function of older patients was affected more than younger patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conventional cytotoxic agents that have been most associated with taste alterations include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , platinum agents, taxanes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Taste alterations have also been reported in patients treated with molecularly targeted agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/125-131\">",
"     125-131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy and targeted therapeutics may affect taste by direct taste receptor stimulation due to secretion of the drug in saliva or via gingival crevice fluid (patients frequently describe a metallic or chemical taste when chemotherapy is delivered), and taste changes may persist after drug clearance due to damage to the taste buds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/1,132\">",
"     1,132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and treatment of disorders of taste and smell are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18455?source=see_link\">",
"     \"Evaluation and treatment of taste and smell disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/59/11186?source=see_link\">",
"       \"Patient information: Mouth sores from cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal manifestation of oral toxicity in patients receiving chemotherapy is mucositis. Direct stomatotoxic effects begin shortly after therapy is begun and usually peak at about day 7. The severity ranges from mild mouth soreness with a paucity of clinical findings to severe erosive mucositis that is accompanied by severe pain and an inability to eat or drink. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among the factors that influence the extent and severity of mucositis are the specific drug, dose, route and frequency of administration, pretreatment oral disease, concomitant use of radiation therapy, and individual patient tolerance. The cytotoxic agents most commonly associated with oral mucositis are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , bolus 5-FU regimens, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Etiology and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Mucositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations for prevention and treatment of mucositis apply to patients receiving standard dose chemotherapy. Recommendations for prevention and treatment of mucositis in patients undergoing high dose chemotherapy and hematopoietic cell transplantation (HCT) are covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our recommendations generally follow the guidelines of a consensus panel on prevention and management of mucositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/22/38250/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Oral prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive oral examination with aggressive preventive oral care prior to chemotherapy appears to diminish the incidence of all oral complications of chemotherapy. Prechemotherapy oral hygiene protocols should include root planing and scaling, caries treatment, and tooth extraction if needed. Patients with chronic periodontal disease can safely proceed with chemotherapy without specific dental intervention, as conversion of chronic dental disease to an acute state during chemotherapy is infrequent. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prophylactic oral care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific preventive strategies can be recommended in the following limited clinical situations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest oral cryotherapy (ice chips swished around the mouth for 30 minutes) in patients receiving bolus 5-FU-containing chemotherapy regimens (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cryotherapy and 5-FU/high-dose melphalan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to its expense and inconvenience, we suggest that the use of prophylactic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"       palifermin",
"      </a>",
"      be limited to patients undergoing high-dose chemotherapy in the setting of HCT using preparative regimens with a high risk of significant mucositis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"       \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36084?source=see_link\">",
"       palifermin",
"      </a>",
"      could be considered as an alternative to dose reduction for subsequent chemotherapy cycles in patients who developed severe (grade 3 or worse) mucositis during treatment with a 5-FU or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -based chemotherapy regimen. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Palifermin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, a less expensive and more convenient alternative in this situation is Saforis, an oral formulation of L-glutamine. Although data are insufficient to support the use of Saforis for routine prophylaxis of oral mucositis, it is a reasonable approach for a patient who developed severe mucositis following chemotherapy with an anthracycline-based regimen and for whom dose reduction is felt to be an undesirable strategy (eg, in the adjuvant, potentially curative setting). In keeping with the consensus guidelines, we recommend that IV glutamine not be used for prophylaxis of mucositis in any setting (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Glutamine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breakdown of the mucosal barrier predisposes to bacterial, fungal (mostly Candida albicans), and viral superinfection, which may remain localized or become disseminated, particularly as the hematologic nadir is reached. In addition, pain may limit the ability to take in adequate fluids and nutrition. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment of established mucositis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment is supportive and mainly aimed at symptom control.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of dentures, atraumatic cleansing, and oral rinses with a weak solution of salt and baking soda (one-half teaspoonful of salt and one teaspoonful of baking soda in a quart of water) every four hours (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Routine oral care'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The oral cavity should be rinsed and wiped after meals, and dentures cleaned and brushed often to remove plaque. Rinsing with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"       artificial saliva",
"      </a>",
"      may lessen the duration and severity of mucositis. A soft toothbrush or foam swab (Toothette&reg;) cleans teeth effectively but may be too harsh for patients with moderate to severe stomatitis.",
"     </li>",
"     <li>",
"      The diet should be limited to foods that do not require significant chewing; acidic, salty, or dry foods should be avoided. If the patient is unable to swallow foods or liquids, parenteral fluid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nutritional support may be needed.",
"     </li>",
"     <li>",
"      A variety of mucosal coating agents are available, including topical",
"      <span class=\"nowrap\">",
"       kaolin/pectin,",
"      </span>",
"      Orabase&reg;,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , oral antacids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38865?source=see_link\">",
"       maltodextrin",
"      </a>",
"      (Gelclair&reg;), and compounded mixtures such as \"miracle mouthwash\" that contain coating agents often in combination with topical anesthetics. There are no randomized trials comparing any of these treatments, and no single approach can be recommended over the others. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Mucosal coating agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate analgesia can sometimes be provided topically (using viscous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , First mouthwash, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      candies), but many patients require systemic narcotics. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that prophylactic administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      suspension or oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      reduces the frequency of superinfection with Candida albicans, and we recommend against this practice (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend topical (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"       clotrimazole",
"      </a>",
"      troches or nystatin suspension) rather than systemic antifungal therapy for patients who develop superficial oropharyngeal candidiasis as a complication of oral mucositis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Oral candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of HSV infection should be considered in a patient who has intraoral vesicles or unusually painful oral ulcerative lesions. In such cases, we recommend a swab for viral culture and initiation of empiric antiviral therapy (ie, parenteral or oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      ) while awaiting culture results (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend that antiviral prophylaxis be limited to patients who are seropositive for HSV and who are undergoing high-dose chemotherapy for a hematologic malignancy or HCT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'HSV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of topical vitamin E is not established, and we suggest not pursuing this strategy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Xerostomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xerostomia is an uncommon complication of chemotherapy. Therapy is symptomatic (eg, rinsing with saline or the use of commercially available saliva substitutes). Dry, cracked lips can be treated with petroleum lubricants. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Xerostomia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Gingival bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gingival bleeding is most commonly caused by thrombocytopenia. If significant spontaneous bleeding occurs, gauze soaked in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    can be locally applied to obtain hemostasis. Bleeding usually resolves rapidly as platelet counts increase following the hematologic nadir. Platelet transfusions are rarely required. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Gingival bleeding'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/1\">",
"      Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012; 62:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/2\">",
"      Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/3\">",
"      Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/4\">",
"      Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/5\">",
"      DePaola LG, Peterson DE, Overholser CD Jr, et al. Dental care for patients receiving chemotherapy. J Am Dent Assoc 1986; 112:198.",
"     </a>",
"    </li>",
"    <li>",
"     Peterson DE, Schubert MM. Oral toxicity. In: The Chemotherapy Source Book, 3rd, Perry MC (Ed), Williams and Wilkins, Baltimore 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/7\">",
"      Boers-Doets CB, Epstein JB, Raber-Durlacher JE, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/8\">",
"      Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 2011; 47:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/9\">",
"      Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010; 116:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/10\">",
"      Vathsala A. Outcomes for kidney transplants at the National University Health System: comparison with overseas transplants. Clin Transpl 2010; :149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/11\">",
"      De Masson A, Fouchard N, M&eacute;ry-Bossard L, Dauendorffer JN. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors. Dermatology 2011; 223:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/12\">",
"      Gomez-Fernandez C, Garden BC, Wu S, et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer 2012; 48:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/13\">",
"      Rosenberg SW. Oral care of chemotherapy patients. Dent Clin North Am 1990; 34:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/14\">",
"      Peterson DE, D'Ambrosio JA. Diagnosis and management of acute and chronic oral complications of nonsurgical cancer therapies. Dent Clin North Am 1992; 36:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/15\">",
"      Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston Park) 2003; 17:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/16\">",
"      Consensus statement: oral complications of cancer therapies. National Institutes of Health Consensus Development Panel. NCI Monogr 1990; :3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/17\">",
"      Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 2003; 39:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/18\">",
"      Sonis ST, Sonis AL, Lieberman A. Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 1978; 97:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/19\">",
"      Sonis ST, Woods PD, White BA. Oral complications of cancer therapies. Pretreatment oral assessment. NCI Monogr 1990; :29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/20\">",
"      Hahn T, Zhelnova E, Sucheston L, et al. A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol Blood Marrow Transplant 2010; 16:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/21\">",
"      Pratesi N, Mangoni M, Mancini I, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol 2011; 99:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/22\">",
"      Bogunia-Kubik K, Mazur G, Urbanowicz I, et al. Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. Int J Immunogenet 2006; 33:21.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute Common Toxicity Criteria file://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/24\">",
"      Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999; 17:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/25\">",
"      Dreizen S, Bodey GP, Valdivieso M. Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg Oral Med Oral Pathol 1983; 55:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/26\">",
"      Weisman SJ, Scoopo FJ, Johnson GM, et al. Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections. J Clin Oncol 1990; 8:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/27\">",
"      Ruescher TJ, Sodeifi A, Scrivani SJ, et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/28\">",
"      DeGregorio MW, Lee WM, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982; 50:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/29\">",
"      M&uuml;cke R, Kaben U, Libera T, et al. Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy. Mycoses 1998; 41:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/30\">",
"      Barrett AP. Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immunosuppressed patients. Oral Surg Oral Med Oral Pathol 1984; 58:148.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/32\">",
"      Redding SW. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr 1990; :103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/33\">",
"      Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982; 73:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/34\">",
"      Mitchell CD, Bean B, Gentry SR, et al. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 1981; 1:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/35\">",
"      Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/36\">",
"      Sonis S, Kunz A. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol 1988; 65:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/37\">",
"      Stevenson-Moore P. Oral complications of cancer therapies. Essential aspects of a pretreatment oral examination. NCI Monogr 1990; :33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/38\">",
"      Peters E, Monopoli M, Woo SB, Sonis S. Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1993; 76:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/39\">",
"      Borowski B, Benhamou E, Pico JL, et al. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 1994; 30B:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/40\">",
"      Levy-Polack MP, Sebelli P, Polack NL. Incidence of oral complications and application of a preventive protocol in children with acute leukemia. Spec Care Dentist 1998; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/41\">",
"      Melkos AB, Massenkeil G, Arnold R, Reichart PA. Dental treatment prior to stem cell transplantation and its influence on the posttransplantation outcome. Clin Oral Investig 2003; 7:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/42\">",
"      Toljanic JA, Bedard JF, Larson RA, Fox JP. A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer. Cancer 1999; 85:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/43\">",
"      Weikel DS, Peterson DE, Rubinstein LE, et al. Incidence of fever following invasive oral interventions in the myelosuppressed cancer patient. Cancer Nurs 1989; 12:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/44\">",
"      Overholser CD, Peterson DE, Bergman SA, Williams LT. Dental extractions in patients with acute nonlymphocytic leukemia. J Oral Maxillofac Surg 1982; 40:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/45\">",
"      Williford SK, Salisbury PL 3rd, Peacock JE Jr, et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol 1989; 7:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/46\">",
"      Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011; :CD000978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/47\">",
"      Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008; 6 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/48\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/49\">",
"      Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991; 9:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/50\">",
"      Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994; 30B:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/51\">",
"      Sorensen JB, Skovsgaard T, Bork E, et al. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 2008; 112:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/52\">",
"      Rocke LK, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993; 72:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/53\">",
"      Peterson DE, Bensadoun RJ, Roila F, ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol 2009; 20 Suppl 4:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/54\">",
"      Aisa Y, Mori T, Kudo M, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 2005; 13:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/55\">",
"      Tartarone A, Matera R, Romano G, et al. Prevention of high-dose melphalan-induced mucositis by cryotherapy. Leuk Lymphoma 2005; 46:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/56\">",
"      Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/57\">",
"      Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/58\">",
"      Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24:5186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/59\">",
"      Vadhan-Raj S, Trent J, Patel S, et al. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 2010; 153:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/60\">",
"      Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/61\">",
"      Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006; 24:5194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/62\">",
"      Cowen D, Tardieu C, Schubert M, et al. Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 38:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/63\">",
"      Barasch A, Peterson DE, Tanzer JM, et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995; 76:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/64\">",
"      Antunes HS, de Azevedo AM, da Silva Bouzas LF, et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 2007; 109:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/65\">",
"      Wong SF, Wilder-Smith P. Pilot study of laser effects on oral mucositis in patients receiving chemotherapy. Cancer J 2002; 8:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/66\">",
"      Schubert MM, Eduardo FP, Guthrie KA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 2007; 15:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/67\">",
"      Bensadoun RJ, Franquin JC, Ciais G, et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 1999; 7:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/68\">",
"      Kuhn A, Vacaro G, Almeida D, et al.. Low-level infra-red laser therapy for chemo- or radiation-induced oral mucositis: a randomized, placebo-controlled study. J Oral Laser Appl 2007; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/69\">",
"      Bjordal JM, Bensadoun RJ, Tun&egrave;r J, et al. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer 2011; 19:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/70\">",
"      Okuno SH, Woodhouse CO, Loprinzi CL, et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol 1999; 22:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/71\">",
"      Jebb SA, Osborne RJ, Maughan TS, et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 1994; 70:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/72\">",
"      Aquino VM, Harvey AR, Garvin JH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 2005; 36:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/73\">",
"      Sonis ST. Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation? Nat Clin Pract Oncol 2006; 3:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/74\">",
"      Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007; 109:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/75\">",
"      Papas AS, Clark RE, Martuscelli G, et al. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/76\">",
"      Tsavaris N, Caragiauris P, Kosmidis P. Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes. Eur J Surg Oncol 1988; 14:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/77\">",
"      Dozono H, Nakamura K, Motoya T, et al. [Prevention of stomatitis induced by anti-cancer drugs]. Gan To Kagaku Ryoho 1989; 16:3449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/78\">",
"      Loprinzi CL, Cianflone SG, Dose AM, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer 1990; 65:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/79\">",
"      Ahmed T, Engelking C, Szalyga J, et al. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 1993; 12:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/80\">",
"      Oblon DJ, Paul SR, Oblon MB, Malik S. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant 1997; 20:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/81\">",
"      Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/82\">",
"      Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995; 13:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/83\">",
"      Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 1994; 5 Suppl 2:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/84\">",
"      Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/85\">",
"      Crawford J, Tomita DK, Mazanet R, et al. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 1999; 5:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/86\">",
"      Cartee L, Petros WP, Rosner GL, et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995; 7:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/87\">",
"      van der Lelie H, Thomas BL, van Oers RH, et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 2001; 80:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/88\">",
"      Ferretti GA, Ash RC, Brown AT, et al. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988; 3:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/89\">",
"      Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/90\">",
"      Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/91\">",
"      Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. Acta Oncol 1990; 29:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/92\">",
"      Nottage M, McLachlan SA, Brittain MA, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Support Care Cancer 2003; 11:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/93\">",
"      Due&ntilde;as-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant 1996; 17:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/94\">",
"      Labar B, Mrsi�� M, Pavleti�� Z, et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993; 11:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/95\">",
"      Fidler P, Loprinzi CL, O'Fallon JR, et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 1996; 77:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/96\">",
"      El-Sayed S, Nabid A, Shelley W, et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 2002; 20:3956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/97\">",
"      Sonis S, Muska A, O'Brien J, et al. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Cancer B Oral Oncol 1995; 31B:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/98\">",
"      Sonis ST, Van Vugt AG, McDonald J, et al. Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine 1997; 9:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/99\">",
"      de Koning BA, Philipsen-Geerling B, Hoijer M, et al. Protection against chemotherapy induced mucositis by TGF-beta(2) in childhood cancer patients: results from a randomized cross-over study. Pediatr Blood Cancer 2007; 48:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/100\">",
"      Antin JH, Lee SJ, Neuberg D, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/101\">",
"      Wymenga AN, van der Graaf WT, Hofstra LS, et al. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res 1999; 5:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/102\">",
"      Foncuberta MC, Cagnoni PJ, Brandts CH, et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother 2001; 24:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/103\">",
"      Peterson DE, Barker NP, Akhmadullina LI, et al. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol 2009; 27:4333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/104\">",
"      Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2002; :CD001973.",
"     </a>",
"    </li>",
"    <li>",
"     Gelclair drug information file://www.helsinn.com/Institutional.aspx?Root=212&amp;L2=232&amp;L3=274&amp;L4=270&amp;Lingua=EN (Accessed on April 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/106\">",
"      Hita-Iglesias P, Torres-Lagares D, Guti&eacute;rrez-P&eacute;rez JL. Evaluation of the clinical behaviour of a polyvinylpyrrolidone and sodium hyalonurate gel (Gelclair) in patients subjected to surgical treatment with CO2 laser. Int J Oral Maxillofac Surg 2006; 35:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/107\">",
"      Innocenti M, Moscatelli G, Lopez S. Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J Pain Symptom Manage 2002; 24:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/108\">",
"      Wadleigh RG, Redman RS, Graham ML, et al. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 1992; 92:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/109\">",
"      Lopez I, Goudou C, Ribrag V, et al. [Treatment of mucositis with vitamin E during administration of neutropenic antineoplastic agents]. Ann Med Interne (Paris) 1994; 145:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/110\">",
"      Carnel SB, Blakeslee DB, Oswald SG, Barnes M. Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg 1990; 102:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/111\">",
"      Cerchietti LC, Navigante AH, Bonomi MR, et al. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 2002; 95:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/112\">",
"      Coda BA, O'Sullivan B, Donaldson G, et al. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 1997; 72:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/113\">",
"      Berger A, Henderson M, Nadoolman W, et al. Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy. J Pain Symptom Manage 1995; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     Capsaicin candy recipe and the Candy Kraft contact information www.sciential.net/capsaicin_candies.htm (Accessed on April 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/115\">",
"      Montecucco C, Caporali R, Rossi S, Porta C. Allopurinol mouthwashes in methotrexate-induced stomatitis. Arthritis Rheum 1994; 37:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/116\">",
"      Main BE, Calman KC, Ferguson MM, et al. The effect of cytotoxic therapy on saliva and oral flora. Oral Surg Oral Med Oral Pathol 1984; 58:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/117\">",
"      Schum CA, Izutsu KT, Molbo DM, et al. Changes in salivary buffer capacity in patients undergoing cancer chemotherapy. J Oral Med 1979; 34:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/118\">",
"      Peterson DE, D'Ambrosio JA. Nonsurgical management of head and neck cancer patients. Dent Clin North Am 1994; 38:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/119\">",
"      Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008; 26:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/120\">",
"      Chura JC, Van Iseghem K, Downs LS Jr, et al. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007; 107:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/121\">",
"      Zabernigg A, Gamper EM, Giesinger JM, et al. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist 2010; 15:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/122\">",
"      Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 2008; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/123\">",
"      Hong JH, Omur-Ozbek P, Stanek BT, et al. Taste and odor abnormalities in cancer patients. J Support Oncol 2009; 7:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/124\">",
"      Steinbach S, Hummel T, B&ouml;hner C, et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 2009; 27:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/125\">",
"      Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007; 13:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/126\">",
"      Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer 2008; 113:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/127\">",
"      Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/128\">",
"      Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/129\">",
"      Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010; 40:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/130\">",
"      Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25:3978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/131\">",
"      Kimball KJ, Numnum TM, Kirby TO, et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008; 111:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/22/38250/abstract/132\">",
"      Bergdahl M, Bergdahl J. Perceived taste disturbance in adults: prevalence and association with oral and psychological factors and medication. Clin Oral Investig 2002; 6:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1152 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38250=[""].join("\n");
var outline_f37_22_38250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MUCOSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathobiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Grading systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infectious complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Oral candidiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - HSV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prophylactic oral care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pulpoperiapical disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Periodontal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Tooth extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Preventive treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cryotherapy and 5-FU/high-dose melphalan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Palifermin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Laser therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Glutamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Calcium phosphate rinse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other prophylactic approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment of established mucositis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Routine oral care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Mucosal coating agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      XEROSTOMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      GINGIVAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20051867\">",
"      ALTERATIONS IN TASTE AND SMELL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Mucositis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Oral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Xerostomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Gingival bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/1152\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1152|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/47/41724\" title=\"table 1\">",
"      Chemo agents and mucositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/30/15851\" title=\"table 2\">",
"      Grading severity mucositis according to the NCI CTCAE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=related_link\">",
"      Epidemiology of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18455?source=related_link\">",
"      Evaluation and treatment of taste and smell disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14185?source=related_link\">",
"      Oral health in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/59/11186?source=related_link\">",
"      Patient information: Mouth sores from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36762?source=related_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_22_38251="Anemia in elderly adults";
var content_f37_22_38251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed lower limits of normal for hemoglobin concentration in white and black adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Group",
"      </td>",
"      <td class=\"subtitle1\">",
"       Hemoglobin, g/dL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       White men, y",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       20-59",
"      </td>",
"      <td>",
"       13.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       60+",
"      </td>",
"      <td>",
"       13.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       White women, y",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       20-49",
"      </td>",
"      <td>",
"       12.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       50+",
"      </td>",
"      <td>",
"       12.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Black men, y",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       20-59",
"      </td>",
"      <td>",
"       12.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       60+",
"      </td>",
"      <td>",
"       12.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Black women, y",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       20-49",
"      </td>",
"      <td>",
"       11.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       50+",
"      </td>",
"      <td>",
"       11.5",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Based on Scripps-Kaiser data for the 5th percentiles for the populations in question. NHANES data are considered to be confirmatory. To convert hemoglobin from grams per deciliter to grams per liter, multiply grams per deciliter by 10.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Beutler, E, Waalen, J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747. Copyright &copy; 2006 The American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38251=[""].join("\n");
var outline_f37_22_38251=null;
var title_f37_22_38252="EVALuate trial";
var content_f37_22_38252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    EVAluate trial of complications of hysterectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Abdominal trial",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Vaginal Trial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Abdominal hysterectomy (n = 292)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Laparoscopic hysterectomy (n = 584)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Vaginal hysterectomy (n = 168)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Laparoscopic hysterectomy (n = 336)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major hemorrhage",
"       </td>",
"       <td>",
"        7* (2.4)",
"       </td>",
"       <td>",
"        27* (4.6)",
"       </td>",
"       <td>",
"        5 (2.9)",
"       </td>",
"       <td>",
"        17 (5.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel injury",
"       </td>",
"       <td>",
"        3 (1)",
"       </td>",
"       <td>",
"        1 (0.2)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ureteric injury",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5 (0.9)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1 (0.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder injury",
"       </td>",
"       <td>",
"        3 (1)",
"       </td>",
"       <td>",
"        12* (2.1)",
"       </td>",
"       <td>",
"        2 (1.2)",
"       </td>",
"       <td>",
"        3 (0.9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraoperative conversion",
"       </td>",
"       <td>",
"        1&bull; (0.3)",
"       </td>",
"       <td>",
"        23 (3.9)",
"       </td>",
"       <td>",
"        7 (4.2)",
"       </td>",
"       <td>",
"        9 (2.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wound dehiscence",
"       </td>",
"       <td>",
"        1 (0.3)",
"       </td>",
"       <td>",
"        1(0.2)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1 (0.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematoma&nbsp;",
"       </td>",
"       <td>",
"        2 (0.7)",
"       </td>",
"       <td>",
"        4 (0.7)",
"       </td>",
"       <td>",
"        2 (1.2)",
"       </td>",
"       <td>",
"        7 (2.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At least one major complication",
"       </td>",
"       <td>",
"        18 (6.2)",
"       </td>",
"       <td>",
"        65 (11.1)",
"       </td>",
"       <td>",
"        16 (9.5)",
"       </td>",
"       <td>",
"        33 (9.8)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A patient may have more than one complication.",
"    <div class=\"footnotes\">",
"     * These patients converted procedure before the operation: one patient undergoing abdominal hysterectomy converted to laparoscopic hysterectomy before the operation in the abdominal trial and had a major hemorrhage. Two patients in the abdominal trial who were undergoing laparoscopic hysterectomy converted to abdominal hysterectomy before the operation and had a major hemorrhage. One patient undergoing laparoscopic hysterectomy in the abdominal trial converted to abdominal hysterectomy before the operation and had a major anesthetic problem. One patient undergoing laparoscopic hysterectomy in the abdominal trial converted to abdominal hysterectomy before the operation and had a bladder injury.",
"     <br>",
"      &bull; This patient in the abdominal trial was randomized to abdominal hysterectomy, converted to laparoscopic hysterectomy before the operation and then converted back to abdominal hysterectomy during the operation.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Garry, R, Fountain, J, Mason, S, et al. BMJ 2004; 328:129.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38252=[""].join("\n");
var outline_f37_22_38252=null;
var title_f37_22_38253="Response to antihypertensives in blacks";
var content_f37_22_38253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Antihypertensive response to different drugs in blacks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Response rates to single drug therapy for hypertension in blacks over the age of 60 years. The highest response was seen with diltiazem and hydrochlorothiazide (HCTZ) and the lowest with captopril. A response was defined as a diastolic pressure below 90 mmHg at the end of the titration phase and below 95 mmHg at one year. The pattern of response was similar but the success rate for each drug was reduced by 5 to 15 percent if goal diastolic pressure were less than 90 mm Hg at one year. There were between 42 and 53 patients in each group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995; 8:189.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38253=[""].join("\n");
var outline_f37_22_38253=null;
var title_f37_22_38254="PD survival and creat clearance";
var content_f37_22_38254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Graph showing predicted probability of survival among CAPD patients according to weekly creatinine clearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 383px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Predicted probability of survival in patients treated with continuous peritoneal dialysis according to the weekly creatinine clearance (CCr). A progressive decline in two-year survival is noted at lower values for CCr. The values were 86 percent at a CCr of 95 L/week versus only 72 percent at a CCr of 55 L/week.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from CANADA-USA (CANUSA) Peritoneal Dialysis Study Group, J Am Soc Nephrol 1996; 7:198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38254=[""].join("\n");
var outline_f37_22_38254=null;
var title_f37_22_38255="Hematoma umbilical cord";
var content_f37_22_38255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Gross section of umbilical cord revealing localized hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_22_38255=[""].join("\n");
var outline_f37_22_38255=null;
